Wayne State University
Wayne State University Dissertations
1-1-2019

Role Of Dyslipidemia On Lipid Metabolism In Maintenance
Hemodialysis Patients
Eno Latifi
Wayne State University

Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Biochemistry Commons, Medicine and Health Sciences Commons, and the Nutrition
Commons

Recommended Citation
Latifi, Eno, "Role Of Dyslipidemia On Lipid Metabolism In Maintenance Hemodialysis Patients" (2019).
Wayne State University Dissertations. 2361.
https://digitalcommons.wayne.edu/oa_dissertations/2361

This Open Access Embargo is brought to you for free and open access by DigitalCommons@WayneState. It has
been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of
DigitalCommons@WayneState.

ROLE OF DYSLIPIDEMIA ON LIPID METABOLISM IN MAINTENANCE
HEMODIALYSIS PATIENTS
by
ENO LATIFI
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2019
MAJOR: NUTRITION AND FOOD SCIENCE
Approved By:
_________________________________________
Advisor
Date
_________________________________________
_________________________________________
_________________________________________

© COPYRIGHT BY
ENO LATIFI
2019
All Rights Reserved

DEDICATION
This thesis is dedicated to all the significant people in my life, who have supported me
through this journey:
My parents, Benereta & Sulejman Latifi
First and foremost, I would like to thank both my beloved parents, who never failed to
support me through all my ups and downs in life. I would like to thank them for all their sacrifices
and teaching me many life lessons that have carried to this point. Moreover, I am grateful for
instilling in me the hard work, loyalty, and compassion for others.
My sibling, Ivi Latifi
I would like to thank my beloved brother, who has always been there and support me
throughout the years. I thank him for believing in me, my goals, and my dreams in life. Lastly, I
am extremely proud of the great person and physician you have become.
Others
I would like to extend my appreciation to my extended family here in the United States and
back home to my birthplace Albania, my aunts and uncles, and my beloved grandparents.

ii

ACKNOWLEDGEMENTS
It is a pleasure to thank those who have made this dissertation possible, beginning with my
four committee mentors, my colleagues in the lab, and colleagues at the dialysis clinics that were
involved in the study. First and foremost, I owe my deepest gratitude to my supervisor, Dr. Pramod
Khosla, who has guided and supported me from the very beginning of this journey, from allowing
me to join his lab as an undergraduate student, mentoring me as I pursued my master’s degree and
continue into the doctorate program. Furthermore, I am grateful to him for allowing me to see
possibilities of what I can achieve. I would like to extend my appreciation to Dr. Smiti Gupta for
the advice and her tutelage throughout the years. I would also like to extend my gratitude to Dr.
Ahmad Heydari for investing in me as a graduate teaching assistant, and for his guidance
throughout the years. Next, I would like to thank Dr. James Sondheimer for his clinical expertise
and guidance for this study. I would also like to extend my gratitude for help and advice throughout
the years to Dr. Paul Burghardt and Dr. Diane Cress.
A significant appreciation goes to all the dialysis clinics in the US (Great Lakes dialysis,
DaVita, and Henry Ford) and Malaysia with our colleagues Dr. Tilakavati Karupaih, Dr. Karuthan
Chinna, Dr. Zulfitri Mat Azuan Daud, Dr. Ban Hock, and Dr. Sharmela Sahatheva. I am also
indebted to my lab colleagues starting with Dr. Deepinder Kaur, who has been a mentor and a
friend, ever since the day she recruited me to join Khosla’s Lab. Lastly, I would like to extend my
gratitude to my other colleagues Dina Tallman, Bayan Tashkandi, Tanjina Rahman, Ushaasri
Gullapalli, and Jayamini Shanika Arachchige.

iii

TABLE OF CONTENTS
DEDICATION ............................................................................................................................ ii
ACKNOWLEDGEMENTS ....................................................................................................... iii
LIST OF TABLES .................................................................................................................... vii
LIST OF FIGURES .................................................................................................................... ix
LIST OF ABBREVIATIONS AND ACRONYMS ................................................................... xi
CHAPTER 1: INTRODUCTION ............................................................................................ 1
Chronic Kidney Disease (CKD) .............................................................................................. 1
End-stage renal disease (ESRD) and Maintenance hemodialysis (MHD) .............................. 3
Lipid and Lipoproteins ............................................................................................................ 5
Exogenous Lipid Metabolism Pathway ................................................................................... 9
Endogenous Lipid Metabolism Pathway ............................................................................... 11
Reverse cholesterol transport pathway .................................................................................. 14
RCT mechanism and disease complications ......................................................................... 18
Dyslipidemia in Lipid Metabolism ........................................................................................ 20
HDL controversy ................................................................................................................... 23
Non-traditional disorders ....................................................................................................... 28
The rationale for the study ..................................................................................................... 34
Specific Aims ........................................................................................................................ 35
Tables Chapter 1 .................................................................................................................... 37

iv

Figures Chapter 1................................................................................................................... 44
CHAPTER 2: METHODOLOGY ......................................................................................... 54
General study design ............................................................................................................. 54
Ethics and Human Subjects’ .................................................................................................. 55
Inclusion and Exclusion Criteria’s ........................................................................................ 55
General blood collection, handling, and processing of samples............................................ 56
Anthropometry and other measurements ............................................................................... 57
Biochemical Analysis ............................................................................................................ 57
Lipid Profile ........................................................................................................................... 57
HDL and LDL lipoprotein subfractions analysis (Lipoprint) ................................................ 57
HDL metabolism enzymes analysis ...................................................................................... 59
Cholesteryl ester transfer protein (CETP) activity analysis .................................................. 59
Lecithin-cholesterol acyltransferase (LCAT) activity analysis ............................................. 59
Inflammatory marker: C-reactive protein (CRP)................................................................... 60
Oxidative stress marker: Nε-(carboxymethyl) lysine (CML) ................................................ 60
Statistical Analysis ................................................................................................................ 61
Tables Chapter 2 .................................................................................................................... 63
Figures Chapter 2................................................................................................................... 65
CHAPTER 3: RESULTS – SPECIFIC AIM 1: TO DOCUMENT THE DEGREE OF
DYSLIPIDEMIA IN A COHORT OF MHD PATIENTS AND CHARACTERIZE
LIPIDS, AND LIPOPROTEIN PARTICLE COMPOSITIONS........................................ 67

v

CHAPTER 4: RESULTS – SPECIFIC AIM 2: TO CHARACTERIZE DYSLIPIDEMIA
ACROSS A MULTI-ETHNIC COHORT OF MHD PATIENTS. ..................................... 74
CHAPTER 5: RESULTS – SPECIFIC AIM 3: TO DOCUMENT THE EXTENT TO
WHICH HDL ENZYMES CONTRIBUTE TO DYSLIPIDEMIA IN MHD PATIENTS.
................................................................................................................................................... 94
CHAPTER 6: DISCUSSION ............................................................................................... 107
CHAPTER 7: CONCLUSION AND RECOMMENDATIONS ....................................... 115
Summary conclusion ........................................................................................................... 115
Recommendation and future directions ............................................................................... 117
APPENDIX A ......................................................................................................................... 119
APPENDIX B: Other Analyses............................................................................................... 125
REFERENCES ........................................................................................................................ 133
ABSTRACT ........................................................................................................................... 165
AUTOBIOGRAPHICAL STATEMENT ............................................................................... 167

vi

LIST OF TABLES
Table 1-1: Dyslipidemic characteristics in lipid parameters for different CRF conditions. ........ 37
Table 1-2: Lipoprotein classes and their characteristics. .............................................................. 38
Table 1-3: Apolipoproteins of human plasma lipoproteins. ......................................................... 39
Table 1-4: Efflux genes linked to RCT metabolism. .................................................................... 41
Table 1-5: Influx genes linked to RCT metabolism...................................................................... 43
Table 2-1: Study inclusion criteria. .............................................................................................. 63
Table 2-2: Study exclusion criteria. .............................................................................................. 64
Table 3-1: Characteristics of the African American (AA) cohort. ............................................... 69
Table 3-2: Plasma lipids in the AA cohort.................................................................................... 70
Table 3-3: Lipoprotein subfraction composition in the AA cohort. ............................................. 72
Table 3-4: Cholesterol ester transfer protein (CETP) and Lecithin cholesterol acyl transferase
(LCAT) activity in the AA cohort. ............................................................................................... 73
Table 4-1: Characteristics of the Malaysian cohort. .................................................................... 76
Table 4-2: Plasma lipids in the Malaysian cohort ......................................................................... 77
Table 4-3: Plasma lipid analyses based on TAG/HDL ration in the Malaysian cohort. ............... 78
Table 4-4: Lipoprotein subfraction composition in the Malaysian cohort. .................................. 80
Table 4-5: Lipoprotein composition according to, TAG/HDL-C ration (≥ or < 3.8) in the
Malaysian cohort ........................................................................................................................... 82
Table 4-6: Dyslipidemia in plasma lipids amongst ethnicities. .................................................... 84
Table 4-7: Dyslipidemia in lipoprotein subfractions amongst ethnicities. ................................... 91
Table 5-1: AGEs-CML analyses in the US cohort. .................................................................... 104
Appendix Tables 1: Dyslipidemic profile criteria assessed based Adult treatment panel III (ATP
III) guidelines. ............................................................................................................................. 119
Appendix Tables 2: Recommended lipid ranges. ....................................................................... 120
vii

Appendix B Table 1: Demographics of the collective in the US and Malaysian cohort. ......... 129
Appendix B Table 2: Lipoprotein composition between genders and ethnicities. ..................... 130
Appendix B Table 3: Lipid analyses in statin analyses. ............................................................. 131
Appendix B Table 4: Subfraction composition in the statin analyses. ....................................... 132

viii

LIST OF FIGURES
Figure 1-1: Stages of chronic kidney disease (CKD). ................................................................. 44
Figure 1-2: Prevalence of CKD in the US by stages of NHANES participants. .......................... 45
Figure 1-3: Prevalence of CKD among US adults’ gender and ethnic distribution...................... 46
Figure 1-4: CKD among Malaysian adults’ gender and ethnic composition................................ 47
Figure 1-5: Incidence of ESRD internationally. ........................................................................... 48
Figure 1-6: Projected ESRD incidence and prevalence in the US through 2030. ........................ 49
Figure 1-7: Treatment options for patients with end-stage kidney disease. ................................. 50
Figure 1-8: Causes of ESRD in the United States. ....................................................................... 51
Figure 2-1: HDL lipoprint subfraction band separation on polyacrylamide gel tube. ................. 65
Figure 2-2: LDL lipoprint subfraction band separation on polyacrylamide gel tube. .................. 66
Figure 3-1: Specific Aim 1 study flow......................................................................................... 68
Figure 4-1: Specific Aim 2 study flow......................................................................................... 75
Figure 4-2: HDL subfractions composition amongst ethnicities. ................................................. 86
Figure 4-3: VLDL and IDL subfraction composition between ethnicities. .................................. 87
Figure 4-4: LDL lipoprotein subfraction composition between ethnicities. ................................. 88
Figure 4-5: Dyslipidemic in lipoprotein subfractions in the overall study cohort. ....................... 90
Figure 4-6: Dyslipidemia in mean LDL particle size within ethnicities. ...................................... 93
Figure 5-1: Aim 3 study flow. ...................................................................................................... 95
Figure 5-2: CETP activity amongst the ethnicities in the study cohort. ....................................... 96
Figure 5-3: CETP activity based on categorical TAG/HDL-C ratio (≥ or < 3.8). ........................ 97
Figure 5-4: CETP activity between dyslipidemic groups. ............................................................ 98
Figure 5-5: LCAT activity between the ethnicities....................................................................... 99

ix

Figure 5-6: LCAT activity based on the categorical TAG/HDL-C ratio (≥ or < 3.8). ............... 100
Figure 5-7: LCAT activity between dyslipidemic groups. ......................................................... 101
Figure 5-8: Overall summary of the samples measured in the overall investigation.................. 102
Figure 5-9: C-reactive protein levels between the ethnicities. .................................................... 103
Appendix Figures 1: CRP versus hs-CRP in the Malaysian plasma samples. .......................... 121
Appendix Figures 2: CETP activity and TAG concentration correlation for all samples. ......... 122
Appendix Figures 3: CETP activity and TAG/HDL-C ratio correlation for all samples. .......... 123
Appendix Figures 4: LCAT activity and TAG concentration correlation for all samples. ......... 124
Appendix B Figures 1: AGEs-CML based on BMI analyses in the US cohort. ....................... 125
Appendix B Figures 2: Percent risk factor and atherogenic index of plasma in MHD ethnic
patients. ....................................................................................................................................... 126
Appendix B Figures 3: CRP analyses based on dyslipidemia. ................................................... 127
Appendix B Figures 4: CRP among ethnicities according to TAG/HDL-C ratios ≥ or < 3.8. ... 128

x

LIST OF ABBREVIATIONS AND ACRONYMS
[D]

:

Dyslipidemic patients

[MD]

:

Mixed dyslipidemic patients

[NL]

:

Normo-lipidemic patients

AA

:

African Americans

ACAT

:

Acyl CoA: cholesterol acyltransferase

AGEs

:

Advance glycation end-products

AHA

:

American Heart Association

Apo

:

Apolipoprotein [A-I; A-II; A-IV; B-48; B-100; C-I; C-II; C-III; E; D]

ATP

:

Adenosine triphosphate

BCAA

:

Branched chain amino acids

BMI

:

Body Mass Index

CE

:

Cholesterol Ester

CETP

:

Cholesteryl ester transfer protein

CKD

:

Chronic kidney diseases

CM

:

Chylomicron

CML

:

Nε-carboxymethyl-lysine

CRF

:

Chronic renal failure

CRP

:

C-reactive protein

CVD

:

Cardiovascular diseases

DL

:

Dyslipidemia

DM

:

Diabetes mellitus

EDTA-K2

:

Ethylenediaminetetraacetic acid K2 anticoagulant

xi

eGFR

:

Estimated glomerular filtration rate

ELISA

:

Enzyme-linked immunosorbent assays

ER

:

Endoplasmic reticulum

ESRD

:

End-stage renal disease

FA

:

Fatty acids

FFA

:

Free fatty acids

GFR

:

Glomerular filtration rate

HD

:

Hemodialysis

HDL-C

:

High-density lipoprotein cholesterol

HMGCR

:

3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A Reductase
(HMG-CoA reductase)

hsCRP

:

High-sensitive c-reactive protein

HTN

:

Hypertension

IDL

:

Intermediate-low density lipoprotein

I-HDL

:

Intermediate high-density lipoprotein subfraction particle

IL

:

Interleukin

I-LDL

:

Intermediate low-density lipoprotein subfraction particle

K/DOQI

:

Kidney Disease Outcomes Quality Initiative

Kt/V

:

Dialyzer clearance of urea multiplied by the dialysis time divided by the
volume of distribution of urea, approximately equal to the patient’s total
body water

LCAT

:

Lecithin-cholesterol acyltransferase

LDL-C

:

Low-density lipoprotein cholesterol

xii

LDLR

:

Low-density lipoprotein receptor

LH

:

Lithium heparin

L-HDL

:

Large high-density lipoprotein subfraction particle

L-LDL

:

Large low-density lipoprotein subfraction particle

Lp (a)

:

Lipoprotein (a)

LPL

:

Lipoprotein lipase

LRP1

:

LDL receptor-related protein 1

MC

:

Malaysian-Chinese

MHD

:

Maintenance hemodialysis

MI

:

Malaysian-Indians

MICS

:

Malnutrition-inflammation complex syndrome.

MM

:

Malaysian-Malays

MTS

:

Microsomal triglyceride transfer protein

MUFA

:

Monounsaturated fatty acids

MYI

:

Myocardial infarction

N.S.

:

Not significantly different (no changes statistically)

OS

:

Oxidative stress

PD

:

Peritoneal dialysis

PEW

:

Protein-energy wasting

RCT

:

Reverse cholesterol transport

ROS

:

Reactive oxygen species

RRT

:

Renal replacement therapy

SD

:

Standard deviation

xiii

S-HDL

:

Small high-density lipoprotein subfraction particle

S-LDL

:

Small low-density lipoprotein subfraction particle

SR-B1

:

Scavenger receptor class B type I

SREBPs

:

Sterol regulatory element binding protein

TAG

:

Triglyceride or triacylglycerol

TC

:

Total cholesterol

TCA

:

Tricarboxylic acid cycle

TP

:

Tocotrienols

TRF

:

Tocotrienols rich fractions

TT

:

Tocotrinols

URR

:

Urea reduction ratio

USRDS

:

US Renal Data System

VLDL

:

Very low-density lipoprotein

xiv

1

CHAPTER 1: INTRODUCTION
Chronic Kidney Disease (CKD)
Chronic Kidney Disease (CKD) is defined as an irreversible and gradual loss of kidney
function over time. Characterized by damage to the kidneys, with structural or functional
abnormalities of the organs, with or without decreases in glomerular filtration rate (GFR)
manifested by either pathological irregularities such as the composition of the blood or urine or in
imaging testing [1]. Moreover, the GFR could be < 60 ml/min/1.73 m2 for ≥ 3 months or > 60
ml/min/1.73 m2 with kidney impairment (marked by high levels of albumin in the urine) indicates
CKD [1]. Numerous studies have linked CKD as an independent risk factor for cardiovascular
disease (CVD) related event [2-4]. Moreover, CKD patients are at an increased risk at all stages of
the disease for a CVD event, which is the primary contributor to morbidity and mortality in this
population [5]. Adults with CKD are at a higher risk of early death compared to individuals without
CKD of the same age. It is estimated that 5-10 times, CKD patients are more likely to die before
even reaching ESRD [6, 7]. Also, the decline in the quality of life within this population further
exacerbates the disease [8]. The added decline in GFR is also associated with increased risk for a
CVD event, irrespective of gender or age [8].
According to the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, CKD,
and the progressive decline of kidney function can be classified into five stages. Stage-1 of CKD
is characterized by a GFR of (> 90 ml/min/1.73 m2), which is estimated to have a 10% decrease
of the filtration rate, leaving the kidneys at a 90% functional capacity, but presented with some
urinary abnormality reflective of proteinuria or hematuria. However, as the disease progresses, and
the GFR declines furthermore from stage-2 to stage-5, kidney functions reduce below 15% or less,
and is unable to filter and remove toxins (Figure 1-1) [9]. Moreover, according to the National
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Institute for Health and Care Excellence (NICE), there is a rise in mortality at stage-3, therefore,
this phase is monitored and is segmented into two additional groupings. Stage-3a – where the
kidney’s filtration rate declines from 59% to 45 % and then as the disease progresses there is a
further decline in kidney function from 44% to 30 % defining stage-3b, which is reflective and is
associated with an increase in CVD risk. Moreover, stage-3 seems to signify a standpoint of no
return in kidney function, which is further validated by the sheer number of CKD patients which
happen to be affected (Figure 1-2). In the US alone, 14.8% of the general adult population has
CKD of which 6.4% are at stage-3 [10-12].
Numerous issues can lead to kidney disease; however, the leading causes of CKD in almost
all income groups globally and responsible for two-thirds of the cases are diabetes mellitus (DM),
followed by hypertension (HTN) [7]. CKD is further exacerbated by the continuing increase in
DM, wherein 1 in 3 adults have been diagnosed. HTN is also an influencing factor, which currently
affects 1 in 5 adults and is also on the rise [13]. Further complications include obstructions to the
kidneys (caused by kidney stones), tumors, repeated urinary infections, as well as drugs that are
toxic to the kidney [14].
Patients with CKD are additionally affected by systemic syndromes such as dyslipidemia
(D), oxidative stress (OS), and inflammation [4]. Proteinuria in the urine is an indicator of kidney
damage and further increases the risk of CKD progression into end-stage renal disease (ESRD) [7,
8]. In the US, approximately 37 million Americans have CKD [13]. Disease prevalence
distribution based on the ethnicities in the US has African Americans (AA) at (18%) and Mexican
Americans-Hispanics (15%), which are the highest prevalence rate when compared to Caucasian
Americans at (13%) (Figure 1-3). Moreover, the disease amongst genders affects women (16%)
more often than men (13%) (Figure 1-3) [6]. Around the world, CKD has increased significantly
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in South Asian countries such as Malaysia where multiple-ethnicities are affected by CKD, the
percent composition is highest on the local Malays (MM) (53.7%), followed by Chinese (MC)
(21.1%), Indians (MI) (20.2%) and other ethnicities at (5%) (Figure 1-4). Gender wise, Malaysia
is similar to the US, were more women (52.1%) than men (47.9%) are affected (Figure 1-4) [15].
End-stage renal disease (ESRD) and Maintenance hemodialysis (MHD)
As CKD progresses, estimated GFR (eGFR) declines from stage 1 all the way to stage 5,
leading to kidney failure or ESRD. ESRD observed a steady rise in the US from 1980 to 2001,
which then flattened in the early 2000s. While the US has seen a steady and gradual average of a
2% rise in the incidents of ESRD, countries, such as Taiwan. Thailand, Malaysia, the Republic of
Korea, Jalisco of Mexico, Singapore, and the Philippines have experienced a 6% to 9% rise in the
incidence rate of treated ESRD (Figure 1-5) [16]. Due to obesity and other comorbidities, the
latest CDC simulation models have projected a rise between 11% % - 18% in crude incidence rate
from 2015 – 2030. Moreover, the number of ESRD patients could jump 29% – 68% during the
same period (971,000 – 1,259,000 patients) by 2030 (Figure 1-6) [17] .
According to K/DOQI guidelines, once CKD patients gradually lose kidney functions,
filtration declines and reach its final stage-5, where GFR falls to or below (<15ml/min/1.73 m2)
the least optimal working condition for the kidneys. At this stage, patients are classified to be in
kidney failure, wherein the patients need to undergo renal replacement therapy (RRT) [18, 19].
However, not all undertake dialysis treatment; since subjects may or may not have a residual renal
function with urine outputs and some clearance. Thus, patients are monitored by health
professionals for further loss of renal functions before being placed under dialysis treatment. The
most common RRT in the United States (US) is hemodialysis (HD), also termed as maintenance
hemodialysis (MHD). MHD treatment accounts for 98% of the total ESRD patients on dialysis
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today [20]. Hemodialysis is carried out at regular intervals (generally 3-days per week), serving as
a lifesaving procedure that removes toxin build-up and excess fluids in the patients’ bodies. This
is achieved via the utilization of the principles of hydrostatic pressure and diffusion across the
concentration gradient, which is the equivalent of what kidneys are responsible for (Figure 1-7
A).
Other treatments are available such as peritoneal dialysis (PD), a similar principle to HD
treatment at the dialysis centers, although PD could be conducted at home. In PD treatments,
patients’ peritoneum membrane linings of the abdominal cavity serves as the filter, which helps
facilitate the removal of waste solution and fluid. However, in this case, a sterile dialysate solution
composed of ions, bicarbonates, and glucose is introduced in the abdominal cavity via a catheter.
For several hours (4 – 6 hours), the dialysate solution helps and allows to facilitate waste exchange
across the concentration gradient before being drained and replaced by the new dialysate (Figure
1-7 B) [21]. Renal transplant is the treatment of choice for ESRD, which involves the donation of
the healthy kidney and surgically placement of the donor's kidney in the iliac fossa (Figure 1-7
C).
For years, hemodialysis has been a lifesaving procedure. However, the prevalence of
coronary heart disease (CHD) has seen an increase in these patients, and so has the mortality from
CVD events at rates 10-30 times higher when compared to the general population [5]. CVDs
account for more than 50% of the deaths in ESRD patients, due to acute myocardial infarction
(MYI), atherosclerotic vascular disease, which could be characterized by chronic coronary artery
disease, strokes, ischemic attacks, and or peripheral arterial diseases [22]. Irrespective of CVD,
other factors that lead to the development of ESRD, can be explained by the rise in DM, which is
ranked first, followed secondly by HTN and then glomerular disease (Figure 1-8). However, the
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increased mortality in this population cannot only be explained by traditional cardiovascular risk
causes alone, such as DM, HTN, advanced aging, but a combination of abnormal disorders of the
non-traditional nature such as, malnutrition, inflammation, oxidative stress (OS), dyslipidemia
(D), endothelial dysfunction, and vascular calcification have also been implicated [23, 24].
Lipid and Lipoproteins
Lipids
Lipids are defined as non-polar molecules that can dissolve other hydrocarbons; however,
are unable to dissolve in aqueous solution (water). Lipid complexes can be in fatty acids (FA)
form, waxes, phospholipids, or sterols (steroids and or cholesterol). When three FAs link
covalently to a glycerol backbone molecule via an ester bond, it leads to the formation of
triglycerides (TAG) [25]. Fats such as TAGs play numerous roles in the human body biochemistry,
since they can be stored, when in excess, in the adipose fatty tissues and can be used for energy
production (adenosine triphosphate – ATP) when required. Another function of lipids, in
mammals, is to provide protection and insulation, by preventing heat loss, as well as being good
at shock-absorbing, which serves as cushions to significant organs (kidneys, gonads, heart, liver,
and others.). Accumulated lipids such as phospholipids, glycolipids, and sterols (cholesterol) play
a significant role in cellular membrane biogenesis (making new biological membranes).
Cholesterol helps the cell membrane to maintain its fluidity. A feature and the interaction with
phospholipids of the lipid-bilayer, allows cholesterol to increases membrane packing, thus altering
the membrane fluidity and integrity of the cell membrane [26]. Moreover, cholesterol facilitates
the synthesis of steroid hormones, which assists in the absorption of the fat-soluble vitamins (A,
D, E, and K).
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Lipoprotein functions
Lipids are insoluble in an aqueous environment; therefore, they need to be packaged in a
form that will allow for transportation throughout the bloodstream. Hence for such transport to
ensue, lipids are organized into lipid-protein complexes known as lipoproteins [27]. The most
prominent lipoproteins are the chylomicrons (CM), very-low-density lipoproteins (VLDL),
intermediate-low density lipoproteins (IDL), low-density lipoproteins (LDL) and high-density
lipoprotein (HDL). While the lipoproteins differ in their functionality, they also share similarities,
specifically in the inner structure, the amphipathic phospholipid particles, which are composed of
hydrophilic polar heads and the hydrophobic nonpolar FA tails. In addition to lipids such as TAG
and cholesterol esters (CE) residing in the core of the formed sphere.
The differences in their functionality are due to the surface proteins, known as
apolipoproteins or apoproteins. These apoproteins can be peripheral or integral proteins, and many
times serve as enzymes or as ligands for cell receptors. Hence lipoproteins have a different
proportion of triglycerides, phospholipids, cholesterol, and proteins, which further differentiates
their functional roles in metabolism. CMs are primarily involved in exogenous lipid transport.
Dietary lipids are packaged into chylomicrons within the enterocyte of the small intestine and
distributed to peripheral tissues, mainly the muscle and or adipose tissues [27].
However, before CMs reach the bloodstream, they must follow the path from gut to the
blood circulation, passing through the lymphatic system by entering specialized lymphatic vessels,
knowns as lacteals, in the villi of the intestine. Once in the lymphatic system, CMs travel through
these lymph vessels and will exit at formed ducts (left or right thoracic ducts), which ultimately
empty into veins, allowing for CM to reach the circulatory system [28]. Uniquely, CMs are known
to have the largest particle size (75-1200 nm) of the lipoproteins, with the lowest density at (<
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0.930 g/mL) and are a major transporter of (90%) of exogenous TAG. Additionally, CM particles
are composed of roughly (2%) proteins, (3%) phospholipids, and (5%) cholesterol, which is
embedded in particle phospholipid and or inside its core. Moreover, due to its versatility, CMs
have many apoproteins on the periphery or integrated into the monolayer of the lipoproteins,
typified by ApoB-48 which the hallmark of CM particles, in addition to other Apolipoprotein AI, ApoA-II, Apo-IV, ApoC-I, C-II, C-III, and ApoE (Table 1-2).
While CMs play a specific role, mainly being involved in the exogenous lipid
transportation, other lipoproteins such as VLDL, IDL, and LDL function as the endogenous
transporters in delivering lipids to tissues. An additional key difference between these lipoproteins
are noted in the type of ApoB which they carry. Although both ApoB’s come from the same gene,
due genetic differentiation, ApoB-48 is made explicitly in the intestine and resides in the CMs,
while ApoB-100s are made in the liver and found in VLDL, IDL and LDL particles. When
comparing the VLDL in relation to CM particles, the VLDLs lipoprotein transports less TAG
content (60% vs. 90%), more phospholipid (14%), proteins (6%) and (20%) CE. Furthermore, the
VLDL lipoproteins have a greater particle density (0.930 – 1.006 g/mL) with a smaller diameter
(30 – 80 nm). Other important apoproteins associated with VLDL are ApoC-I, C-II, C-III, and
ApoE (Table 1-2). As VLDL goes through changes, depicted by the losses of TAGs due to
hydrolysis by lipoprotein lipase (LPL), it gains more CE, the particle converts into IDL. These
lipoproteins carry less TAG (20%) compared to CMs, and they attain an increase in phospholipids
(22%), CE (40%), and proteins (18%). Moreover, the IDL particles have a higher density of (1.006
– 1.019 g/mL), smaller particle diameter (25 – 35 nm), and are associated having ApoC and ApoE
(Table 1-2) [27, 29].
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Similar to VLDL, there are changes to IDL which are altered into LDL lipoprotein. In the
endogenous lipid metabolism pathway, LDL lipoproteins carry significantly less TAG (7%), more
phospholipid (22%), proteins (21%), and significantly more CE (50%) content, which is delivered
to tissues. The LDL has an increased particle density (1.019 – 1.063 g/mL), and smaller particle
diameter (18 – 25 nm) with ApoB-100 as the only apoprotein for the lipoprotein (Table 1-2). An
increase in plasma LDL is considered to be the “bad cholesterol;” due to having the ability to
transports cholesterol to the peripheral tissues and or macrophages where the potential for
oxidation is high, in which case can lead to the development of atherosclerosis. Although VLDL,
IDL, and LDL are commonly known to transfer lipids such as cholesterol to tissues, these
lipoproteins can also ensure the opposite; where cholesterol is transported back to the liver for
excretion. However, it is mainly the HDL lipoproteins which are commonly known as the “good
cholesterol” since it has the ability to retrieve free cholesterol and brings it back to the liver for
multiple fates for excretion, making bile acid and/or hormones. The HDL lipoproteins also are
characterized to have the highest particle density when compared to the other lipoproteins at (1.063
– 1.210 g/mL), and the smallest diameter of (5 – 12 nm). Embedded in the bilayer of HDL are
numerous apoproteins, with most prominent apolipoprotein being ApoA-I, followed by ApoA-II,
and others such as A-IV, ApoC-I, C-II, C-III, and ApoE (detail remarks on apoproteins: Table 13). Overall, HDL lipoproteins are composed of less TAG content at (5%), in comparison to other
lipoproteins, CE (25%), phospholipids at (26%), and the highest content are proteins (44%).
While the main function of the different class of lipoproteins is transportation of lipids in
the blood, they also specialize in the type of lipid transportation which are involved in, thus, lipid
metabolism can be summarized by the three key pathways: exogenous, endogenous, and reverse
cholesterol transport (RCT) [30, 31]. The exogenous transport system revolves around the use of
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CM as the lipoprotein, which helps facilitates the transport of dietary fats such as TAG, from the
intestine to peripheral tissues for either storage or energy utilization. The system is mainly active
during the time when fat-containing meals are consumed. The endogenous system involves VLDL,
IDL, and LDL lipoprotein particles, in which case the transportation of triacylglycerol molecules
from the liver during normal metabolic conditions to the peripheral tissues occurs again for storage
or energy use. Different from these two systems is the RCT pathway, which uses HDL lipoproteins
to pick up the excess cholesterol from the peripheral tissues in order to transport and deliver it back
to the liver [27].
Exogenous Lipid Metabolism Pathway
The exogenous pathway begins when food, which contains dietary fat, is consumed and
digested. Post digestion, the absorption process follows, where fat in the form TAGs are broken
down by brush borders lipases and pancreatic lipases located in the intestinal lumen [32]. The
breakdown of lipids is further assisted by the release of bile salts, which is created by the liver and
stored in the gallbladder. Bile salts are cholesterol derivatives which act both as a detergent and an
emulsification agent due to its amphipathic capabilities. This allows for easier access by the
lipases. TAGs molecules are hydrolyzed by lipases when they break the ester linkages with the
addition of a water molecule, and still within the micelles environment, leads to the production of
smaller products which are mono-, di-acylglycerols, free fatty acids (FFA), monoacylglycerol
(glycerol) and free cholesterol.
Lipid micelles particles are taken by the enterocytes, lead through various transporters, in
order to be further processed by endoplasmic reticulum (ER). In the ER, the broken lipids are then
used to resynthesize TAG, phospholipids, and CE. Following the re-synthesis of lipids in the ER,
the compounds require to be packaged before they are transported, and the process occurs by a
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carrier molecule known as lipoproteins. Specifically, the CMs are the main lipoprotein in the
exogenous system. CMs also recruit the aid of ApoB-48 proteins, which are made by the intestine.
Therefore, lipids are packaged into large, spherical TAG-rich lipoproteins along with any
other hydrophobic such as cholesterol are sequestered into the core of a protein molecule, which
has polar heads, allowing for interaction with the aqueous environment and the hydrophobic
molecules which reside in the core. The packaging occurs in the ER, with further help from ApoB48, a scaffolding protein, and by microsomal triglyceride transfer protein (MTS) another necessary
lipoprotein assembler [33, 34]. In addition to ApoB-48, several exchangeable apolipoproteins can
be found on the surface of the CM. Once CMs enter the blood via the lymphatic system, they
acquire additional apoproteins (mainly ApoE and ApoC-2), which are mostly transferred from
HDL lipoproteins through interactions in the circulation.
The entrance of the CMs in the blood circulation is a slow process, which could take up to
14 hours after consumption depending on the TAG-rich dietary food consumed. On the other hand,
plasma TAG concentration, unlike chylomicrons, usually, peak 30 minutes to 3 hours after meal
consumption and return to nearly normal within 5-6 hours [27]. The final act for the CM is the
deliverance of TAG to tissues other than the liver, but mainly muscles and adipose tissues. Once
at the surface of the targeted cell, CMs are engaged by LPL enzymes. The enzyme facilitates the
hydrolyzes of the TAG, from CM particles into FFA and 2-monoacylglycerols, which then are
taken by the cells [35, 36]. Tissues such as adipose and muscle are unable to phosphorylate glycerol
which, leads for these molecules being transferred to the serum and picked up by the liver or
kidney. As the CMs are depleted from TAG-rich lipoproteins, the molecule becomes a
chylomicron remnant, which before it is processed by the liver, it transfers the apoproteins such as
(ApoAs and ApoCs) back to the HDL particles. The CM remnants travel to the liver were a specific
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receptor; LDL receptor-related protein 1 (LRP1) is able to recognize ApoE component, which
allows for the particle to be taken entirely into hepatocytes, where hepatic lipase further hydrolyzes
the remnants CM for any leftover TAG or phospholipids.
Endogenous Lipid Metabolism Pathway
The liver is one of the essential organs, which plays a fundamental role in the management
of various metabolic mechanisms, and the endogenous lipid pathway is one of these critical
processes. When TAGs, come together with CEs, and ApoB-100, they are assembled and packaged
by the Golgi apparatus in the hepatocytes, resulting in the formation of nascent VLDL particles.
[29]. In its infant stage, the VLDL particles are composed of three important apoproteins, ApoB100, ApoC-I, and few ApoE. Once the lipoproteins are released in the circulation, the nascent
VLDLs interact with HDL particles, where apoproteins such as ApoC-II and additional ApoE are
picked up, resulting in the maturation of particle. The mature VLDL particles during circulation
are exposed to inactive LPL enzymes, which are expressed on endothelial tissues; however, it is
the ApoC-II on the lipoprotein surfaces which leads into activating the enzyme. Ultimately the
activated LPL initiates the hydrolyzes of TAG by breaking the ester bonds, which leads to the
release of generated glycerol and FA byproducts. The molecules of glycerol and FA are absorbed
in the blood by peripheral tissues depictive of adipose and muscle tissues. The compounds are
resynthesized back to TAG molecules, inside the cells, in order to be used for energy production
or storage. As VLDLs are metabolized, they are depleted of TAG, making the particle denser, in
addition to exchanging ApoC-II for more ApoE, which eventually changes VLDL into a transient
IDL particle.
The IDL lipoprotein is hydrolyzed by LPL, which leads to the loss of more TAG. It is
estimated that 50% of the IDL particles can either be taken up into the liver or the other 50%, also
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lose the ApoE [37]. This is followed by an increase in cholesterol concentration, leaving the ApoB100 as the primary apolipoprotein, thus producing the LDL lipoprotein [38]. It is worth noting that
in a transient environment, an added path can be taken by both VLDL, IDL, or any other ApoE
containing lipoproteins, which is to utilize the LDL receptor (LDLR) at the hepatocyte surface,
where via the process of endocytosis they are removed from circulation. Once inside the liver, the
VLDL and IDL are degraded by hepatic lipases were TAG and cholesterol are recycled for other
metabolic processes.
The VLDL is characterized as a TAG-rich lipoprotein, whereas the LDL lipoprotein is the
composite of the remaining lipids that were secreted by the liver, mainly phospholipids, free
cholesterol, and CE making, the LDL particle primarily a transporter for cholesterol [27, 39].
While LDL particles shrink in size as they are depleted of TAG, it only retains apolipoprotein
ApoB-100, which constitutes one per molecule. The particle size is additionally affected by the
interactions with LPL, as well as other lipoproteins where lipid exchange can occur. Therefore,
because of these multitudes of interactions, it leads to various sizes of the LDL particle, which can
range from small, intermediate or large. Many clinical studies have associated the small dense
LDL (S-LDL) as more atherogenic than larger LDL, emphasizing the importance of LDL
cholesterol removal from the blood in order to prevent the accumulation in arterial wall or tissues
[40]. Thus, clearance of the LDL from the blood is accomplished via cell surface receptors.
Specifically, the LDLR found in the liver and non-hepatic tissues which recognizes the ApoB-100.
Upon binding to the LDL lipoproteins, the particles and LDLR are internalized by endocytosis.
In the cell, the LDL particle is carried to the lysosomes, while LDLR is released for either
returning on the cell surface or recycled. At the lysosome, the LDL lipoprotein is hydrolyzed via
lysosomal enzymes into amino acids, FFA, and free cholesterol. The new influx of cholesterol has
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various metabolic fates such as bile acids, and/or hormone production. The entry into the cell also
exerts a more profound function on the cellular internal cholesterol products; it acts as a feedback
inhibitor. Largely the high amount of cholesterol acts on the rate-limiting enzyme for cholesterol
biosynthesis: HMG-CoA reductase as it suppresses the enzyme by decreasing the transcription of
the reductase gene and concurrently increases the degradation of the enzyme [41]. Moreover, part
of the cholesterol which is not used for metabolic processes is stored away in the form of CE,
where is modified by cholesterol esterification by acyl CoA: cholesterol acyltransferase (ACAT).
Lipids that have successfully been targeted by the medical and pharmaceutical community
in the past decade, have been the TC and LDL-C. The mechanism by which reduction in TC and
LDL-C has been accomplished is through targeting HMG-CoA reductase pathway and the LDLR.
Medications such as lovastatin, pravastatin, rosuvastatin, or atorvastatin are HMG-CoA reductase
inhibitors drugs which block the rate-limiting enzyme HMG-CoA reductase in the cell which is
involved in the synthesis of cholesterol via the mevalonate pathway. The low yield of internal
cholesterol forces an upregulating and synthesis of new LDLR, resulting in an increased clearance
of LDL particles from the circulation, thus lowering blood cholesterol from the body [42]. The
efficacy of statins as lipid-lowering drugs has been considered to be one of the most significant
discoveries of the decade. Notably, since it lowers LDL-C, and its use as primary prevention in
people with high risk for CVD as well as secondary prevention treatment for those who may
develop CVD [43, 44].
There are other medications such as Ezetimibe, which target cholesterol-lowering by
reducing the intestinal absorption of cholesterol; however, it is frequently combined with statins
[45]. Niacin (B3), a water-soluble vitamin is another product that lowers LDL by selectively
inhibiting hepatic diacylglycerol acyltransferase, thus reducing TAG synthesis and VLDL
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secretion [46, 47]. The use of Tocotrienols (TT), a fat-soluble compound derived from the vitamin
E family, part of the isomer, especially a delta- and gamma-TT in an in vitro setting have shown
the ability to treat high cholesterol. The gamma-TT has also shown to work as another HMG-CoA
reductase inhibitor, which reduces cholesterol production. Though there have been various
investigations in TT in examining their effects, only to conclude with mixed results [23, 48].
Reverse cholesterol transport pathway
Reverse cholesterol transport (RCT) (Figure 1-9) is the process where excess cholesterol
from peripheral tissues is picked up by the HDL particles and delivered to the liver for excretion
from the body as either bile acids or free cholesterol [27]. The RCT is a multiple-step mechanism
involving many cell surface receptors, intravascular enzymes, and transfer of lipids among
circulating lipoproteins; moreover, the cholesterol from the peripheral tissues comes back to the
liver for removal from circulation [49]. The HDL particle is raised entirely within the intravascular
space, starting with ApoA-I. The lipid-free ApoA-I is created and secreted by both liver and the
small intestine; where ApoA-I protein can also be picked up from CM and VLDL during their
TAG hydrolysis which can allow onto giving rise to new HDL particle.
ApoA-I is the major protein of HDL lipoprotein particles and plays a vital role in its
development. It serves as an acceptor for phospholipids and facilitates the cholesterol transfers
from the liver via ATP-binding cassette transports (ABCA1) which results in the formation of the
nascent HDL particle [50]. Like ApoA-I, the ABCA1 protein, not only aids in the formation of
HDL, but it is also known as the cholesterol efflux regulatory protein (CERP) which is a protein
coded by ABCA1 gene [51]. Moreover, it is known as a major regulator of cellular cholesterol and
phospholipid homeostasis. Additionally, ABCA1 mediates the cholesterol efflux between the
lipids and apoproteins such as ApoA-I and ApoE [52]. Nascent HDL acquires additional
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phospholipids and cholesterol when it interacts with other ABCA1 protein receptors in the
peripheral tissues. An undeveloped HDL particle has a discoidal shape, which retains the
amphipathic property to form a bilayer, thus more cholesterol is picked from peripheral tissues
through another receptor aside from ABCA1, which happens to be the scavenger receptor class B
type 1 (SR-B1); a receptor that is located in the peripheral tissues of muscles, adipose, and
macrophages within coronary arteries [27, 53].
The abilities for nascent HDL lipoproteins to accept cholesterol from macrophages not only
aids in the HDL particle maturation but also the removal of cholesterol from the circulation is
beneficial to the cardiovascular system. The removal of excess cholesterol leads to decreased
deposition of CE in the vascular endothelium, thus decreasing CVD or atherosclerotic events [54].
Moreover, the nascent HDL throughout this process acquires an intravascular enzyme known as
lecithin-cholesterol acyltransferase (LCAT). This is a key enzyme that helps form CE by
catalyzing the transfer of fatty acids from the sn-2 position of phosphatidylcholine to free
cholesterol within the HDL particle. Furthermore, since the CE particles are nonpolar, they migrate
to the core of the lipoprotein, thus forming a mature HDL particle.
Small spherical HDL can further interact with peripheral tissues as the ApoA-I binds to
SR-B1 and another receptor ATP-binding cassette sub-family G member 1 (ABCG1) in the
peripheral tissues where more cholesterol is acquired during the efflux transportation mechanism.
The ABCG1 belongs and is encoded by a gene which is part of a superfamily of ATP-binding
cassette (ABC) transporters; which serves as transporters that are involved in the macrophage,
cholesterol and phospholipids transportation, which further enables the regulation of cellular lipid
homeostasis [55]. On the other hand, mature HDL lipoproteins can bind to the receptor ABCG1
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(on the macrophage), but not ABCA1. Whereas both nascent and mature HDL can bind to SR-B1,
at the liver or peripheral tissue (macrophase, muscles, or adipose) for the cholesterol exchanged.
The binding to the cell receptors and continuous action of LCAT facilitates esterification
of cholesterol into CE, which allows for the new formed CE to be sequestered in the HDL
lipoprotein, thus, assisting the particle in growing in size, into a large HDL. However, due to
metabolism being very transient, there can be transfers of CE from HDL into other lipoproteins
(such as VLDL, IDL, LDL). Enabling such action between HDL and lipoproteins such as VLDL
as well as LDL, is the cholesterol ester transfer protein (CETP) enzyme [56]. CETP is in the
plasma, is a lipid transfer protein that facilitates the transport of CE and TAG between the
lipoproteins in a heteroexchange trade mechanism. It exchanges TAG from VLDL and LDL in
return for the CE from the HDL particle, in which case retains the TAG from the two lipoproteins
during the exchange, thus depleting an HDL particle of CE, which was on its way back to the liver
for excretion. Furthermore, the exchange of CE through CETP in the plasma has been associated
in reducing the size of HDL particles, which benefits the lipoprotein into making it more conducive
to the interactions with cell surface receptors, thus increasing the HDL’s ability to accept more
cholesterol for removal.
While but not always, the exchange can lead to health complications in various individuals
who are presented with metabolic syndromes featured by low HDL, and high TAG, TC, and LDL.
Such individuals are at a higher risk for developing atherosclerosis since the cholesterol, which
was meant for excretion was diverted into other pathways. When CE are relocated from HDL into
VLDL and or LDL lipoproteins, these molecules take a new path away from being unloaded to the
liver, thus, this new fate usually consists with CE being deposited into tissues, especially arteries,
where it accumulates, becoming prone to oxidation or leading to an artery blockage which further
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exacerbates the risk for cardiovascular disease [57]. Various pharmacological clinical trials have
been and are being conducted in improving HDL, by using drugs to inhibit CETP (CETP inhibiting
such as a Torcetrapib agent) [58]. However, studies with mortality and decline in cardiovascular
events have primarily been inconclusive with disappointing results [59].
One more critical regulatory protein in RCT metabolism is protein phospholipid transfer
protein (PLTP), found in the human plasma, which helps to facilitate the transfer of phospholipids
or excess of surface lipids from TAG-rich lipoprotein to HDL. PLTP, including CETP, belongs to
a family of lipid transferring lipopolysaccharide-binding proteins (LBP) and a bactericidal
permeability-increasing protein (BPI). It is worth noting that besides cholesterol and
phospholipids, PLTP also has the ability to transfer diacylglycerols and alpha-tocopherol,
cerebroside, and lipopolysaccharides thus, the reason why is portrayed as a nonspecific lipid
transfer protein. In the plasma, there are two forms of PLTP, that play important roles in lipid
metabolism; the active form which has been associated with ApoA-I, whereas the inactive form
has been linked to the ApoE [60]. Hence, the activity of PLTP has lead to the formation of smaller
lipoprotein remnants, which form into LDL. On similar roles, like CETP, PLTP helps to facilitate
the maturation of HDL particles, as well as regulate the size and composition of the HDL
lipoprotein which is crucial to the plasma HDL-C levels in the blood [61]. Further actions by PLTP
in lipid metabolism are to assist into the uptake of cholesterol for periphery tissues in the which
are transported for degradation and excretion by the liver. Other linked interactions with ApoA-I
and ApoA-II have shown that PLTP seems to exert effects onto the apoprotein lipidation as well
as nascent HDL biogenesis in the hepatocytes, by stimulating the ABCA1 efflux and remodeling
of nascent HDL particles [62-64].
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The final step in RCT is the binding of HDL to SR-B1 receptor on the surface of the
hepatocytes. Upon binding and removal of CE from the particle core, the HDL lipoprotein enters
a two fate pathway. One possible fate, for the HDL lipoproteins, once the cholesterol is removed,
is on being released in the circulation for reuse in the collection of more free cholesterol, or the
entire HDL lipoprotein is internalized and degraded in the lysosomes similar to the degradation of
LDLR. Once internalized for degradation, CE molecules are hydrolyzed by cholesterol ester
hydrolase enzymes, thus freeing the cholesterol and directed by the liver for bile acid production
or the formation of steroidal hormones.
RCT mechanism and disease complications
In general, HDL is perceived to function as atheroprotective particles, which promotes
RCT, induces cholesterol efflux from peripheral tissues such as macrophages foam cells that are
taken into the hepatocytes in a known process that is considered to be beneficial to cardiac health.
However, this process appears to be compromised in MHD patients. Various studies in MHD
subjects have linked HDL particles being defective and compromised, a link which is further
exacerbated by dysregulation of lipid metabolism, which has been associated with the
dysfunctionality activity in RCT [65]. Other key modulators in the RCT pathway believed to be
affected are the LCAT enzymes. Under normal conditions LCAT is involved in HDL maturation
to a spherical-shaped particle; however, in ESRD patients, the enzyme has shown low activity. A
decreased LCAT activity is problematic since it has been associated with the formation of nonmature or smaller HDL particles. The non-mature HDL lipoproteins have been linked in being
ineffective in performing regular RCT functions. Therefore, this would impede the HDL-mediated
RCT pathway of disposing of excessive cholesterol from extrahepatic tissues and walls of the
blood vessel [66].
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While not conclusively, but it is hypothesized that MHD patients have HDL particle
impairment, which could lead to lack of particle maturation, thus lipoprotein dysfunction, and this
could be due to the downregulation of LCAT as well as increased CETP activity [67]. Additional
plasma CETP has shown to play a vital role in RCT, evidenced by the upregulated levels of this
enzyme that increases the transportation and exchange of TAG in VLDL or LDL in return for CE
from HDL. Other compromised key modulators in RCT metabolism are the efflux genes such as
ABCA1, ABCG1, LXR-α, SR-B1 (Table 1-4), and the influx of downstream related genes CD36,
LOX01 and or SRA1 (Table 1-5) [68-70]. Multiple pathways are affected; thus, additional studies
are needed to determine what else may increase the risk for CVD events. Therefore, it is imperative
to understanding HDL metabolism, specifically how RCT may be impacted by D in ESRD patients
undergoing hemodialysis. As is currently understood, dysfunctional RCT in MHD patients is
characterized by increased levels of TAG, elevated VLDL, IDL, as well as CETP activity and
ApoB-100 protein; whereas TC and LDL-C lipids can be either normal to marginally decreased.
Moreover, the HDL-C levels are noted to be decreased, so are the ApoA-I levels, and similar
LCAT activities are downregulated as well (Figure 1-10).
Furthermore, TAG enrichment of HDL particle could be multifactorial; the transfer of CE
occurs between other lipoproteins, apart for CETP being a culprit which facilitates this exchange.
It is believed that another influencer has been linked and identified and that being the hepatic lipase
(HL), which serves as a catalyst in the hydrolysis of TAG. However, mutations in the HL gene
leads to an enzyme deficiency, an event that ultimately results in an increase in TAG level and
increased risks for CVD. Moreover, HL facilitates the clearance of TAG from VLDL.
Additionally, HL function is further regulated and controlled by the quality and composition of
HDL lipoprotein, which in MHD patients is presented by declined HDL levels. Additionally, HDL
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regulates the release of HL enzyme from the liver, and the enzyme activation occurs in the
circulation for which case is transported by the HDL particles [71].
Patients affected by CKD and ESRD present with hypertriglyceridemia, impaired
clearance of TAG-rich lipoproteins and their remnants, abnormal composition are all chiefly due
to the downregulation of LPL, HL, VLDL-receptor, LDL-receptor in conjugation with a
concurrent upregulated hepatic ACAT [67, 72]. Conversely, an impaired HDL metabolism
contributes to the disturbances of TAG-rich lipoprotein metabolism. Intensifying the dysfunction
in HDL metabolism for the MHD patients is the downregulation of the apolipoproteins (most
abounded protein in HDL particles) ApoA-I, ApoA-II, and ApoC-II [67]. When evaluated together
with these abnormalities of the malnutrition-inflammation complex syndrome (MICS), coupled
with OS, inflammation, and D, it makes it highly conducive to exacerbate atherosclerosis in HD
population.
Dyslipidemia in Lipid Metabolism
MHD patients on dialysis are also affected by the systemic syndromes known as D [4]. It
is an intrusive factor, similar to malnutrition and inflammation with a high association with CVD
and increased mortality [73]. The term D is defined as dysregulation of lipid metabolism, which is
marked by abnormalities in plasma lipids, lipoproteins as well as other lipid-related parameters,
including associated enzymes. While the subject of D is not fully understood, more work is
required in order to comprehend the overall extent of this dysfunction. Exacerbating the issue is
the fact that there is limited knowledge, which is due to the low volume of clinical studies.
However, a general hypothesis, by understanding lipid metabolism have been advanced on how D
may affect lipids, lipoproteins, and enzyme at different stages of the disease Table 1-1 [72, 74].

21

In CKD, the primary complication due to D is associated with the metabolism of HDL and
TAG-rich lipoproteins resulting in low HDL-C and elevated TAG [75, 76]. Moreover, the plasma
concentration of apolipoproteins A-I and II are reduced, whereas ApoA-IV is increased. The
HDL/TAG ratio and pre-β1 HDL (a discoid-shaped HDL particle), which contains ApoA-I,
phospholipids, unesterified cholesterol, are elevated, and this due to the impaired maturation of
the HDL particle. The failure for the improperly developed HDL particle leads to the impairment
of RCT, which is analogous to the decline in HDL-C levels [75, 77]. Furthermore, linked to the
decline in HDL-C concentration are two RCT enzymes: CETP, which its activity is seen to be
elevated, while LCAT enzyme activity is decreased [72, 74]. Additional lipid parameters affect
are shown in (Table 1-1).
As CKD advances to ESRD, the lipid parameters also change. In ESRD patients
undergoing hemodialysis, lipid parameters for LDL-C and TC are normal or decreased, whereas,
in CKD, they are elevated. In both CKD and ESRD, IDL, VLDL, Lp(a), small-dense LDL, and
TAG levels are increased. Irrespective of the disease state, HDL-C levels are decreased in the
MHD patients analogous with CKD patients. Non-HDL-C and ApoB are either normal or
decreased in ESRD when compared to CKD, which are elevated. As for the reverse cholesterol
transport enzymes, CETP is increased, and LCAT is decreased in ESRD, as well as in CKD
patients (Table 1-1). ESRD patients have an accumulation of oxidized lipids, lipoproteins
followed by low plasma HDL-C along with impaired HDL maturation and function [78]. Impaired
synthesis and activity of HDL and the delayed catabolism of TAG-rich Apo-B containing
lipoprotein subsequently leads to elevated TAG and low HDL-C levels [67]. The rise in TAG
levels can be additionally explained by the impaired clearance of VLDL, IDL, and the
accumulating CM remnant which, too, are accompanied by a significant increase in plasma ApoC-
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III (a potent inhibitor of LPL) and reduced ApoC-II the activator of LPL [67, 79]. The Framingham
Study recommended desired lipid parameter ranges reflective of moderate (too low) TAG levels;
high HDL-C followed by lower LDL-C because it was shown to be protective against CVD.
However, the recommendations were indicative of the general population [80].
ESRD patients are challenged by a phenomenon known as “reverse epidemiology,” in
which parameters such as high HDL-C and low LDL-C plasma concentration may not be as
protective when compared to their healthy counterpart [81]. Various studies have examined how
to control DL by raising the HDL and stabilizing the remainder of the lipid profiles. Kilpatrick et
al. (2007) found that serum HDL-C showed no clear association to improve or worsen survival
however, patients presented with elevated TAG showed improvements in survival between
concentrations levels of 200-250 mg/dL and above 250 mg/dL mortality rates increased, likewise
LDL-C levels of < 70 mg/dL was associated with low survival. This phenomenon of high TAG
and low LDL-C affects AA patients as well; however, elevated serum LDL-C (>100 mg/dL)
showed a two-fold risk for CVD, unlike others [82]. On the other hand, Moradi et al. (2014) found
that increases in HDL-C concentration up to 50 mg/dL was favorably associated with a reduction
of CVD and mortality.
Nonetheless, incremental increases in HDL-C of greater than 50 mg/dL were paradoxically
associated with increased deaths [83]. These findings were further validated by Chang et al. (2018)
in a large MHD cohort, which found that incremental increases in serum HDL-C over 5-years did
not associate with the improved outcome on cardiac incidents [84]. There has been evidence that
serum parameters such as non-HDL-C are more accurate predictors for CVD outcomes compared
to LDL-C. Chang et al. (2018) looked into the inverse association between serum non-HDL-C
levels and mortality in patients undergoing dialysis, and reported the decline in non-HDL levels
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(< 100 mg/dL) in addition to the reduced non-HDL/HDL-C ratio (< 2.5) showed paradoxical
association with increased all-cause of mortality [85]. High TAG/HDL ratio in the general
population has been associated with risk, however, in HD patients, Chang et al. (2017), found that
elevated TAG/HDL (ratio ≥ 3.64) when compared with a (ratio < 3.64), the latter had a higher allcause and CV mortality rates. The findings heighten the importance of qualitative in addition to
quantitative evaluation of lipids and lipoproteins in the ESRD population [86]. The 4D study (Die
Deutsche Diabetes Dialysis) revealed that the quality of HDL and LDL composition and function
might be more critical than their serum levels. Studies suggest that lipoproteins may serve as a
biomarker to assess disease; thus, these metabolic proteins can be used in order to discover new
therapeutic and diagnostic tools [87].
HDL controversy
HDL-C is recognized as “good cholesterol,” which is protective against CHD. In the
Framingham study between 1969 and 1971, it was established that HDL in both genders had an
inverse association with the incidence of CHD, thus, considered to be protective [80].
Epidemiological studies have further associated the low HDL-C levels as an independent risk
factor, and irrespective of LDL-C levels, this is considered to be adverse in attaining CVD
outcomes [88]. Moreover, lower concentrations of HDL-C has been recognized to be problematic
in both genders and a potent predictor of CHD death, in men with HDL-C less than 40 mg/dL and
women less than 50 mg/dL [88, 89]. Such findings were further reinforced by various
observational studies throughout the world which have demonstrated that an increase in serum
HDL-C levels can be beneficial, by reducing the risk for CHD, even so, many investigations have
cautioned this belief by stating that further studies were required for verification [90, 91].
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Furthermore, data generated through various meta-analysis studies, in association with
understanding HDL metabolism, and its role in RCT pathway, combined with various computer
models, have confirmed a positive correlation in raising HDL being correlated in the removal of
cholesterol thus, decreasing CVD rates [92]. With no clinical trial intervention to verify the result
of HDL protective effects, the pharmaceutical companies entered into the picture, where studies
were initiated with the sole purpose of increasing HDL via pharmacological treatments. While the
general thought has been that HDL is inversely related with CVD, several failed clinical trials have
created doubts on whether HDL has the capacity in being protective and whether if it still attains
the capacity to conduct RCT in patients with hypercholesterolemia in order to facilitate the
removal of cholesterol and decreasing CHD for those at risk [91]. Clinical trials that used fibrates,
niacin, or CETP inhibiting drugs, have shown non-conclusive or at best-scattered results in some
patients [93].
Interventions that looked at genetic outcomes of raising HDL observed no association in
reducing the risk of an MYI [94]. Various clinical studies have investigated statin drug use as a
way to raise HDL-C levels. In rare cases an increase in HDL-C levels was recorded; however,
these effects have been inconclusive in a clinical setting, although beneficiary in decreasing LDLC [95]. In the ENHANCE clinical trial, ezetimibe was combined with simvastatin, resulting in
lower LDL-C and raising HDL-C levels; however, the safety and efficacy of the drugs were not
determined, thus raising concerns in endorsing prolonged use [96]. Most noted failure in raising
HDL-C came through a pharmaceutical intervention when Pfizer, shut down its phase III clinical
trial of torcetrapid, a CETP inhibitor since the drug reported to have compromised patients' safety
negatively [97].
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While the focus for many years has been to raise the HDL-C, doubts due to non-conclusive
results raise scrutiny in whether high HDL-C is good and/or protective. This is a further issue in a
population of ESRD patients where D has been linked to being a factor that contributes to the
formation of dysfunctional HDL particles. Moreover, impaired HDL particles have been
associated with lower antioxidant activity, as well as a decrease in anti-inflammatory protective
effect; therefore, serum HDL-C has been relegated in being not a dependable indicator for a CVD
[66]. In CKD subjects, a U-shaped association between serum HDL-C levels and mortality has
been observed; similarly, in ESRD subjects, a J-shape association between HDL-C and mortality,
has been noted. Nonetheless, in both populations, CKD and ESRD increased serum HDL-C
overtime is linked paradoxically with outcomes worsening in the patients' mortality [84]. This,
suggests a window where lower than<30 mg/dL and higher than ≥60 mg/dL of HDL-C levels may
be detrimental, and additionally, associated with changes in the lipoprotein functionality [98].
The failed clinical trials in rising HDL-C safely, combined with data results which
demonstrated that higher serum HDL-C (≥60 mg/dL) could negatively impact patients' health.
Therefore the focus has shifted to where HDL lipoprotein functionality could be more important
than the circulating concentration levels itself. It has been postulated that HDL functionality plays
a critical role in protection against atherosclerosis than the general HDL-C concentration levels.
Furthermore, what makes such particle atheroprotective, are the antioxidant properties, antiinflammatory, antithrombotic, and cytoprotective function [99].
HDL particles are noted in being protective against CHD; additionally, this protection
extends to the LDL particles from inhibiting the generation of proinflammatory oxidized lipid,
thus helping in preventing its oxidation. Serving as a protective mechanism to the HDL particle
from becoming oxidized or dysfunctional from exposure to a disease state and or inflammation, is
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paraoxonase 1 (PON1) hydrolytic enzyme. PON1 is known as an esterase, homocysteine
thiolactonase enzyme which is encoded by the PON1 gene [100].
Itself the enzyme is considered to be an antiatherogenic component of HDL, which is
highly associated with the lipoprotein and their functional outcome, and its antioxidant properties
are protective agents against CHD [101, 102]. It is activated by peroxisome proliferator-activated
receptor gamma (PPAR-γ), a nuclear receptor, which has been implicated various metabolic
pathways, in and has been associated with numerous disease; from obesity to DM; nonetheless, it
has also been used in the treatment of hyperlipidemia and hyperglycemia [103]. An added property
of PPAR-γ is its ability to decrease inflammatory response in many cardiovascular cells, such as
endothelial cells; as well as to increase the synthesis of paraoxonase-1 from the liver, and like
PON1, the PPAR-γ has been linked to reducing atherosclerosis [104]. PON1 has been investigated
in various clinical settings, and its relevance was depicted by Azarsiz et al. [105] and Sharma et
al. [106], which demonstrated that serum PON1 activity was significantly low in CHD patients,
thus congruently affecting the HDL and its functional behavior.
For LDL particle fractions, based on several investigations, there is strong body of evidence
that suggests that small dense LDL (S-LDL) particles are more atherogenic than larger buoyant
LDL particles (L-LDL). This is because S-LDL fractions have an enhanced ability to penetrate the
arterial wall, which leads to the development of atherosclerotic plaques [107]. On the other side,
there are the HDL particles. Wherein could be classified into two subfractions, large buoyant HDL
(L-HDL) and small dense HDL (S-HDL).
While the LDL subfractions have a strong body of evidence in the relevance to a clinical
setting pertaining to CVD; evidence on the large, and small-HDL is unclear and controversial.
Results from two studies the IDEAL (Incremental Decrease in End Points through Aggressive
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Lipid Lowering) trial, and the EPIC (European Prospective Investigation) a case-control study,
which showed that elevated plasma HDL-C levels (≥70 mg/dL) and the L-HDL particles were
associated with a higher risk for CVD. In contrast, the S-HDL particle has shown that it may be
more functional thus, more efficient in promoting cholesterol efflux from macrophage to remove
excess cholesterol [108].
The S-HDL also exhibiting more antioxidant capacity, anti-inflammatory properties,
antithrombotic, and anti-infectious activity when compared to the L-HDL particles. Moreover,
irrespective of the two lipoproteins, higher levels of ApoA-I in the plasma uniformly show a lower
risk for a CVD event [109]. Studies that used CETP inhibitors and niacin have displayed evidence
to increase the levels of L-HDL [108, 110]. In this case, data from experimental studies also
showed a cholesterol overload HDL, which happens to be abnormal, thus have an impaired
antiatherogenic potential and presents with a negative effect on the efflux potential [111].
A retrospective meta-analysis study by Pirillo et al. (2013) agreed upon the fact that the
functionality of HDL may be more significant than HDL-C levels. However, these findings
revealed that due to dyslipidemia, L-HDL levels are decreased whereas S-HDL particles were
increased in CHD patients [112]. A study by Pascot et al., (2001) looked into reducing HDL
particle in relation to D due to abdominal obesity; to discover that men presented with more LHDL, had a more favorable plasma lipoprotein-lipid profile when compared with the S-HDL
lipoprotein particles. Additionally, these men with higher levels of L-HDL were also observed to
have reduced adiposity, lower visceral fat, and reduced insulin-glycemic response [113]. In
patients who have CKD and ESRD, data is scarce and so are the clinical trial, in attempting to
understand the functional role of HDL particle size in preventing CVD.
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Non-traditional disorders
Malnutrition
Malnutrition is characterized as irregularities in forms of fatigue, loss of body weight
accompanied by losses of lean muscle mass that are replaced by fatty tissues, a decline in body
mass index (BMI), and a decrease in serum proteins [114, 115]. Approximately 18-75% of CKD
patients undergoing MHD are presented with evidence of wasting syndrome, often referred to as
uremic cachexia, or MICS or protein-energy wasting (PEW), all of which are a strong predictor
for adverse outcomes [116-119]. Kidney disease is also accompanied by metabolic acidosis, which
irreversibly destroys the essential branched-chain amino acids (BCAA), proteins, and muscle
protein, which leads to low levels of serum albumin (hypoalbuminemia) [115]. Serum albumin
serves many functions that help maintain intravascular colloidal osmotic pressure and
hypoalbuminemia, where is a key nutritional marker used to identify malnutrition [120].
Inflammation
The elevated inflammation levels are additional critical issues that confront both
individuals who are affected by CKD as well as MHD patients. Inflammation is a biological
response instigated by stimuli such as injury, pathogen invasion, cell damage, or irritants, and in
kidney disease, this is caused due to many factors, associated explicitly with nephron damage
[121]. Within physiological limits, an inflammatory response facilitates the removal of the inciting
agent and initiates the healing process [122]. Many studies have been conducted to understand the
role of inflammation in the CKD population Armdur et al. 2016 [123] found that elevated plasma
levels of fibrinogen, interleukins (IL-1, IL-6) and cytokines (TNF-alpha) are involved in the
systemic inflammatory mechanism, and these markers have been linked to a faster decline in eGFR
which corresponds to the progression CKD into ESRD [123].
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Moreover, systemic inflammation is highly prevalent among CKD and HD patients and
has been associated with a high mortality rate due to the development and progression of CVD in
subjects undergoing hemodialysis [124-126]. In the ESRD population, inflammation is
characterized as a multifactorial and an underlying reason for the development of CVD. An acutephase protein (reaction) has been associated with causing vascular injury by several pathogenetic
mechanisms directly. Available data suggests that proinflammatory cytokines also play a central
role in the genesis of both malnutrition and CVD in ESRD [127].
Furthermore, the inflammation response in ESRD patients is a multifactorial stimuli event.
Some of the influencers are typified by: hypoalbuminemia, malnutrition, advanced oxidation of
protein products, atherosclerosis, uremia, anemia, dialysis vascular access infection, obesity, and
the elevated activity of the thiobarbituric acid reactive system (TBARS) which leads to the
upregulation of multiple pathways, giving rise to inflammation [128]. Elevated inflammation
contributes to the progression of CKD by inducing the release of cytokines, which in turn leads to
increased production and activity of adhesion molecules. This leads to T-cell adhesion, which
migrates into the interstitium, and subsequently attracts pro-fibrotic factors [128]. The prolonged
exposure to pro-inflammatory mediators with the concurrent build-up of pro-fibrotic factors, in
turn, secretes high levels of matrix metalloproteinases, and other extracellular matrices proteins,
followed by degrading enzyme, that converts fibroblast into fibrosis tissue. These fibrotic and
connective tissues matrixes accumulate over time and breach the smooth muscles of the heart
[129]. Over time a constant pressure of the ventricular contraction causes the weakening of the
structural integrity of the heart muscle, followed by the loss of strength in the fibrotic matrix, that
leads to compromised ventricles chamber matrix. This ultimately caves and results in MYI or
rupture [129].
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A systemic review by Agrawal et al. (2015) looked at the importance of both
pharmacological and non-pharmacological strategies in the management of coronary artery disease
in CKD and in dialysis subjects for what could improve the outcomes in the populations' mortality
[130]. However, evidence showed that therapeutic options presented may be helpful only in a set
of patients with CHD in the general population, but not beneficial in subjects with advanced CKD.
Other studies have examined the effects of antioxidant therapy on markers of inflammation and
OS with mixed results. A study by Ikizler et al. (2013), in a placebo-controlled, double-blinded
(PATH) clinical trial intervened for 6-month using a combination of mixed tocopherols (666 IU/d)
plus a-lipoic acid (ALA; 600 mg/d) looking at the inflammatory markers and OS in MHD subjects.
Results showed a non-significant decline in high-sensitivity C-reactive protein (hsCRP), IL-6
concentration, F2- isoprostanes, and isofurans, biomarkers for OS [131].
Since inflammation plays an essential role in the etiology and outcome of atherosclerosis,
one prominent maker is C-reactive protein (CRP). Made in the liver, the ringed-shaped pentameric
acute-phase protein circulates the blood. Furthermore, the protein is activated due to response to
inflammation, which is followed by the increases of interleukin-6 (IL-6), who is further secreted
by the macrophages and T-cell. Also, the CRP as a marker is well recognized not only as a
predictor of inflammation, but CRP categories were significantly associated with all-cause
mortality [132, 133]. Various studies correlate that elevated CRP concentrations ( > 3 mg/L) with
cardiovascular deaths in the general population and dialysis patients.
Moreover, HD patients are 5- to 10- fold higher at risk of such events than their healthy
counterparts [134, 135]. A study by Panichi et al. (2008) followed 757 HD patients for 30 months
to understand the relationship between hsCRP, IL-6, IL-8, and serum albumin in relation to
mortality and morbidity. It was concluded that CRP was the most powerful predictive factor for a
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cardiac event even after adjustments for age, DM comorbidity and BMI, that individuals who
present with CRP plasma levels > 5 mg/L were at higher risk for all-cause [136].
Oxidative stress
Another issue that both CKD and ESRD patients face is OS, which has been linked to the
development of atherosclerosis within the population [137]. OS is defined as an imbalance
between pro- and anti-oxidant systems and is elevated in these patients compared to the general
healthy population [138]. In HD patients, OS is attributed to increased reactive oxygen species
(ROS) production, reduced clearance, a poor antioxidant defense system, which is associated with
CVD by propagating the oxidation and modification of lipids and lipoproteins such as LDL and
proteins [139, 140]. Oxidized LDL (oxLDL) can promote and initiate a cascade of reactions,
including adhesion of circulating monocytes on the endothelial cell. This leads to migration of the
monocytes into the arterial intima, followed by platelet activation, and concomitantly the
expression of tissue factor and(plasminogen activator inhibitor 1) PAI-1 by endothelial cells [139,
141]. Foam cell formation in the macrophages at the arterial walls has also been linked to the
pathogenesis of atherosclerosis. This is due to increased uptake of oxidized lipids such as oxLDL,
which have also been associated to decrease SR-B1 expression and lipid flux while at the same
time facilitate the increase of class B scavenger receptor CD36 [142, 143]. Boaz et al. (2000) in
the SPACE clinical trial were able to show that 800 IU/day of vitamin E (an antioxidant), in a
cohort of MHD patients, could reduce composite CVD endpoints and MYI [144].
OS additionally is implicated in the etiology of other confounders, such as advanced
glycation end-products (AGEs) [145], which are pro-oxidative and pro-inflammatory compounds.
[145]. In general, AGEs are formed by the Maillard-reaction after initial binding of aldehydes with
amines or amides in heated food or in living organisms [146]. Furthermore, AGEs can be derived
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from glucose-protein or glucose-lipid interactions, implicated in diabetes, and aging [147]. They
are created through a nonenzymatic reaction between reducing sugars and free amino groups of
proteins, lipids, or nucleic acids. AGEs are not only produced endogenously, but they can also be
obtained through exogenous sources such as diet (dAGEs). The dAGE are produced due to high
temperature, boiling, broiling, frying, and roasting of the foods.
Moreover, AGEs in the plasma have been associated with increased risks for higher OS
and inflammation that are further linked with DM and higher risk for CVD events [148]. The
pathologic effects of AGEs are mainly related to their ability to promote OS and inflammation by
binding with cell surface receptors or cross-linking with proteins, which leads to the alteration of
structures and functions [149]. Nε-carboxymethyl-lysine (CML) are among the better-studied
AGEs due to its compound stability, which can be measured in the plasma and analyzed via dietary
records [150]. Moreover, it has also been suggested that in hemodialysis subjects, AGEs could
accumulate due to uremic status as a consequence of diminished clearance. This has drastic
consequences for the patients because it may accelerate vascular disease, renal failure progression,
and dialysis-related amyloidosis [151, 152]. Lopez-Moreno et al. (2016) found that the
Mediterranean diet, supplemented with coenzyme-Q10 in elderly men and women showed a
decline for CML protein adducts in the plasma [153]. Nevertheless, further investigations specific
in the ESRD-MHD population is needed to validate such findings.
Antioxidant studies
Tocotrienol rich-fraction (TRF) is part of the vitamin E family, comprising of eight
isomers. Tocopherols (TP) and tocotrienols (TT) have four isomers α-, β-, γ-, and δ- characterized
by different numbers and positions of the methyl group attached on the chromanol ring [23]. Unlike
TP’s which have a saturated aliphatic tail, TT’s have an unsaturated chain tail [154]. Additionally,

33

TT’s have a superior antioxidant activity than TP due to their trans-double bound (at 3’, 7’, and
11’ positions ) [155]. TTs have gained significant attention due to their diverse capabilities in being
cardioprotective, anti-atherosclerotic, anti-hypercholesterolemic, anti-cancer, anti-diabetic,
neuroprotective, linked in the regulation of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
(HMG-CoA reductase), as well as being lipid-lowering, and having anti-oxidative properties [154,
156]. Currently, in the United States, TT’s have a GRAS chemical recognized status [157, 158].
TRF supplementation on ESRD patients for 16 weeks, showed that TT help to normalize
triglyceride (TAG) levels, increase HDL-C concentration, and ApoA-I levels, and decreased in
CETP in the TRF group. As for nutritional, inflammatory, and oxidative status, the answer to these
parameters is unresolved [23]. Other reviews have emphasized the effects of TT in being able to
reduce CRP and AGEs levels [155]. In a six month intervention by Heng et al. (2013)
supplementing with TT in healthy young (32±2 yrs.) and older (52±2 yrs.) adult volunteers,
resulted in lower CRP levels, a prognostic indicator for CVD [156]. A six-month study by Chin et
al. (2011) in healthy elderly adults supplemented with palm oil derived TRF found improvement
in plasma cholesterol, increased HDL-C, and reduction of AGEs as well as reduced protein damage
[159]. It has been postulated that TRF has the ability to suppress and stimulate ubiquitination and
degradation of HMG-CoA reductase, in addition to blocking the processing of sterol regulatory
element-binding proteins (SREBPs) which has been demonstrated in vitro studies' [160, 161].
SREBPs are membrane-bound transcriptional factors which bind to sterol regulating elements in
the DNA sequence, which plays a critical role in the synthesis of enzymes involved in the sterol
syntheses, therefore a key regulator in cholesterol metabolism [162, 163]. Noted regulation by
SREBPs via the feedback system is the transcription of HMG-CoA reductase, as well as other
enzymes in the cholesterol biosynthetic pathway [163].
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Many interventions have tackle ESRD abnormalities by targeting inflammatory and
oxidative status parameters, and some studies have been successful (SPACE) and others (PATH)
with mix results. In a previews pilot study by our group, we used tocotrienols rich fractions (TRF)
supplementation in a small cohort, which showed positive results on D, OS, and inflammation
[23].
The rationale for the study
Both CKD and ESRD patients experience accelerated atherosclerosis driven by
multifactorial abnormalities such as malnutrition-inflammation complex syndrome, oxidative
stress, protein energy-wasting, impaired antioxidant system, and D. Several other factors including
the presence of proteinuria, dietary restrictions, pharmacological therapy, genetics, disorders of
lipid metabolism and abnormal lipids further exacerbates the progression of CKD into ESRD
which has been associated with mortality 10-times higher than in the general population. In the
last decade, much research has been conducted to understand the pathophysiology of these
disorders; however, the various strategies to correct these problems have been inconclusive. In
MHD patients, D is primarily the result of decreased HDL and increased TAG with normal and/or
increased LDL. However, the contribution of each of these parameters to D is poorly understood;
moreover, the contribution of the following parameters to D in different ethnicities is unknown.
Hence, the objective of this study is to characterize D in a multi-ethnic cohort of ESRD patients
undergoing MHD.
The current investigation is a snapshot in time, (baseline data analysis only), in a subset of
MHD patients, partaking in PATCH USA and Malaysia clinical trial. The primary study is a 1year trial, double-blinded, placebo-control intervention using Vitamin E Tocotrienol Rich Fraction
(TRF) an antioxidant supplement for which subjects receive for consumption 2 capsules, each 150
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mg of daily (tocotrienols or placebo) for a total 300 mg. Tocotrienols (TT), are isomers of vitamin
E, having anti-inflammatory and antioxidant properties which in some cases are superior to those
of tocopherols. Previously, TT was shown to improve D over 16-wks in a pilot study, but the
effects on lipoprotein subfractions, inflammation, and OS were unresolved [23].
The central hypothesis of this study is that D amongst MHD patients of different ethnicities
will reflect underlying alterations in lipoproteins and enzymes of lipid metabolism. The rationale
for the proposed study was that once a dyslipidemic MHD profile is determined, targeted
interventions could be used to manage D.
Specific Aims
Specific Aim 1): To document the degree of dyslipidemia in a cohort of MHD patients and
characterize lipids, and lipoprotein particle compositions and associated enzymes of lipid
metabolism.
 The analysis is depictive of baseline plasma samples (n = 123) from African American
(AA) MHD patients participating in the PATCH USA clinical trial (NCT02358967).
 In this study, we measured lipids, characterized lipoprotein subfractions, and examined
lipid metabolism enzymes: CETP and LCAT.
 D was assessed based on criteria from the Adult Treatment Panel (ATP III) guidelines,
using the category TAG/HDL-C ratios (≥ or < 3.8).
Specific Aim 2): To characterize dyslipidemia across a multi-ethnic cohort of MHD patients.
 Examined baseline plasma samples of (n = 225) from the PATCH Malaysia study
(NCT02913690). A cohort composed of three ethnicities: Malaysian-Malays (MM),
Malaysian-Chinese (MC), and Malaysian-Indians (MI).
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 D was assessed based on criteria from the Adult Treatment Panel (ATP III) guidelines:
TAG/HDL-C ratio (≥ or <) 3.8. Ratios are based on ATP cut-offs of < or ≥ 150 mg/dL for
TAG and < or ≥ 40 mg/dL for HDL-C.
 Data from the Malaysian cohort (comprising MC, MI, and MM) will be compared with the
US cohort of AA patients.
Specific Aim 3): To document the extent to which HDL enzymes contribute to dyslipidemia in
MHD patients.
 Plasma samples from the US cohort and Malaysian cohort were analyzed to determine
enzymatic activity in:
 Cholesteryl ester transfer protein (CETP)
 Lecithin-cholesterol acyltransferase (LCAT)
 The key enzymes which play a role in the HDL RCT pathway were analyzed to understand
the role played in association with lipids and lipoprotein subfractions.
 C-reactive protein marker was analyzed in all ethnicities to determine the degree of
inflammation between the cohorts and the multi-ethnicities.
 Exclusively for PATCH USA, a subset of the samples were measured for Nεcarboxymethyl-lysine (CML), to discern levels of advanced glycation end-products
(AGEs) in the plasma since is recognized as an oxidative stress marker.
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Tables Chapter 1
Table 1-1: Dyslipidemic characteristics in lipid parameters for different CRF conditions.
CKD
(1 – 5)

ESRD-MHD
Hemodialysis

Nephrotic
Syndrome

PD

RT

TC

↗

↔ or ↓

↑↑

↑

↑

LDL-C

↗

↔ or ↓

↑↑

↑

↑

HDL-C

↓

↓

↓

↓

↓

Non-HDL-C

↗

↔ or ↓

↑↑

↑

↑

TAG

↗

↑

↑↑

↑

↑

Lp(a)

↗

↑

↑↑

↑↑

-

IDL

↗

↑

↑

↑

-

VLDL

↗

↑

↑

↑

↑

Sd-LDL

↗

↑

↑

↑

-

ApoA-I

↘

↓

↗

↓

-

ApoA-IV

↗

↑

↑ or ↘

↑

-

ApoB

↗

↔ or ↓

↑↑

↑

-

CETP

↑

↑

↑

-

-

LCAT

↓

↓

↑

-

-

Parameters

Symbols: Increase (↗) and decrease (↘) in plasma levels with decreasing GFR; Increase (↑), markedly increased (↑↑)
and decrease (↓) plasma levels compared with non-uremic individuals, (↔) normal, (-) data inconclusive.
TAG: Triacylglyceride; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; LDL-C: low-density
lipoprotein cholesterol; NonHDL: Non-high-density lipoprotein cholesterol: ApoA-1: apolipoprotein A-1; ApoA-IV:
apolipoprotein A-IV; ApoB: apolipoprotein B; S-LDL: small dense LDL CETP: cholesterol ester transfer protein;
LCAT: lecithin-cholesterol acyltransferase.
Adopted source: Society of Nephrology. Kwan BCH. [5, 164]
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Table 1-2: Lipoprotein classes and their characteristics.

Lipoproteins

Density
(g/mL)

Size
(nm)

Relative
Content %

Apoproteins

TAG

Ch

Pl

Pr

< 0.930

75-1200

90

5

3

2

ApoB-48;
ApoC-I, ApoC-II, ApoC-III;
ApoA-I, ApoA-II, ApoA-IV;
ApoE

VLDL

0.930 – 1.006

30 – 80

60

20

14

6

ApoB-100, ApoC-II,
ApoC-III; ApoE

IDL

1.006 – 1.019

25 – 35

20

40

22

18

Apo B-100, Apo C, Apo E

LDL

1.019 – 1.063

18 – 25

7

50

22

21

ApoB-100

HDL

1.063 – 1.210

12 – 5

5

25

26

44

ApoA-I, ApoA-II, ApoA-IV
ApoC, ApoE

Chylomicrons

Abbreviations: TAG, Triaglycerides; Ch, Cholesterol; Pl, Phospholipids; Pr, Protein
Adopted source: Feingold. K et al. and Kwan. B CH et. al [29, 164]
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Table 1-3: Apolipoproteins of human plasma lipoproteins.

Apoprotein

Lipoprotein

Additional remarks

ApoA-I

HDL, CM

 A major component comprises about 70% of the HDL
protein mass [165].
 The HDL helps to sequesters phospholipids and
cholesterol and interact with plasma enzyme and
cellular receptors [166].
 Activates LCAT which helps in the formation of
cholesterol ester which leads to the HDL maturation.
 Ligand for HDL receptor [167].
 Enables efflux by accepting fats from within cells
(interacts with ABCA1, GPLD1, and PLTP) [63, 168].
 Often used as a biomarker for predicting CVD [169].

ApoA-II

HLD, CM

 Second most abundant protein in HDL [165].
 The structure is identical monomers joined by a
disulfide bridge [29].
 Gene defects may result in ApoA-II deficiency or
hypercholesterolemia [170].
 Has shown to interact with PLTP [63].

ApoA-IV

Secreted with CM but  No primary function in humans has been established;
transferred to HDL
however, it has been linked in many pathways.
 Synthesis in humans limited to the intestine.
 It is associated with the formation of triacylglycerolrich lipoprotein [171].
 Invitro aids in the activation of LCAT and CETP [172].

ApoB-48

CM only and CM
remnant

 Synthesized exclusively in by the small intestine.
 Primary protein component of the CM particles.
 It contains the same amino acid sequence and similar
N-terminal sequence as ApoB-100, however, it lacks
C-terminal LDLR-binding region [173].
 After lipids have been absorbed, it returns to the liver
with CM remnant to be endocytosed and degraded.

ApoB-100

VLDL, IDL, LDL

 Synthesized in the liver [174].
 Serves as a ligand for the LDLR [173].
 Has been associated as a marker for coronary heart
disease [175].
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ApoC-I

VLDL, HDL, CM

 Activator for LCAT in order to help with cholesterol
esterification [176].
 The main function to inhibit CETP [177].

ApoC-II

VLDL, HDL, CM

 Protein acts as an activator for (LPL), which
hydrolyzes TAG, thus freeing FA from cells [178].
 Mutation in the gene causes hyperlipoproteinemia that
is characterized by xanthomas, pancreatitis, and
hepatosplenomegaly, but not the increased for
atherosclerosis [179].

ApoC-III

VLDL, HDL, CM

 Secreted by the liver and small intestine and found on
TAG-rich lipoproteins [180].
 Inhibited LPL and hepatic lipase and believed to inhibit
hepatic uptake of TAG particles [181].
 It also delays the catabolism of TAG-rich particles [182].
 Overexpression can contribute to atherosclerosis [180].
 It may explain the presence of hypertriglyceridemia
associated with ABCA1 deficiency in patients with
Tangier’s disease [183].

ApoE

VLD, HDL, CM, and  Produced in liver and macrophages.
CM remnant
 Ligand for chylomicron remnant receptor [184].
 Transport fat-soluble vitamins and cholesterol into the
lymph system and then blood.
 Interacts with LDLR [185].
 Mediates cholesterol metabolism;
 Principal cholesterol carrier in the brain;
 Risk factors for Alzheimer’s disease, atherosclerosis,
and cardiovascular disease [184].
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Table 1-4: Efflux genes linked to RCT metabolism.
Efflux genes
ABCA1

ABCG1

Additional remarks
 The protein ATP-binding cassette transporter ABCA1: is encoded by a
member of the superfamily of ATP-binding cassette (ABC) transporter gene.
Moreover, ABC is divided into seven distinct subfamilies (ABCA,
MDR/TAP, MRP, ALD, OABP, GCN20, White) [186, 187].
 Specific (ABCA1) is a protein encoded by the member-1 of the human
transporter sub-family of ABCA gene, found exclusively in eukaryotes,
which functions as a cholesterol efflux regulatory protein (CERP) [51].
 ABCA1 is an important regulator in cellular cholesterol and phospholipid
homeostasis [188].
 Cholesterol is the substrate to ABCA1, whose primary function is as a
cholesterol efflux pump in the cellular lipid removal pathway, moreover, it is
known as a gatekeeper for eliminating excess tissue cholesterol [189].
 ABCA1 protein is also believed to play a protective role against CVD by
mediating efflux of cholesterol to lipid poor ApoA-I and ApoE which leads
to the formation of nascent HDL, which ultimately grows into a mature HDL.
[189].
 Downregulation of ABCA1 in aging or compromised macrophages disrupts
cholesterol from being removed from the cytoplasm. This leads to the
promotion of pathologic atherogenesis which can develop into diseases such
as atherosclerosis, CVD, cancer, macular degeneration, and dyslipidemia [190,
191].
 In case of a mutation of the ABCA1 gene, it can lead to Tangiers disease,
presented with HDL-C deficiency and the increased risk for developing CVD
[192].
 The protein ATP-binding cassette sub-family G member 1: is encoded by the
ABCG1 gene, a member of the superfamily of ABC transporters.
 Similar to ABCA1 protein, ABCG1 may be involved in the macrophage,
cholesterol, and phospholipid transport and the regulation of cellular lipid
homeostasis [193].
 Various studies have suggested that ABCG1 protein is primarily an
intracellular sterol transporter, localizes endocytic vesicles, which may
facilitate the efflux of cellular sterols to exogenous HDLs lipoprotein [194].
 Aside from performing cholesterol efflux to the HDL lipoprotein, ABCG1
also effluxes cholesterol to the LDL lipoproteins, liposomes and cyclodextrin.
Additional it can export sphingomyelin, phosphatidylcholine, and oxysterols
to HDL and albumin [195].
 Downregulation of ABCG1 has been associated with a 30% decrease in
intracellular cholesterol efflux, followed by increases 3-4 times higher levels
of IL-6, and TNFα, as well decreased eNOs protein by 50% [196].
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LXR-α

SR-B1
(dual roles)

 Liver X receptor alpha, is a nuclear receptor protein in humans encoded by
NR1H3 family gene [197].
 The LXR-α is highly expressed in organs such as the liver, adrenal gland,
intestine, kidneys, and lungs. It is expressed in tissues such as adipose and
macrophages [198].
 Both LXR-α and LXR-β proteins are critical regulators of macrophage
functions [198, 199].
 Moreover, both proteins are involved in transcriptional programming which
deals with lipid homeostasis and inflammation [199].
 LXR is hypothesized to act as a cholesterol sensor, which inhibits intestinal
cholesterol absorption in order to protect from overload. It does so by
stimulating cholesterol efflux from cells to HDL lipoproteins, which in the
end is transported to the liver to be processed for various fates; either
converted into bile acid, biliary excretion or hormone syntheses [200].
 In macrophages, LXR signal leads to the initiation of homeostatic responses
to cellular lipid loading, which facilitates cholesterol efflux as ABCA1,
PLTP, and ApoE finally transfer the free excess cholesterol to ApoA-I and
ApoE-binding lipoproteins. Moreover, synthetic LXRs have shown to reduce
the rate of atherosclerosis via the removal of excess cholesterol in animal
models [201].
 LXR also works as an agonist which leads to activation of FA synthesis by
initiating a cascade that expresses the initiation of lipogenic transcription
factor SREBP-1c, which results in TAG elevation in the plasma and liver
steatosis [200].
 Scavenger receptor class B type 1 is a protein encoded by the SCARB1 gene.
SR-B1 functions as a receptor for HDL lipoprotein [202].
 This integral membrane protein is found in various types of tissues, including
liver, macrophages and adrenal, where the job is to facilitate the uptake of CE
from HDL in the liver known as RCT [53].
 Additionally, the function of SR-B1 is crucial in lipid-soluble vitamin update
and to viral entry into host cells [203].
 Dual function, primary role to mediate the selective influx of HDL derived
CE into cells and tissues; or to facilitate the cholesterol efflux from peripheral
tissues, including macrophages back to the liver [203].
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Table 1-5: Influx genes linked to RCT metabolism.
Influx genes

Additional remarks

CD36

 Clusters of differentiation 36; are glycoproteins in human coded by the
CD36 gene; moreover, they also are known as fatty acid translocases
(FAT), platelet glycoprotein 4, scavenger receptor class B member 4
(SCARB3) and glycoprotein 88 (GP88).
 Additionally, CD36 is an integral membrane protein found on the surface
of several cells (muscle and adipose), which play an essential role in lipid
homeostasis, specifically in long-chain fatty acids transportation [204].
 It is part of class B scavenger receptor family; however, CD36 contributes
to the atherosclerosis progression due to modification of LDL
phagocytosis, disturbed macrophage migration, which leads to foam cell
formation [204].

LOX-1



SRA1

Lectin-type oxidizes LDL receptor-1, also known as oxidized low-density
lipoprotein receptor (Ox-LDL receptor 1) is a protein in humans encoded
by the OLR1 gene [205].
 It is known as the main receptor for oxidized LDL on endothelial cells,
muscles, and macrophages, but it is worth noting that the TLR4 and CD36
receptor also recognizes oxidize LDL [206, 207].
 Upon binding to Oxi-LDL, the LOX-1 initiates a cascade in which leads
to the activation of NF-KB, which leads to monocyte adhesion to
endothelial cells, which ultimately leads to the formation of foam cells
and atherosclerosis [208].
 Steroid receptor RNA activator protein, a human protein coded by the
SRA1 gene [209].
 Similar to CD36, SRA1 is a scavenger receptor that has been associated
with the modification of LDL upon macrophage loading. In particular,
OxLDL which leads to the development of atherosclerosis [210].
 Binding of oxidized LOX-1 and SRA-1 with oxidized phospholipid
receptors on monocytes and macrophages initiates a cascade in which
pro-inflammatory cytokines and chemokines are released [211].
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Figures Chapter 1
Figure 1-1: Stages of chronic kidney disease (CKD).

(> 90 ml/min/1.73 m2)

(60 - 89 ml/min/1.73 m2)

(45 - 59 ml/min/1.73 m2)

(30 - 44 ml/min/1.73 m2)

(15 - 29 ml/min/1.73 m2)

(< 15 ml/min/1.73 m2)

Source by: National Kidney Foundation [1]
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Figure 1-2: Prevalence of CKD in the US by stages of NHANES participants.

(NHANES), 2001-2004, 2005-2008, 2009-2012 & 2013–2016 participants aged 20 & older. Whisker lines indicate
95% confidence intervals. Abbreviation: CKD, chronic kidney disease, [12].
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Figure 1-3: Prevalence of CKD among US adults’ gender and ethnic distribution.
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Figure 1-4: CKD among Malaysian adults’ gender and ethnic composition.
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Figure 1-5: Incidence of ESRD internationally.

Source: USRDS, 2016 [16]
The incidence rate of treated ESRD (pre-million population) by country, 2016.
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Figure 1-6: Projected ESRD incidence and prevalence in the US through 2030.

Source: American Society of Nephrology, McCullough, et al., 2019 [17]
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Figure 1-7: Treatment options for patients with end-stage kidney disease.

A

B

C

Legend: A- Hemodialysis (Source: RenalMed UK); B- Peritoneal dialysis (Source: Mayo Clinic); C- Renal transplant
(Source: NIDDK-NIH)
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Figure 1-8: Causes of ESRD in the United States.
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Source: US Renal Data System, 2019, CDC.gov
N = 726,331 (all ages, 2016); includes polycystic kidney disease (PKD), among other causes. [6].
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Figure 1-9: Reverse cholesterol transport.

ApoB-100

Source: Circulation, Duff D., et al., [212]

HDL lipoprotein promotes and facilitates the process of RCT, whereby excess cholesterol from the macrophages are
effluxed into HDL. During the transfer, cholesterol is esterified by LCAT into CE. Through this time, the nascent
HDL undergoes through changes as it fills up with CE where it becomes a mature HDL particle. After this point, the
mature HDL returns to the liver for excretion of CE via the liver SR-BI receptor. However, this RCT process has a
second pathway, wherein CETP working in cohort with ApoB-100 facilitates exchange of CE for TAG between HDL
and VLDL/LDL lipoproteins.
(A-1) ApoA-1; (FC) indicates free cholesterol; (BA) bile acids; (LDLR) LDL receptor; (TG) triglycerides; (CE)
Cholesterol ester; (PLTP) Phospholipid transfer protein; (CETP) Cholesteryl ester transfer protein.
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Figure 1-10: Dysfunctionality of RCT metabolism in MHD patients.
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Source: European heart journal Supplements, Barter 2005, [213]
The figure shows an overview of believed lipoprotein metabolism in dyslipidemic MHD patients.
In MHD patients, DL is highly prevalent and is characterized by delayed TAG-rich lipoproteins catabolism which in
turn leads to elevated TAG levels, VLDL, IDL, and low HDLC due to suppressed/decreased ApoA-1 production.
Moreover, the HDL level may decline because CETP activity may be elevated, and LCAT activity is reduced. Other
lipids such as TC, LDL-C may be presented as decreased or normal.
Symbols: Increased (↑) and decrease (↓) plasma levels, (↔) normal.
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CHAPTER 2: METHODOLOGY
General study design
The general purpose of this study is to characterize DL in lipids, and lipoprotein
subfractions in a multi-ethnic cohort of ESRD patients undergoing MHD. This dissertation
integrates MHD subjects from both PATCH USA clinical trial (NCT02358967) comprised of
African Americans, and PATCH MALAYSIA clinical trial (NCT02913690) a cohort composed
of three ethnicities; Malays, Malaysian-Chinese and Malaysian-Indians. Moreover, this
investigation focusses on key HDL enzymes, which partake in the RCT mechanism linked in DL
in MHD subjects.
Specific Aim 1 is representative of baseline data, in a cohort of African American (AA)
patients undergoing hemodialysis treatment thrice weekly, for which we documented individuals’
degree of dyslipidemia by characterizing lipids and lipoprotein particle compositions
Specific Aim 2 characterizes dyslipidemia across a multi-ethnic cohort of MHD patients
Malays (MM), Malaysian-Chinese (MC), Malaysian-Indians (MI), and the US- AA patients).
Moreover, examine differences in lipid parameters amongst the two cohorts of US and Malaysian
patients.
Lastly, specific Aim 3 investigates the extent to which HDL enzyme, in the RCT pathway,
contributes to dyslipidemia in MHD patients.
This chapter will describe the specific methodology and procedures of all the experiments and
assays that were conducted for the studies as described in the specific chapters (Chapters III, IV,
and V).
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Ethics and Human Subjects’
The Palm Tocotrienols in Chronic Hemodialysis (PATCH) is an ongoing, multi-center,
longitudinal, randomized, double-blinded, placebo-controlled study for 15-months involving
MHD patients in Michigan, Malaysia, Bangladesh, and India. All study participants were dialyzed
thrice weekly.
Subjects were assigned randomly to receive 300 mg of TRF or placebo daily for 12-months,
followed by a 3-month washout period. Patients in the US cohort for Great Lakes Dialysis, DaVita:
Kresge, Highland Park, and Redford dialysis units were given TRF or placebo capsules during
their dialysis sessions under the supervision of a staff member, then the remainder of capsules
were consumed at home by the patients. MHD subjects from Henry Ford Medical Centers of
Fairlane and West Pavilion dialysis, in addition to all Malaysia, enrolled patients, consumed all
capsules at home.
Ethical approvals for the US and Malaysian cohort were obtained from the Human Ethics
Committee at Wayne State University (WSU-IRB 123314MP4F), and the Malaysian Ministry of
Health. Additional approvals were obtained from participating dialysis units. Written informed
consents were also obtained from all the patients. Demographics data and routine biochemical
parameters were obtained from patients’ medical records provided by the respective units.
Inclusion and Exclusion Criteria’s
The two studies for both PATCH USA and Malaysia share mostly but not all requirements,
with minor differences. These criteria are shown in Table 2-1 (for inclusion) and Table 2-2
(exclusion).
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General blood collection, handling, and processing of samples
The US cohort followed a group of African American MHD patients for a duration of
15 months, where blood was obtained every 3 months. Approximately 10 mL of whole blood
samples were collected from study subjects using commercially available pre-coated EDTA-K2
or LH vacutainers (Becton Dickinson, Franklin Lakes, NJ, USA), in which case subjects were not
required to fast. While past guidelines have suggested measuring fasting blood lipids, new
guidelines from the European Federation of Clinical Chemistry and Laboratory Medicine
recommend that the use of both fasting and non-fasting measurements are similar for evaluation
and thus appropriate to use [214].
The samples were transported to the WSU laboratory within 2-3 hours post blood draw.
Plasma was isolated from whole blood via centrifugation (Beckman Coulter Centrifuge, Lakeview
Parkway, IN, USA) at 2,500 rpm for 15 minutes at 4°C. Plasma was then dispersed in Eppendorf
microcentrifuge tubes and immediately transferred into -80°C freezer until further analysis
The Malaysian blood samples were collected and processed following a similar protocol
but with minor differences. Roughly, 10 mL of blood was collected into EDTA-K2 or LH
vacutainers (Becton Dickinson, Franklin Lakes, NJ, USA). Samples were immediately centrifuged
at 3000g for 10 minutes to separate plasma [215]. Afterward, plasma was dispersed into Eppendorf
tubes and snap-frozen with liquid nitrogen. The frozen aliquots were then placed in dry ice
containers and transported to the laboratory for storage at -80°C (IsotempTM, FisherbrandTM,
Hampton, NH, USA). A subset of the baseline plasma samples of both LH and EDTA-K2 collected
samples from the Malaysian cohort were shipped to Wayne State University, for additional
analysis.
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Anthropometry and other measurements
The anthropometric measurements for height, weight, estimated dry weight were
conducted by PATCH lab investigators. Height was measured to the nearest centimeter (0.1 cm),
and body weight was measured to the nearest kilogram (0.1). Body mass index (BMI), was
calculated using Quetelet’s Index : [ BMI (kg/m2) = weight (kg) / height (m2)] [216]. Patient
medical history, such as medications, were self-reported: blood pressure, diabetic, statin use, were
collected.
Biochemical Analysis
Lipid Profile
Lipids in the Malaysian study were measured by an external laboratory in Kuala Lumpur,
Malaysia. The lipid parameters for PATCH USA study along with a subset of (n = 57) samples
from the Malaysian cohort were measured using EDTA-K2 collected plasma. The TAG, HDL-C,
and TC were analyzed using enzymatic kit (Pointe Scientific Inc., Canton, MI, USA), performed
according to manufactures protocol, whereas LDL-C was calculated using the Friedewald formula
[217]. From the 57 samples measured in both the US and Malaysia; TAG showed a correlation
with an r = 0.934 (p < 0.001), and HDL-C measurements had an r = 0.854 (p < 0.001). TC had an
r = 0.974 (p < 0.001), whereas LDL-C had an r = 0.961 (p < 0.001).
HDL and LDL lipoprotein subfractions analysis (Lipoprint)
The assessment of lipoproteins was carried out using Quantimetrix LipoprintTM System
(Quantimetrix Corp., Redondo Beach, CA, USA). EDTA-K2 plasma samples were used in the
measurements for both HDL and LDL lipoprotein subfraction in accordance with the
manufacturers' protocol. Plasma was added to a precasted linear polyacrylamide gel tube and
loaded with a lipophilic (blue) dye. The dye binds proportionally to the cholesterol in each
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lipoprotein, when the prestained lipoproteins undergo electrophoresis. During this phase, particles
migrate through the separated gel matrix into appropriate lipoproteins bands according to the
particle, charge, and size from largest to smallest due to the sieving action of the gel.
HDL lipoprotein analysis has many subfraction bands. Subfraction bands [HDL1-3] makes
up the large buoyant HDL (L-HDL) lipoprotein, bands [HDL 4-7] make up the intermediateHDL (I-HDL), and [HDL 8-10] bands constitute the small HDL (S-HDL) subfraction. Albumin
is the last band in the gel tube with LDL/VLD remaining at the stacking and separating gels
interface (Figure 2-1).
LDL lipoprotein analysis can also generate multiple bands. There are a total of 12 bands,
with the top band being VLDL and the last migrating lipoprotein being HDL. The MID-bands are
composed of three sub-bands (IDL-C, IDL-B, and IDL-A). LDL lipoprotein subfractions, are
further separated into three categories: [LDL 1] makes up large buoyant LDL (L-LDL)
subfraction; band [LDL 2] composes the intermediate LDL (I-LDL) subfraction, and combined
bands [LDL 3-7] includes the small dense LDL (S-LDL) subfractions (Figure 2-2). LDLlipoprotein testing can detect and differentiate the mean particle-size in angstroms (Å) units, for
which a set range of particle sizes is depictive of a phenotype profile. Phenotype: Type-A is
associated with more large buoyant LDL particles. The atherogenic lipoprotein profile is Type-B
(denser LDL subspecies) and Type-intermediate or [AB] phenotype, which is the lesser
atherogenic and prone to change [218]. LDL lipoprint program algorithm utilizes the guidelines of
the National Cholesterol Education Program and Adult Treatment Panel III (ATP III) as normal
reference range.
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HDL metabolism enzymes analysis
Cholesteryl ester transfer protein (CETP) activity analysis
CETP was measured in LH plasma samples, using CETP activity assay kit (RB-CETP,
Roar Biomedical, Broadway, NY, USA). The assay uses a proprietary substrate donor molecule
that enables the detection of CETP mediated transfer of neutral lipid from the substrate to a
physiological acceptor. The assay is a fluorometric method, at wavelengths of (465Ex nm / 535Em
nm). The analysis was conducted as described in the manufacturer protocol with the results, of
CETP activity being expressed in nmol/mL/hrs.
Lecithin-cholesterol acyltransferase (LCAT) activity analysis
LCAT was measured using in LH plasma samples, using the LCAT activity assay kit (RBLCAT, Roar Biomedical, Broadway, NY, USA). The assay is a fluorometric assay which measures
the phospholipase activity of the LCAT. The samples were read using a fluorimeter plate reader at
two different wavelengths (340Ex nm/470Em nm) and at (340Ex nm/390Em nm). The two distinct
intensity peaks depend upon the concentration of the hydrolized and the intact substrate present in
the assay. In the case of the substrate being intact, the fluorophores that are nearby are excited and
result in the dissipation of radiationless transitions. The emission is predominately at the less
energetic state of 470 nm peak, representative of hydrolysis of the substrate by LCAT, where the
fluorophores are not able to energetically interact, leads to a shift that causes intensity in the form
of emission at 390 nm. The final results of the LCAT activity were expressed as a ratio between
the two readings (470/390 nm), which is the rate of change per min/uL/plasma in accordance with
the protocol.
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Inflammatory marker: C-reactive protein (CRP)
C-reactive protein (CRP) levels were measured using commercial enzyme-linked
immunosorbent assay (ELISA) kit (Cayman Chemical, Ann Arbor, MI, USA). A total of 10 µL of
LH or EDTA-K2 plasma was diluted in the assay buffer into 1:18,200. After sample preparations,
the CRP standards were made following a sequence of serial dilutions per manufacturer's protocol.
Subsequently, a total of 100 µL of each prepared solution was dispersed in duplicates into precoated 96-well plates with a monoclonal antibody for human CRP. Following appropriate
incubations and washes, the plate was measured at 450 nm wavelength (MultiskanTM FC, Thermo
ScientifcTM, MA USA), where the results were analyzed using Prism (GraphPad, Software v7.0,
San Diego, CA, USA), with final concentrations expressed in mg/L.
The Malaysian study measured this inflammatory marker using a high-sensitive CRP
(hs-CRP) method through an external laboratory in Kuala Lumpur, Malaysia. During the analyses
of the PATCH, USA study, a subset of Malaysian samples (n = 36) were measured using the
Cayman Chemicals ELISA kit. Results showed a high correlation between the two techniques with
an r = 0.965 (p < 0.001), which was used to adjust the hs-CRP results (Appendix Figure 1).
Oxidative stress marker: Nε-(carboxymethyl) lysine (CML)
CML is a form of advanced glycation end-product (AGE) adduct in human plasma.
OxiSelect™ CML competitive ELISA kit (STA-816, Cell Biolabs Inc., San Diego, CA, USA) was
used to measure Nε-(carboxymethyl) lysine adducts in LH or EDTA-K2 plasma. Quantity of CML
adducts in the protein plasma samples were determined by comparing its absorbances with a CMLBSA standard curve, as specified by the manufacturer’s protocol, at a wavelength of 450 nm using
a microplate reader (MultiskanTM FC, Thermo ScientificTM, MA USA). Data analysis required a
4PL standard curve, which allowed for extrapolation of the sample’s concentrations by using the
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graphical analyzer Prism (GraphPad, Software v7.0, San Diego, CA, USA). Concentrations were
expressed in ng/mL.
Statistical Analysis
Results were expressed as mean and standard deviation (mean±SD) for continues variables
with a normal distribution. Categorical variables of ordinal or nominal nature were expressed as
percentages (%) when appropriate. To verify the normal distribution of variables, we used the
Shapiro-Wilk test, as for analysis for homogeneity of variances, we used Levene’s test. Categorical
data and data that were not normally distributed were tested using Chi-square test and
nonparametric test, respectively. Differences in the mean between groups were tested using OneWay ANOVA and General linear model (GLM) (Univariate) necessary. One-Way ANOVA
analysis (between and or within groups), utilized Post-hoc Bonferroni test was employed for
multiple detailed comparisons (two more groups), whereas the Dunnett’s T3 test was used in the
analysis when equal variance was not assumed when appropriate. Data were corrected for any
confounding variables. Covariate factors were adjusted (Age, BMI, Albumin, Systolic BP,
Diastolic BP, Risk factor, Kt/V) using ANCOVA, Post-hoc Bonferroni test, in regards to fixed
factors (Ethnicities, gender, smoking, DM, HTN, Statin).
An independent sample t-test was applied when was appropriate for non-normally distributed
parameters. Additionally, Chi-square χ2 was used to test for independence of continues categorical
or nominal variables when relevant.
Percent risk factor (PRF) was used to evaluate the percent increased risk, using an online
published calculator for atherosclerotic cardiovascular disease (ASCVD). It covers a 10-years risks
of heart disease and stroke factor, with algorithms by ACC/AHA Guidelines based on Framingham
risk score (FRS) parameters [219]. The calculator incorporates numerous parameters such as age,
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gender, race, blood pressure, lipids, history of DM, smoking, statin use, HTN, and aspirin therapy.
The atherogenic risk is an estimated value of the Atherogenic Index of Plasma. It is calculated
using the triglycerides and HDL-C in AIP, reflecting the balance between the atherogenic and
protective lipoproteins. (AIP = =LOG10 ((TAG*0.0113)/ (HDL-C*0.0259)) [220].
The (α)-value was set to be at (p<0.05) for the two-sided tail test, representing statistical
significance. GraphPad Prism 7.0 (GraphPad, Software v7.0, San Diego, CA, USA) was used for
graphing, and curve fitting in ELISA assays whereas analysis and calculations were completed
with the use of (SPSS) v25.0 software by (IBM, Chicago, IL, USA)
.
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Tables Chapter 2
Table 2-1: Study inclusion criteria.
PATCH USA and Malaysia
Patients had to be of age 18 years or older.
They had to be undergoing chronic hemodialysis treatment for more than three months.
To be able and willing to comply with all trial requirements.
Willing to notify his or her Physician/Nephrologist/General Practitioner for participating in the
trial.
PATCH Malaysia Only
They must adequately be dialyzed (Kt/V > 1.2 or have a urea reduction ratio (URR) of 65%.
Patients also must have hs-CRP levels of less than 20 mg/dL.
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Table 2-2: Study exclusion criteria.
PATCH USA and Malaysia
Subjects who had been involved with another investigatory trial within the past 12 weeks.
Patients with a history of functional kidney transplant 6 months before the study and or waiting
for donor kidney transplant over the study duration.
Any participants who had taken vitamin E- containing supplement > 60 IU/day during the past
30 before study enrollment.
Any patients with a history of poor adherence to HD or medical regimen.
Any patients that are currently on active treatment for cancer, excluding basal cell carcinoma
of the skins.
Participating subjects diagnosed with HIV/AIDS and/or are on any anti-HIV therapy.
Any patients taking anti-inflammatory medication, except aspirin < 325 mg/d, over the past
30 days before study enrollment.
Any pregnant female patients and or lactating or planning pregnancy during the course of the
trial.
Hospitalizations within the last 90 days and more than two times, or one hospitalization within
the 30 days preceding enrollment, were excluded.
Subjects receiving nutritional support via enteral and intra-venous routine.
Using a temporary catheter or receiving a graft/fistula within the 6-month study period.
PATCH Malaysia Only
Patients with Hepatitis B or C.
Additional diseases or disorders where the opinion of nephrologists may affect the end result
of the study.
Patients with known allergies towards fish-based products.
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Figures Chapter 2
Figure 2-1: HDL lipoprint subfraction band separation on polyacrylamide gel tube.

Source: Quantimetrix, Laboratory Lipoprint, 2019
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Figure 2-2: LDL lipoprint subfraction band separation on polyacrylamide gel tube.

Source: Quantimetrix, Laboratory Lipoprint, 2019
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CHAPTER 3: RESULTS – SPECIFIC AIM 1: TO DOCUMENT THE DEGREE OF
DYSLIPIDEMIA IN A COHORT OF MHD PATIENTS AND CHARACTERIZE LIPIDS,
AND LIPOPROTEIN PARTICLE COMPOSITIONS.
The study flow is shown in Figure 3-1. From 135 patients, 12 subjects were excluded from
the analyses (not African–American or incomplete data). Thus, 123 subjects (all AA) were used.
The plasma analyzed from these subjects represented the baseline samples collected (i.e., prior to
study randomization) in the PATCH study (NCT02358967). Patient demographics are shown in
Table 3-1. The mean age of the cohort was 59±13 years, with 63%% males and 37% females. The
majority of the participants (71%) were non-smokers. Almost 55% of the cohort had DM, while
88% were hypertensive. Additionally, 55% were prescribed statin drugs. It should be noted that as
part of the patients’ routine care, medications would have been prescribed to manage blood
pressure and LDL-C to target desirable levels. The overall cohort was classified as obese (BMI
30.0 ± 7.5 kg/m2 ). Both systolic and diastolic B/P were within the normal range, creatinine levels
were elevated, while albumin was marginally below the recommended values. The Dialysis
vintage of the cohort was 66 ± 65 months, and Kt/V was within optimal range
Table 3-2 shows the plasma lipids in this cohort. Collectively, the cohort had lipids in the
normal range. To examine the level of dyslipidemia, lipids were separated into two groups; ≥ 3.8
TAG/HDL-C ratio or < 3.8 TAG/HDL-C ratio. (This is based on the recommended target values
of TAG <150 mg/dL and HDL-C > 40 mg/dL). This analyses showed that 17 subjects (14% of the
cohort) had a TAG/HDL-C ration ratio ≥ 3.8 resulting in significantly higher TAG (179±38 vs.
79±31 mg/dL) and LDL-C (110±36 vs 75±38 mg/dL), while HDL-C was significantly lower (34±6
vs 53±189 mg/dL). As a consequence, ratios of TAG/HDL-C, TC/HDL-C and LDL-C/HDL-C
were all significantly higher in subjects with TAG/HDL-C ratios ≥ 3.8

68

Figure 3-1: Specific Aim 1 study flow.

Aim 1 Study: PATCH (USA)
(N = 135) – Consented
Specific aim 1 parameters measured:
 Lipid profiles analyses
-TAG, HDL-C, & TC
Baseline Total Enrollment:



African American:
Other ethnicities:

n, (%)
128, (95)
7, (5)

-Calculated:
(LDL-C, Non-HDL,
TAG/HDL-C, TC/HDL-C,
LDL/HDL-C ratios)
 Lipoprotein Subfraction Particles
-HDL,& LDL Analysis

Not part of the current study: 12 Patients



 Inflammatory markers
-CRP
-AGEs-CML (pilot inquiry USA only)

(n = 5, early, drop outs)
(n = 7, other ethnicities)

Baseline Samples Analyzed
(n) = 123
AA, African Americans; TC, total cholesterol; TAG, triacylglycerol; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; AGEs-CML, Advanced glycation end-products
- Nε-carboxymethyl-lysine.
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Table 3-1: Characteristics of the African American (AA) cohort.
Demographics
Age (yrs.)
Gender (n, %)
Males
Females
Ethnicity (n, %)
African American
Tobacco Smokers (n, %)
Smokers
Non-Smokers
Diabetes Mellitus (DM) (n, %)
DM
Non-DM
Hypertension (HTN) (n, %)
HTN
Non-HTN
Statin (n, %)
User
Non-User
BMI (kg/m2)
Creatinine (mg/dL)
Albumin (g/dL)
Systolic B/P (mmHg)
Diastolic B/P (mmHg)
Time on Dialysis/Vintage (months)
Kt/V
Values are mean ± SD, n=123

59 ± 13
77 (62.6)
46 (37.4)
123 (100)
36 (29.3)
87 (70.7)
68 (55.3)
55 (44.7)
108 (87.8)
15 (12.2)
55 (44.7)
68 (55.3)
30.0 ± 7.5
9.5 ± 2.8
3.83 ± 0.32
140 ± 21
79 ± 15
66 ± 65
1.52 ± 0.22
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Table 3-2: Plasma lipids in the AA cohort.
Lipid Parameters

Total

_________TAG/HDL-C_______

(n = 123)

ratio ≥ 3.8
(n = 17)

ratio < 3.8
(n = 106)

TAG (mg/dL)

93 ± 47

179 ± 38 a

79 ± 31 b

HDL-C (mg/dL)

50 ± 19

34 ± 6 a

53 ± 19 b

TC (mg/dL)

148 ± 42

179 ± 36 a

143 ± 41 b

LDL-C (mg/dL)

80 ± 39

110 ± 36 a

75 ± 38 b

NonHDL (mg/dL)

98 ± 45

145 ± 36 a

91 ± 41 b

TAG/HDL-C Ratio

2.24 ± 1.59

5.40 ± 1.18 a

1.74 ± 0.93 b

TC/HDL-C Ratio

3.33 ± 1.51

5.47 ± 1.54 a

2.99 ± 1.19 b

LDL/HDL-C Ratio

1.89 ± 1.26

3.39 ± 1.46 a

1.65 ± 1.05 b

1

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given row with different superscriptsab
were significantly different from each other (p < 0.05), using one-way ANOVA.
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Table 3-3 shows the lipoprotein subfraction composition in the AA cohort. Collectively,
the L-HDL ( 22.0 ± 15.9 mg/dL) and I-HDL ( 22.1 ± 5.74 mg/dL) are the most prominent HDL
particles, whereas the S-HDL (5.94 ± 3.19 mg/dL) is the least. LDL subfraction analysis is made
up of multiple subfractions (VLDL, IDL, L-LDL, I-LDL, and S-LDL), which were IDL (46.8 ±
15.4 mg/dL) and VLDL (25.4 ± 10.2 mg/dL) are the most predominant subfractions. This is
followed by L-LDL particle (22.3 ± 9.53 mg/dL), as the most prominent subfraction with respect
to I-LDL (12.5 ± 8.00 mg/dL) and S-LDL (3.85 ± 6.11 mg/dL). Phenotype analyses resulted in
type “A” as the dominant profile 65%, followed by type “B” 19.5%, and “AB,” known as the
intermediate phenotype, present 15.4% in the AA cohort. D was assessed by separating subjects
into two groups, ≥ or < 3.8 TAG/HDL-C ratio. The 17 patients in the ≥ 3.8 TAG/HDL-C ratio
group, had significantly lower L-HDL (8.59±4.21 vs. 24.2±16.0 mg/dL), I-HDL (17.5±5.34 vs.
22.9±5.47 mg/dL), and higher S-HDL (7.65±2.96 vs. 5.67±3.15 mg/dL). Furthermore, the subsets
had significantly higher IDL (61.4±14.5 vs. 44.4±14.3 mg/dL), and S-LDL (9.47±10.7 vs.
2.94±4.49 mg/dL), with LDL phenotype “B” becoming the predominant profile in 47% of AA
subjects.
Table 3-4 shows CETP and LCAT enzymatic activities in the AA cohort. Average CETP
activity was noted to be (41.6 ± 18.7 nmol/mL/hr.), whereas LCAT (0.89 ± 0.17 ratio 470 / 390 nm).
To discern the effects of D on the two enzyme activity, samples were allocated into two groups. ≥
or < 3.8 TAG/HDL-C ratios. The 17 AA subjects within ≥ 3.8 TAG/HDL-C ratio group displayed
a significantly lower CETP activity (32.1±14.0 vs. 43.1 ± 19 nmol/mL/hr.), whereas the LCAT
differences were marginal (0.87±0.17 vs 0.89±0.16 ratio 470 / 390 nm).
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Table 3-3: Lipoprotein subfraction composition in the AA cohort.
Lipoproteins

Total

_________TAG/HDL-C_______

(n = 123)

ratio ≥ 3.8
(n = 17)

ratio < 3.8
(n = 106)

L-HDL (mg/dL)

22.0 ± 15.9

8.59 ± 4.21 a

24.2 ± 16.0 b

I-HDL (mg/dL)

22.1 ± 5.74

17.5 ± 5.34 a

22.9 ± 5.47 b

S-HDL (mg/dL)

5.94 ± 3.19

7.65 ± 2.96 a

5.67 ± 3.15 b

VLDL (mg/dL)

25.4 ± 10.2

37.6 ± 9.86 a

23.5 ± 8.82 b

IDL (mg/dL)

46.8 ± 15.4

61.4 ± 14.5 a

44.4 ± 14.3 b

L-LDL (mg/dL)

22.3 ± 9.53

22.2 ± 9.89

22.3 ± 9.52

I-LDL (mg/dL)

12.5 ± 8.00

17.2 ± 8.0 a

11.7 ± 7.78 b

S-LDL (mg/dL)

3.85 ± 6.11

9.47 ± 10.7 a

2.94 ± 4.49 b

Mean LDL size (Å)

269.5 ± 4.64

265.1 ± 5.60 a

270.2 ± 4.07 b

Phenotype “A” (n, %)

80 (65%)

6 (35%)

74 (70%)

Phenotype “B” (n, %)

24 (19.5%)

8 (47%)

11 (10%)

19 (15.4)

3 (18%)

21 (20%)

Subfractions
1

Phenotype “AB” (n, %)

Values are mean ± SD for the numbers in parentheses1. Values in a given row with different superscriptsab were
significantly different from each other (p < 0.05) using one-way ANOVA.
Abbreviations: L-HDL, large-high density lipoprotein; I-HDL, intermediate high-density lipoprotein; S-HDL, small
high-density lipoprotein; VLDL, very-low-density lipoprotein; IDL, intermediate low-density lipoprotein; L-LDL,
large low-density lipoprotein; I-LDL, intermediate low-density lipoprotein; S-LDL, small low-density lipoprotein,
Phenotype “AB,” is a phenotype intermediate between A and B.
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Table 3-4: Cholesterol ester transfer protein (CETP) and Lecithin cholesterol acyl
transferase (LCAT) activity in the AA cohort.

Enzymes

Total
(n = 123)1

CETP nmol/mL/hr.

41.6 ± 18.7

LCAT ratio of 470/390 nm

0.89 ± 0.17

_________TAG/HDL-C_______
ratio ≥ 3.8
(n = 17)

ratio < 3.8
(n = 106)

32.1 ± 14.0 a

43.1 ± 19 b

0.87 ± 0.21

0.89 ± 0.16

Values are mean ± SD for the numbers in parentheses1. Values in a given row with different superscriptsab were
significantly different from each other (p < 0.05) using one-way ANOVA.

74

CHAPTER 4: RESULTS – SPECIFIC AIM 2: TO CHARACTERIZE DYSLIPIDEMIA
ACROSS A MULTI-ETHNIC COHORT OF MHD PATIENTS.
The study flow is shown in Figure 4-1. From 227 enrolled patients, two were excluded
from the analyses due to unavailable data (patients had drop prior blood collection). Thus, of the
225 patients, the Malaysian cohort was divided into three different ethnicities of which; 69 patients
are Malaysian-Malays (MM), 110 are of Malaysian-Chinese (MC), and 46 are of MalaysianIndians (MI) ethnicity. Similar, to the AA cohort, patients' blood collected was representative of
baseline samples gathered before randomization in the PATCH clinical trial (NCT02913690).
Patients demographics are shown in Table 4-1. The mean age of the cohort is 54 ± 13 years of
which 60% are males, and 40% are females. Analyses with respect to age showed that MM (48 ±
14 years) were significantly younger when compared to MC (57 ± 11 years) and MI (55 ± 12
years).
The majority of the participants, 90% were non-smokers. Almost 44% of the cohort had
DM, while 84% were hypertensive. Furthermore, about 60% of patients were prescribed statin
drugs. Overall, cohort patients were classified as overweight with a BMI of (25 ± 4.1 kg/m2),
specifically MM and MI who had significantly higher BMI than MC. Albumin levels were
significantly lower in MM patients (3.8 ± 0.4 g/dL) when compared with MC, and MI. Systolic
B/P was marginally elevated, whereas diastolic B/P was within normal range. Cohort vintage was
77 ± 59 months, with MM dialyzed the longest 84 ± 66 months, wherein Kt/V was within an
optimal range.
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Figure 4-1: Specific Aim 2 study flow.

Aim 2 Study: PATCH (MALAYSIA)
(N = 227) – Consented
Specific aim 2 parameters:
 Lipid profiles analyses
(TAG, HDL-C, TC); Total of (n) = 57
lipids (TC, TAG, HDL-C) were reanalyzed in US.


In this analyses (2) patients
were
excluded
due
to
unavailable data, subjects drop
outs before blood collection.

 Lipoprotein Subfraction Particles
-HDL, & LDL Analysis
 Inflammatory markers
-CRP; Total of (n) = 37 CRP samples
were analyzed.

Eligible for Analyses: At Baseline
(n) = 225

MM

MC

MI

(n) = 69 (30.7%)

(n) = 110 (48.9%)

(n) = 46 (20.4%)

Abbreviations: MM, Malaysian-Malay’s; MC, Malaysian-Chinese; MI, Malaysian-Indians
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Table 4-1: Characteristics of the Malaysian cohort.
Demographics
Age (yrs.)
Gender (n, %)
Males
Females
Tobacco Smokers (n, %)
Smokers
Non-Smokers
Other-unknown
Diabetes (DM) (n, %)
DM
Non-DM
Hypertension (n, %)
HTN
Non-HTN
Statin (n, %)
User
Non-User
BMI (kg/m2)
Albumin (g/dL)
Systolic B/P (mmHg)
Diastolic B/P (mmHg)
Dialysis/Vintage (months)
Kt/V

Total
(n = 225)1

MM
(n = 69)

MC
(n = 110)

MI
(n = 46)

P-value

54 ± 13

48 ± 14a

57 ± 11b

55 ± 12 b

<0.001

134 (59.6)
91 (40.4)

37 (53.6)
32 (46.4)

65 (59.1)
45 (40.9)

32 (69.6)
14 (30.4)

NS

21 (9.3)
202 (89.8)
2 (0.9)

9 (13)
59 (85.5)
1 (1.4)

10 (9.1)
99 (90)
1 (0.90)

2 (4.3)
44 (95.7)
-

NS

99 (44)
126 (56)

27 (39.1)
42 (60.9)

48 (43.6)
62 (56.4)

24 (52.2)
22 (47.8)

NS

188 (83.6)
37 (16.4)

57 (82.6)
12 (17.4)

96 (87.3)
14 (12.7)

35 (76.1)
11 (23.9)

NS

135 (60)
90 (40)

37 (53.6)
32 (46.4)

73 (66.4)
37 (33.6)

25 (54.3)
21 (45.7)

NS

25 ± 4.1
4.0 ± 0.5
156 ± 22
78 ± 15
77 ± 59
1.6 ± 0.3

26 ± 4.6a
3.8 ± 0.4a
151 ± 21
78 ± 16
84 ± 66
1.6 ± 0.3

25 ± 4.2b
4.1 ± 0.4 b
158 ± 21
79 ± 14
76 ± 55
1.6 ± 0.3

26 ± 3.2ab
4.0 ± 0.4b
159 ± 24
77 ± 16
71 ± 56
1.6 ± 0.3

0.025
<0.001
NS
NS
NS
NS

-

Values are mean ± SD for the numbers in paremtheses1. Values in a given row with different superscriptsab were
significantly different from each other (p < 0.05) using one-way ANOVA. Data were adjusted using ANCOVA, in
relation to covariate factors (age, gender, tobacco use, statin usage, BMI, Albumin, blood pressure, as well as Kt/V.
Abbreviations: MM, Malaysian-Malay; MC, Malaysian-Chinese; MI, Malaysian-Indians; NS, Not significant.
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Table 4-2 shows plasma lipids for the Malaysian cohort. Collectively, lipids were
marginally higher than the AA cohort; however, largely, the Malaysian lipids profile were within
normal range. HDL-C results showed to be significantly lower in MM patients (43 ± 10 mg/dL)
when compared with MC (48 ± 14 mg/dL). The TAG levels were higher in MM subjects (142 ±
74 mg/dL) when compared with MC (127 ± 62 mg/dL) and MI (124 ± 77 mg/dL) which did not
meet statistical significance. Moreover, lipid LDL/HDL-C ratios were significantly higher in MI
(2.39 ± 0.91) patients in relation to MC (2.01 ± 0.78).
Table 4-2: Plasma lipids in the Malaysian cohort
Lipid Parameters

Total

MM

MC

MI

(n = 225) 1

(n = 69)

(n = 110)

(n = 46)

TAG (mg/dL)

131 ± 69

142 ± 74

127 ± 62

124 ± 77

HDL-C (mg/dL)

46 ± 13

43 ± 10 a

48 ± 14 b

43 ±11 ab

TC (mg/dL)

163 ± 33

164 ± 34

164 ± 35

163 ± 31

LDL-C (mg/dL)

92 ± 28

93 ± 30

90 ± 28

96 ± 25

NonHDL (mg/dL)

118 ± 34

121 ± 36

115 ± 33

120 ± 33

TAG/HDL-C Ratio

3.29 ± 2.42

3.73 ± 2.58

3.00 ± 2.04

3.32 ± 2.93

TC/HDL-C Ratio

3.81 ± 1.21

4.01 ± 1.29

3.60 ± 1.05

4.03 ± 1.38

LDL/HDL-C Ratio

2.17 ± 0.87

2.29 ± 0.94 ab

2.01 ± 0.78 a

2.39 ± 0.91 b

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given row with different superscriptsab
were significantly different from each other (p < 0.05), using one-way ANOVA.

78

Table 4-3 examines plasma lipid, D within the Malaysian cohort. Lipids were separated
into two groups; ≥ 3.8 TAG/HDL-C ratio or < 3.8 TAG/HDL-C ratio. Analyses showed 65 subjects
(29% of the cohort) had a TAG/HDL-C ratio ≥ 3.8 resulted with significantly higher TAG (216±67
vs. 97±28 mg/dL), and LDL-C (99±32 vs. 90±26 mg/dL) while HDL-C was significantly lower
(35±5 vs. 50±12 mg/dL). In the < 3.8 ratio group, MC patients had lower values in TC/HDL-C
and LDL/HDL-C ratios, compared to MI subjects.
Table 4-3: Plasma lipid analyses based on TAG/HDL ration in the Malaysian cohort.
Lipids

Total

MM

MC

MI

*TAG/HDL ratio ≥ 3.8

(n =65) 1

(n=25)

(n = 28)

(n = 12)

TAG (mg/dL)

216 ± 67

219 ± 64

214 ± 52

215 ± 102

HDL-C (mg/dL)

35 ± 5

35 ± 5

36 ± 5

33 ± 5

TC (mg/dL)
LDL-C (mg/dL)

176 ± 36
99 ± 32

177 ± 38
100 ± 36

175 ± 35
97 ± 32

176 ± 36
100 ± 22

NonHDL (mg/dL)

141 ± 35

143 ± 37

139 ± 33

143 ± 37

TAG/HDL-C Ratio

6.34 ± 2.43

6.51 ± 2.28

6.00 ±1.64

6.77 ± 3.98

TC/HDL-C Ratio

5.11 ± 1.18

5.19 ± 1.20

4.88 ± 0.94

5.44 ± 1.60

LDL/HDL-C Ratio

2.85 ± 0.97

2.92 ± 1.08

2.69 ± 0.88

3.10 ± 0.94

*TAG/HDL ratio < 3.8

(n =160) 1

(n= 44)

(n = 82)

(n = 34)

TAG (mg/dL)

97 ± 28

98 ± 29

97 ± 29

92 ± 23

HDL-C (mg/dL)

50 ± 12

48 ± 9

52 ± 14

47 ± 11

TC (mg/dL)

158 ± 31

156 ± 29

159 ± 33

159 ± 29

90 ±26

89 ± 25

88 ± 27

94 ± 26

NonHDL (mg/dL)

108 ± 29

108 ± 29

107 ± 29

112 ± 28

TAG/HDL-C Ratio

2.05 ± 0.75

2.15 ± 0.78

1.98 ± 0.73

2.10 ± 0.75

TC/HDL-C Ratio

3.29 ± 0.74

3.35 ± 0.74 ab

3.15 ± 0.65 a

3.53 ± 0.87 b

LDL/HDL-C Ratio

1.90 ± 0.66

1.94 ± 0.63 ab

1.77 ± 0.59 a

2.14 ± 0.77 b

LDL-C (mg/dL)

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given row with different superscriptsab
were significantly different from each other (p < 0.05), using one-way ANOVA.
*All lipid values, in the TAG/HDL-C ratio ≥ 3.8 group were significantly different from the corresponding
values in < 3.8 TAG/HDL ratio group.
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Table 4-4 shows the collective composition of the lipoprotein in the Malaysian cohort, and
particle distribution amongst the three ethnicities (MM, MC, and MI). The prominent HDL
subfraction in the Malaysian cohort is shown to be I-HDL (22.9 ± 5.0 mg/dL), followed by L-HDL
(15.8 ± 10.5 mg/dL), and S-HDL (6.88 ± 3.47 mg/dL). While the I-HDL, predominant subfraction,
there are no changes in its content amongst the ethnicities; nevertheless, fluctuations between
subfractions are observed in L-HDL and S-HDL subfractions. The 49% of MC patients had
significantly higher L-HDL (17.5 ± 11.8 mg/dL) in contrast to the 31% of MM (13.6 ± 8.50 mg/dL)
patients. Additionally, MC had a higher content in S-HDL (7.31 ± 3.54 mg/dL) subfraction in
relation to MI (5.50 ± 2.63 mg/dL) subjects. The VLDL was also higher in MC patients, (34.8 ±
10.1 mg/dL) and lower MI (30.2 ± 8.60 mg/dL). Congruently a marginal decrease in IDL
subfraction in MC (46.0 ± 13.4 mg/dL) is seen while MI patients content rises IDL (50.3 ± 14.7
mg/dL). Overall there no significant changes in LDL content were seen amongst ethnicities. A
pattern is perceived for which, a rise in VLDL is concurrently meet with decreases in IDL, L-LDL,
and S-LDL are seen. Cohort mean LDL particle size had an average (269.0 ± 5.78 Å) and other
changes of significance were recorded amongst the ethnicities. Phenotype analyses showed type
“A” LDL pattern as the most prominent, 64% collectively in Malaysian subjects, type “B” is 23%,
and type “AB” is 13%. The distribution of the phenotype amongst ethnicities also showed type
“A” as the dominant pattern in 61% of MM subjects, 64% of MC, and 70% for MI patients.
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Table 4-4: Lipoprotein subfraction composition in the Malaysian cohort.
Lipoprotein
Subfractions

Total
(n = 225) 1

MM
(n = 69)

MC
(n = 110)

MI
(n = 46)

L-HDL (mg/dL)

15.8 ± 10.5

13.6 ± 8.50 a

17.5 ± 11.8 b

14.9 ± 9.5 ab

I-HDL (mg/dL)

22.9 ± 5.0

22.6 ± 4.27

23.3 ±5.55

22.7 ± 4.67

S-HDL (mg/dL)

6.88 ± 3.47

7.12 ± 3.65 ab

7.31 ± 3.54 a

5.50 ± 2.63 b

VLDL (mg/dL)

33.5 ± 9.81

33.8 ± 9.71 ab

34.8 ± 10.1 a

30.2 ± 8.60 b

IDL (mg/dL)

47.2 ± 13.6

47.1 ± 12.8

46.0 ± 13.4

50.3 ± 14.7

L-LDL (mg/dL)

23.7 ± 8.61

23.0 ± 8.11

23.3 ± 9.01

25.6 ± 8.24

I-LDL (mg/dL)

13.2 ± 7.69

14.1 ± 8.93

12.5 ± 6.92

13.8 ± 7.38

S-LDL (mg/dL)

4.78 ± 7.58

5.41 ± 7.47

4.42 ± 6.87

4.70 ± 9.30

Mean LDL size (Å)

269.0 ± 5.78

268.5 ± 5.97

269.1 ± 5.58

269.4 ± 6.04

Phenotype “A” (n, %)

144 (64)

42 (61)

70 (64)

32 (70)

Phenotype “B” (n, %)

52 (23)

22 (32)

22 (20)

8 (17)

Phenotype “AB” (n, %)

29 (13)

5 (7)

18 (16)

6 (13)

Values are mean ± SD for the numbers in parentheses1. Values in a given row with different superscriptsab were
significantly different from each other (p < 0.05) using one-way ANOVA. Abbreviations: L-HDL, large-high density
lipoprotein; I-HDL, intermediate high-density lipoprotein; S-HDL, small high-density lipoprotein; VLDL, very-lowdensity lipoprotein; IDL, intermediate low-density lipoprotein; L-LDL, large low-density lipoprotein; I-LDL,
intermediate low-density lipoprotein; S-LDL, small low-density lipoprotein, Phenotype “AB,” is a phenotype
intermediate between A and B.
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Table 4-5 shows the lipoprotein composition when subfractions are separated into two
groups; ≥ 3.8 TAG/HDL-C ratio or < 3.8 TAG/HDL-C ratio in order to assess dyslipidemia.
Analyses showed that 65 patients (29% of the cohort) allocated in the ≥ 3.8 ration group had
significantly lower L-HDL (7.71 ± 3.76 mg/dL vs. 19.0 ± 10.6 mg/dL) lower I-HDL (19.0 ± 3.46
vs. 24.5 ± 4.65 mg/dL) while S-HDL had increased (8.54 ± 3.60 vs. 6.21 ± 3.19 mg/dL). Other
noted difference; the VLDL lipoprotein, which was significantly higher in the ≥ 3.8 ratio group
(40.8 ± 9.81 vs. 30.6 ± 8.13), also S-LDL was greater (11.6 ± 10.1 vs. 1.99 ± 3.55) whereas the
mean LDL size had decreased (263.6 ± 5.88 vs. 271 ± 2 ± 4.09) when compared to the < 3.8 ratio
group.
In summary: ≥ 3.8 TAG/HLD-C ratio in HDL subfraction analyses, was distinguished by
a decreased in L-HDL, and I-HDL followed by the rise in S-HDL; wherein <3.8 ratio represents
the opposite, depictive of increases in large and I-HDL while S-HDL decreases. For LDL
lipoprotein analyses ≥ 3.8 TAG/HLD-C ratio showed no changes in L-LDL, but changes were
revealed in the form of greater VLDL, I-LDL, S-LDL while mean LDL particle size had
significantly decreased in size. A < 3.8 ratio showed decreases in I-LDL, S-LDL (the dense
atherogenic particle), decreases for both IDL and VLDL, wherein mean LDL size is depicted by
an increase in diameter.
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Table 4-5: Lipoprotein composition according to, TAG/HDL-C ration (≥ or < 3.8) in the
Malaysian cohort

Lipoprotein Subfractions
Total
(n =65) 1

MM
(n=25)

MC
(n = 28)

MI
(n = 12)

L-HDL (mg/dL)

7.71 ± 3.76

7.24 ± 3.50

7.93 ± 3.90

8.17 ± 4.15

I-HDL (mg/dL)

19.0 ± 3.46

19.8 ± 3.49

18.6 ± 3.27

18.3 ± 3.82

S-HDL (mg/dL)

8.54 ± 3.60

8.16 ± 3.54ab

9.68 ± 3.52a

6.67 ± 3.17b

VLDL (mg/dL)

40.8 ± 9.81

39.8 ± 10.6

43.4 ± 9.02

37.0 ± 9.40

IDL (mg/dL)

48.3 ± 13.2

48.4 ± 14.3

47.7 ± 12.8

49.4 ± 12.5

L-LDL (mg/dL)

20.7 ± 7.70

21.0 ± 8.41

19.9 ± 7.92

22.1 ± 5.71

I-LDL (mg/dL)

18.3 ± 7.33

19.5 ± 9.06

16.9 ± 5.81

19.2 ± 6.45

S-LDL (mg/dL)

11.6 ± 10.1

11.8 ± 8.53

11.2 ± 9.23

12.3 ± 15.2

Mean LDL size (Å)

263.6 ± 5.88

263.5 ± 5.64

263.7 ± 5.24

263.9 ±8.04

*TAG/HDL-C ratio < 3.8

(n =160) 1

(n= 44)

(n = 82)

(n = 34)

L-HDL (mg/dL)

19.0 ± 10.6

17.2 ± 8.41

20.8 ± 11.8

17.3 ± 9.75

I-HDL (mg/dL)

24.5 ± 4.65

24.1 ± 3.89

24.8 ± 5.27

24.2 ± 3.95

S-HDL (mg/dL)

6.21 ± 3.19

6.52 ± 3.61

6.50 ± 3.18

5.09 ± 2.33

VLDL (mg/dL)

30.6 ± 8.13

30.3 ± 7.32ab

31.9 ± 8.74 a

27.8 ± 6.70 b

IDL (mg/dL)

46.7 ± 13.7

46.3 ± 11.9

45.3 ± 13.7

50.6 ± 15.6

L-LDL (mg/dL)

24.9 ± 8.68

24.2 ± 7.78

24.5 ± 9.10

26.8 ± 8.69

I-LDL (mg/dL)

11.2 ± 6.85

11.1 ± 7.37

10.9 ± 6.64

11.9 ± 6.80

S-LDL (mg/dL)

1.99 ± 3.55

1.77 ± 3.23

2.11 ± 3.75

2.00 ± 3.54

271 ± 2 ± 4.09

271.4 ± 3.96

271.0 ± 4.36

270.8 ± 4.10

*TAG/HDL-C ratio ≥ 3.8

Mean LDL size (Å)

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given row with different superscriptsab
were significantly different from each other (p < 0.05), using one-way ANOVA.
*All lipoprotein values, in the TAG/HDL-C ratio ≥ 3.8 group were significantly different from the
corresponding values in < 3.8 TAG/HDL-C ratio group, except for IDL and L-LDL subfraction.

83

Table 4-6 it examines D in plasma lipids amongst all ethnicities in the study cohort.
Dyslipidemia is defined on the basis of three categories dyslipidemic [D] (8% of the overall study
cohort), mixed dyslipidemic [MD] (52%) and normo-lipidemic [NL] (40%). All lipid values, in
the [D] group, were significantly different from the corresponding values in [MD and NL] groups.
There are also significant differences when comparing [MD] and [NL] lipid groups. The [D] AA
patients had significantly lower TAG (189 ± 42 mg/dL) levels, when compared with MI (314 ±
123 mg/dL) patients; congruently, TAG/HDL-C ratios in AA was lower compared to MI (5.73 ±
1.29 vs. 10.5 ± 6.11) subjects. Within the [MD] group, TAG levels (109 ± 35 mg/dL) and
TAG/HDL-C ratio (2.87 ± 1.16) of AA patients, which was lower when compared with the MM
patients, but not MC or MI. The [NL] group showed many differences between the AA patients
and the Malaysian.
In summary, the [D] group is typified by very TAG levels followed by low HDL-C levels.
As the degree of dyslipidemic changes and it shifts into mixed dyslipidemia, the very high level
of TAG declines, followed by an increase in HDL-C. A further shift from [MD] to [NL] is shown
to change the TAG level into low to normal TAG levels, whereas HDL-C increases.
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Table 4-6: Dyslipidemia in plasma lipids amongst ethnicities.
*Dyslipidemia [D]
Total (n = 127)
TAG (mg/dL)
HDL-C (mg/dL)
TC (mg/dL)
LDL-C (mg/dL)
NonHDL (mg/dL)
TAG/HDL-C Ratio
TC/HDL-C Ratio
LDL/HDL-C Ratio
*Mixed Dyslipidemia [MD]

Total (n = 181)
TAG (mg/dL)
HDL-C (mg/dL)
TC (mg/dL)
LDL-C (mg/dL)
NonHDL (mg/dL)
TAG/HDL-C Ratio
TC/HDL-C Ratio
LDL/HDL-C Ratio
*Normo-lipidemic [NL]
Total (n = 140)
TAG (mg/dL)
HDL-C (mg/dL)
TC (mg/dL)
LDL-C (mg/dL)
NonHDL (mg/dL)
TAG/HDL-C Ratio
TC/HDL-C Ratio
LDL/HDL-C Ratio

AA
(n = 9)
189 ± 42 a
33 ± 5
202 ± 12
131 ± 17
169 ± 47
5.73 ± 1.29 a
6.21 ± 1.33
4.06 ± 1.24

MM
(n =8)
231 ± 47 ab
33 ± 4
215 ± 28
136 ± 32
181 ± 27
7.09 ± 2.05 ab
6.51 ± 0.98
4.10 ± 0.90

MC
(n = 7)
212 ± 36 ab
35 ± 4
209 ± 18
132 ± 20
173 ± 15
6.16 ± 1.78 ab
5.95 ± 0.43
3.74 ± 0.33

MI
(n= 3)
314 ± 123 b
32 ± 6
224 ± 26
128 ± 7
192 ± 29
10.5 ± 6.11 b
7.20 ± 2.11
4.07 ± 0.84

(n = 55)

(n = 39)

( n= 56)

(n = 31)

109 ± 35 a
40 ± 12
161 ± 44
99 ± 36
121 ± 38
2.87 ± 1.16 a
4.11 ± 1.04
2.55 ± 0.96
(n = 59)

154 ± 74 b
40 ± 8
164 ± 31
94 ± 25
124 ± 27
4.13 ± 2.49 b
4.15 ± 0.72
2.36 ± 0.52
(n = 22)

145 ± 68 b
43 ± 10
168 ± 37
97 ± 30
125 ± 31
3.63 ± 2.12 ab
3.95 ± 0.77
2.25 ± 0.58
(n = 47)

124 ± 57 ab
40 ± 8
164 ± 28
101 ± 22
125 ± 24
3.35 ± 1.96 ab
4.26 ± 0.81
2.62 ± 0.62
(n = 12)

64 ± 26 a
62 ± 18
128 ± 29 a
54 ± 22 a
66 ± 24 a
1.13 ± 0.56 a
2.16 ± 0.53 a
0.94 ± 0.46 a

89 ± 26 b
52 ± 9
145 ± 18 ab
76 ± 18 b
93 ± 20 b
1.81 ± 0.75 b
2.87 ± 0.57 b
1.52 ± 0.48 b

93 ± 30 b
56 ± 16
151 ± 24 b
76 ± 17 b
95 ± 19 b
1.78 ± 0.74 b
2.82 ± 0.53 b
1.46 ± 0.46 b

79 ± 21 ab
55 ±9
144 ± 19 ab
74 ± 16 b
89 ± 18 b
1.45 ± 0.37 ab
2.66 ± 0.48 b
1.38 ± 0.46 b

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given row with different superscriptsab
were significantly different from each other (p < 0.05), using one-way ANOVA. *All lipid values, in the D group
were significantly different from the corresponding values in MD and NL groups; similarly, there were differences
between MD and NL groups. Lipid classification were NL: TAG < 150 mg/dL, HDL-C > 40 mg/dL and LDL-C <
100 m/dL; D: TAG > 150 gm/dL, HDL-C < 40 mg/dL and LDL-C >100 mg/dL; MD: at least one of the D and/or NL
group.
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Figure 4-2 shows the distribution of HDL lipoproteins measured in both US and Malaysian
cohorts. AA patients had significantly higher L-HDL (22 ± 15.9 mg/dL) when compared to MC
(17.5 ± 11.8 mg/dL), MI (14.9 ± 9.51 mg/dL), and MM (13.6 ± 8.50 mg/dL). No changes were
seen in I-HDL subfraction, in all four ethnicities values were equally distributed. The S-HDL
lipoprotein was significantly higher in MC patients (7.31 ± 3.54 mg/dL) when compared with AA
(5.94 ± 3.19 mg/dL) and MI (5.5 ± 2.63 mg/dL) subjects. The analyses showed that most of shifting
and remodeling of the HDL subfractions seems to reside between the large and small-HDL.
Figure 4-3 shows VLDL and IDL subfraction composition for both PATCH trials (total
patients 348). Analyses showed that VLDL lipoproteins were significantly lower (25.4 ± 10.2
mg/dL) with respect to MI, (30.2 ± 8.60 mg/dL), as well as MM (33.8 ± 9.71 mg/dL) and MC
(34.8 ± 10.1 mg/dL). IDL lipoproteins did not show any notable changes in the subfraction
distribution and amongst the four ethnicities. It is worth noting marginal differences between IDL
composition, which was higher in MI patients when comparing differences with MC subjects (50.3
± 14.7 vs. 46.0 ± 13.4 mg/dL).
Figure 4-4 shows the overall LDL lipoprotein subfractions measurements amongst the
ethnicities. The L-LDL subfraction is the predominant lipoprotein in the LDL lipoprotein analyses.
The large buoyant LDL is considered protective with respect to the smaller dense LDL. Current
data between the four ethnicities show no changes, and the L-LDL is equally represented. Ethnic
MI had significant higher L-LDL content (25.6 ± 8.24 mg/dL), whereas the lowest resides with in
AA patients (22.0 ± 15.9 mg/dL). No changes were recorded for the I-LDL, nor in the S-LDL.
However, is worth noting, that MM had the highest content of S-LDL (5.41 ± 6.9 mg/dL) and
lowest in AA, thus shows minor changes within the subfraction.
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Figure 4-2: HDL subfractions composition amongst ethnicities.
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05),
using one-way ANOVA.
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Figure 4-3: VLDL and IDL subfraction composition between ethnicities.
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05),
using one-way ANOVA.
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Figure 4-4: LDL lipoprotein subfraction composition between ethnicities.
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05),
using one-way ANOVA. N.S., differences were observed between the LDL lipoproteins in the ethnic patients.
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Figure 4-5 shows dyslipidemia of lipoprotein subfractions, for the collective cohort of 348
patients analyzed. The investigation found 8% which are [D] patients had significantly lower LHDL (7.56 ± 3.6 mg/dL) and I-HDL (12.7 ± 7.44 mg/dL) while the S-HDL (8.11 ± 3.18 mg/dL)
was higher content.. Additionally, [D] subjects had higher VLDL values (46.6 ± 10.1 mg/dL), as
well as IDL (62.9 ± 11.7 mg/dL). The L-LDL, (25.6 ± 8.80 mg/dL) I-LDL (23.8 ± 7.85 mg/dL),
and S-LDL (16.4 ± 11.3 mg/dL) were also higher in relation to [MD] and [NL] patients.
Table 4-7 shows the analyses of the dyslipidemic lipoproteins amongst ethnicity. Samples
were separated into three groups [D-8%], [MD-52%], and [NL-40%], which allowed us to
compare the subfractions for differences between the four ethnicities. All lipoprotein values, in the
[D] group, were significantly different from the corresponding values in [MD and NL] groups;
similarly, there were differences between [MD] and [NL] groups.
The key feature with the [D] group; as shown in all patients, irrespective of ethnicity, for
which cause subject present a cohort where lower L-HDL, lower I-HDL, followed by the rise in
the S-HDL is common. At the same time, [D] subjects are presented by higher VLDL and IDL,
marginal difference in L-LDL (concerning MD and NL groups), higher I-LDL, and significantly
higher S-LDL followed by a reduced LDL particle size.
Patients in the [D] group, had a greater IDL content, which was found to be higher in AA
(71.0 ± 6.04 mg/dL) patients when compared to MM (56.4 ± 16.9 mg/dL), but not significant with
MC and MI patients. In the [MD] group, I-HDL was higher in MI patients (22.5 ± 4.6 mg/dL)
when compared to AA (19.7 ± 5.09 mg/dL); also, within [MD] group, MC patients (8.04 ± 3.62
mg/dL) had higher values of S-HDL when compared to MI patients (5.81 ± 2.06 mg/dL). VLDL
was lower in the AA (28.8 ± 9.40 mg/dL) patients compared to MC (37.1 ± 9.03) as well MI (31.8
± 6.35 mg/dL). Within the [NL] group, there are differences between AA (31.7 ± 16.3 mg/dL) who
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present with a higher content of L-HDL concerning MM (20.0 ± 9.42 mg/dL) and MC (24.1 ± 13.3
mg/dL). VLDL values for [NL] group was also lower in AA (20.0 ± 6.55 mg/dL) patients in
relation to MM and MC. MI patients had significantly higher L-LDL (26.1 ± 5.43 mg/dL) with
respect to AA in the [NL] group.
Figure 4-5: Dyslipidemic in lipoprotein subfractions in the overall study cohort.
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05),
using one-way ANOVA.
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Table 4-7: Dyslipidemia in lipoprotein subfractions amongst ethnicities.
Lipoprotein
Subfractions
[D] (n=27) 1
L-HDL (mg/dL)
I-HDL (mg/dL)
S-HDL (mg/dL)
VLDL (mg/dL)
IDL (mg/dL)
L-LDL (mg/dL)
I-LDL (mg/dL)
S-LDL (mg/dL)
Mean LDL size (Å)

AA
(n = 9)
8.56 ± 3.84
17.4 ± 1.81
7.56 ± 1.88
40.3 ± 11.2
71.0 ± 6.04a
26.9 ± 8.57
20.8 ± 7.12
11.4 ± 13.5
265.0 ± 6.18

MM
(n = 8)
6.75 ± 2.82
19.6 ± 2.87
7.13 ± 2.53
48.6 ± 9.58
56.4 ± 16.9 b
26.4 ± 10.2
29.0 ± 8.82
17.4 ± 7.11
262.1 ± 3.76

MC
(n = 7)
7.00 ± 3.96
18.0 ± 2.00
10.1 ± 3.29
53.0 ± 4.08
59.1 ± 5.93ab
23.4 ± 9.95
20.6 ± 4.08
18.4 ± 9.85
261.0 ± 5.23

MI
(n = 3)
8.00 ± 5.29
16.3 ± 6.66
7.67 ± 6.51
45.3 ± 11.1
65.0 ± 4.00 ab
24.3 ± 4.62
26.3 ± 9.02
23.7 ± 16.3
259.0 ± 8.54

[MD] (n= 181) 1
L-HDL (mg/dL)
I-HDL (mg/dL)
S-HDL (mg/dL)
VLDL (mg/dL)
IDL (mg/dL)
L-LDL (mg/dL)
I-LDL (mg/dL)
S-LDL (mg/dL)
Mean LDL size (Å)
[NL] (n=140) 1
L-HDL (mg/dL)
I-HDL (mg/dL)
S-HDL (mg/dL)
VLDL (mg/dL)
IDL (mg/dL)
L-LDL (mg/dL)
I-LDL (mg/dL)
S-LDL (mg/dL)
Mean LDL size (Å)

(n = 55)
13.8 ± 8.93
19.7 ± 5.09 a
6.64 ± 3.18 ab
28.8 ± 9.40 a
51.4 ± 15.1
24.6 ± 10.6
15.8 ± 8.47
5.22 ± 5.83
268.1 ± 4.45
(n = 59)
31.7 ± 16.3 a
25.1 ± 5.16
5.05 ± 3.14
20.0 ± 6.55 a
38.7 ± 10.4
19.4 ± 7.74 a
8.17 ± 4.57
1.41 ± 2.26
271.4 ± 3.60

(n = 39)
11.3 ± 6.29
21.5 ± 3.82 ab
7.54 ± 3.83 ab
33.8 ± 8.14 bc
48.3 ± 13.0
22.6 ± 8.19
14.3 ± 6.53
5.46 ± 6.84
267.6 ± 6.2
(n = 22)
20.0 ± 9.42 b
25.5 ± 3.92
6.36 ± 3.67
28.2 ± 6.19 b
41.4 ± 7.61
22.5 ± 7.20 ab
8.46 ± 6.12
0.96 ± 1.99
272.4 ± 3.50

( n = 56)
13.2 ± 7.49
21.9 ± 5.08 ab
8.04 ± 3.62 a
37.1 ± 9.03 b
47.8 ± 15.4
23.8 ± 11.2
13.7 ± 6.58
5.27 ± 6.59
267.9 ± 5.74
(n = 47)
24.1 ± 13.3 b
25.7 ± 5.39
6.02 ± 3.00
29.3 ± 7.36 b
41.8 ± 9.49
22.6 ± 5.31 ab
9.72 ± 6.33
1.32 ± 2.62
271.7 ± 3.46

(n = 31)
11.1 ± 5.31
22.5 ± 4.6 b
5.81 ± 2.06 b
31.8 ± 6.35 c
51.5 ± 15.4
25.5 ± 9.45
14.2 ± 6.89
4.42 ± 8.31
269.3 ± 5.78
(n = 12)
26.5 ± 9.39 ab
24.6 ± 2.78
4.17 ± 2.37
22.4 ± 5.62 ab
43.4 ± 11.3
26.1 ± 5.43 b
9.67 ± 4.07
0.67 ± 1.23
272.3 ± 2.39

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given row with different superscriptsab
were significantly different from each other (p < 0.05), using one-way ANOVA.*All lipoprotein values, in the [D]
group were significantly different from the corresponding values in [MD and NL] groups; similarly, there were
differences between [MD] and [NL] groups.
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Figure 4-6 shows the effect of D on particle size and LDL phenotype. Analyses show that
dyslipidemic [D] subjects are typified by a 63% chance in having a pattern “B” phenotype LDL
particle. Type “B” has been associated with the smaller and dense LDL lipoproteins which have
been linked as a high risk for mortality. Additionally, a type “B” has aa smaller particle size (258.9
± 3.4Å). It is worth noting, that in whether [D] group, [MD], or [NL] the difference between the
particle size is significant, mainly due to the association with the phenotype of the LDL particle.
No major differences were observed within ethnicities. Analysis shows that, as the cohort shifts
from [D] subjects (63% and a type “B”) into [MD] the phenotype shifts into a type “A” 56% also
which is associated with higher particle size (272.0 ± 2.4 Å). A further shift in the cohort [NL]
(type A becomes more prominent and has a higher chance of 84% with an increase in particle size
(272.9 ± 2.2 Å).
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Figure 4-6: Dyslipidemia in mean LDL particle size within ethnicities.

Phenotype

Particle (Å)
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Total (n = 27) 1

(n = 9)

(n =8)

(n = 7)
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A (n, %)

5 (18.5)
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257.7 ± 4.2

261.0 ± 2.2

258.2 ± 1.5

255.0 ± 7.1
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5 (18.5)

3 (33)

0 (-)

1 (14)

1 (33)

266.7 ± 1.2

-

265.0 ± 0

267.0 ± 0.0

c

Particle Size

266.4 ± 1.1

[MD]

Total (n = 181) 1

(n = 55)

(n = 39)

( n= 56)

(n = 31)

A (n, %)

101 (56)

29 (53)

22 (56)

30 (54)

21 (68)

Particle Size

272.0 ± 2.4 a

271.6 ± 2.2

271.7 ± 2.7

272.4 ± 2.2

272.1 ± 2.6

B

47 (26)

13 (24)

13 (33)

15 (27)

6 (19)

Particle Size

260.9 ± 3.8 b

262.0 ± 2.2

260.8 ± 4.5

260.1 ± 2.8

260.7 ± 6.8

AB
Particle Size

33 (18)

13 (24)

4 (10)

11 (20)

4 (13)

266.7 ± 0.8 c

266.5 ± 1.1

267.3 ± 0.5

266.5 ± 0.5

267.0 ± 0.8

[NL]

Total (n = 140) 1

(n = 59)

(n = 22)

(n = 47)

(n = 12)

A (n, %)

117 (84)

48 (81)

19 (86)

39 (83)

11 (92)

Particle Size

272.9 ± 2.2 a

272.7 ± 2.2

273.5 ± 2.3

272.9 ± 2.4

272.8 ± 1.8

B

7 (5)

3 (5)

2 (9)

2 (4)

0

Particle Size

263.1 ± 1.9 b

262.0 ± 2.0

265.0 ± 0.0

263.0 ± 1.4

-

AB
Particle Size

16 (11)

8 (14)

1 (5)

6 (13)

1 (8)

267.1 ± 0.93 c

267.0 ± 0.9

267.0 ± 0.0

267.2 ± 1.2

267.0 ± 0.0

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given column with different
superscriptsabc were significantly different from each other (p < 0.05), using one-way ANOVA.
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CHAPTER 5: RESULTS – SPECIFIC AIM 3: TO DOCUMENT THE EXTENT TO
WHICH HDL ENZYMES CONTRIBUTE TO DYSLIPIDEMIA IN MHD PATIENTS.
The study flow is shown in Figure 5-1. The study was the collective analysis of RCT
enzymes CETP and LCAT. Samples from the PATCH (USA) (n = 123), additionally to the
PATCH Malaysia (n = 225), were used. From n =348 samples, three were excluded during LCAT
measurements (samples were beyond the detection range). Since this investigation was an
extension of subset inquiry from the joint PATCH studies, no additional approvals were required.
Figure 5-2 shows the CETP activity measured in 348 participating patients. Analyses
showed that the mean collective cohort for CETP activity was (41.0 ± 18.6 nmol/mL/hr). Results
showed that MC subjects (35.8 ± 17.0 nmol/mL/hrs.) had a significantly lower CETP activity than
MM (45.8 ± 19 nmol/mL/hrs.) and MI (44.7 ± 18.9 nmol/mL/hrs.) patients. No difference was
recorded amongst AA (41.6 ± 18.7 nmol/mL/hrs.) patients and the other ethnicities. CETP is
known to facilitate the exchange between CE and TAG amongst HDL and VLDL/LDL particles,
and within this study, we recorded a strong inverse correlation (r = -0.201) (p<0.001) between
CETP activity and TAG levels (Appendix Figure 2).
Figure 5-3. CETP activity was analyzed amongst ethnic patients. To examine the effect of
D on CETP activity, we separated data into two groups ≥ or < 3.8 TAG/HDL ratio. Analyses
showed that AA patients had significantly lower CETP activity in subjects allocated into the ≥ 3.8
TAG/HDL-C ratio (32.1 ± 14.0 vs. 43.1 ± 19.0 nmol/mL/hrs.) in relation to AA patients with <
3.8 TAG/HDL-C ratio. No other differences were recorded amongst MM, MC and MI patients.
Additional analyses found a correlation between CETP and TAG/HDL-C ratio, which was noted
to be a strong inverse association (r = -0.153) (p<0.004) (Appendix Figure 3).
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Figure 5-1: Aim 3 study flow.
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Figure 5-2: CETP activity amongst the ethnicities in the study cohort.
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05)
using one-way ANOVA.
Average CETP activity for all (n=348) patients: 41.0 ± 18.6 nmol/mL/hr.
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Figure 5-3: CETP activity based on categorical TAG/HDL-C ratio (≥ or < 3.8).
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05)
using one-way ANOVA.
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Figure 5-4 shows CETP activity analyzed based on the dyslipidemic criteria. Results
showed that [D] (36.0 ± 14.5 nmol/mL/hrs.), [MD] (41.6 ± 20.1 nmol/mL/hrs.) and [NL] (41.2 ±
17.2 nmol/mL/hrs.) patients showed no differences in the activity.
Figure 5-4: CETP activity between dyslipidemic groups.

72
41.6 ± 20.1

64

CETP Activity ( nmol/ mL / hr.)

56
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48
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(n = 27)

[MD]
(n = 181)
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05)
using one-way ANOVA. Classification: [NL]: TAG < 150 mg/dL, HDL-C > 40 mg/dL and LDL-C < 100 m/dL;
[D]: TAG > 150 gm/dL, HDL-C < 40 mg/dL and LDL-C >100 mg/dL; [MD]: at least one of D and /orNL group.
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Figure 5-5 shows LCAT activity amongst the four ethnicities. In a collective cohort of 345
patients, the mean average LCAT activity was (0.86 ± 0.13 ratio of 470/390 nm ). Analyses
showed, that AA patients had significantly higher LCAT activity (0.89 ± 0.17 ratio of 470/390
nm) when compared to MC (0.84 ± 0.10 ratio of 470/390 nm) subjects and MI patients (0.81 ±
0.06 ratio of 470/390 nm.)
Figure 5-5: LCAT activity between the ethnicities.
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05)
using one-way ANOVA. Total of (n = 345) MHD plasma samples were analyzed, for a cohort average of (0.86 ± 0.13
ratio of 470/390 nm)
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Figure 5-6: shows LCAT activity measured between the four ethnic patients. Analyzed
samples were separated into two groups ≥ or < 3.8 TAG/HDL ratios. Results showed that there
were no differences between the ethnicities. Additionally, a correlation between LCAT activity
and TAG levels was conducted, (r = -0141) (p<0.009) (Appendix Figure 4).
Figure 5-6: LCAT activity based on the categorical TAG/HDL-C ratio (≥ or < 3.8).
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05)
using one-way ANOVA.
NS, values were recorded between LCAT activities amongst ethnicities.
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Figure 5-7 shows the analyses of LCAT activity between D on the bases of [D, MD, NL].
We noted that LCAT activity was significantly lower in [D] patient (0.81 ± 0.12 ratio of 470/390
nm) when compared against [MD] (0.86 ± 0.12 ratio of 470/390 nm) and [NL] (0.87 ± 0.12 470/390
nm).

Figure 5-7: LCAT activity between dyslipidemic groups.
1.2
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05)
using one-way ANOVA.
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Figure 5-8 shows the overall summary of samples analyzed in the investigation including
CRP (n = 324) and AGE-CML, a subset from the AA cohort (n = 59). In the CRP analyses, while
the complete set was measured, n = 24 samples were excluded (plasma samples were beyond the
detection range). Similarly, n = 1 in the AGE-CML analyses was excluded due to the sample being
beyond the detection range.
Figure 5-8: Overall summary of the samples measured in the overall investigation.
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Figure 5-9 shows, analyses of the baseline CRP for the collective PATCH trial. The study
measured (n = 324) plasma samples. The analysis showed elevated CRP levels in both cohorts for
an average mean 9.61 ± 9.72 mg/L. CRP concentration amongst ethnicities was noted to be
statistically higher in AA patients (13.0 ± 12.6 mg/L) when compared to MM (7.6 ± 6.9 mg/L),
and MC (7.3 ± 6.9 mg/L), however not the MI (10.1 ± 9.1 mg/L) patients.
Figure 5-9: C-reactive protein levels between the ethnicities.
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Values are mean ± SD. Values with different superscriptsab were significantly different from each other (p < 0.05)
using one-way ANOVA. Overall study CRP plasma levels for (n) = 324 subjects at baseline: 9.61 ± 9.72 mg/L. Data
were adjusted using ANCOVA, for the covariate factor such as BMI.
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Table 3-13 shows the analyses of advanced glycation products. AGEs-CML were
measured in the plasma from a subset of AA patients (n = 59). The overall analyses measured an
average AGE-CML concentration of 4.2 ± 2.4 ng/ml. There were no differences in AGE-CML
amongst gender groups; no difference were observed in the DM versus non-DM group. The lipid
ratios of TAG/HDL-C ratios and [D, MD, NL], also recorded no significant change amongst the
groups in AGE-CML levels.
Table 5-1: AGEs-CML analyses in the US cohort.
Parameter

AGEs – CML (ng/mL)
(n = 59)1

P-values

Total concentration levels

4.2 ± 2.4

-

Men (n = 37)

4.5 ± 2.4

Female (n =22)

3.6 ± 2.2

DM (n = 40)

4.3 ± 2.6

Non-DM (n =19)

3.9 ± 1.9

TAG/HDL-C ratio ≥ 3.8 (n=12)

4.2 ± 2.2

TAG/HDL-C ratio < 3.8 (12 = 47)

4.2 ± 2.5

[D] (n = 6)

4.7 ± 2.7

[MD] (n = 31)

3.6 ± 2.1

[NL] (n = 22)

4.7 ± 2.6

0.134

0.584

0.972

0.217

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given group with different superscriptsab
were significantly different from each other (p < 0.05), using one-way ANOVA. Type-II DM patients had higher CML
in the plasma (4.3 ± 2.6 ng/mL) vs. Non-DM (3.9 ± 1.9 ng/mL) and higher CRP (14.2 ± 13.7 mg/L vs 11.9 ± 10.9
mg/L), but, the patterns did not show a correlation based on Person R which recorded a p=-0.107. Abbreviation:
AGEs-CML, Advanced glycation end-products- Nε-carboxymethyl-lysine
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Additional analyses and results
Appendix B Figure 1 shows AGE-CML plasma analyses in relation to BMI. It was
observed that lower BMI had higher CML levels (6.37 ± 0.61 ng/mL). As BMI increased, CML
levels declined gradually, with a higher BMI of ≥45 having the lowest CML levels (0.92 ± 0.5
ng/ML) in plasma. These findings were not significant, and the sample size was not large.
Appendix B Figure 2 shows the percent risk fact and the atherogenic index were evaluated
for the collective cohort. Data showed that AA patients were at a higher risk (23%) when compared
to MM, MC, and MI. The findings were compared with the atherogenic index of plasma, in which
case, MM, MC, and MI patients of the Malaysian cohort were at higher risk and not AA. These
two contradictory findings are in dispute and need to be further evaluated on a future study when
mortality rate data is available.
Appendix B Figure 3 shows the analyses of CRP in relation to dyslipidemia. Data shows
a decreasing trend from [D] to [MD] and [NL]; however, these changes did not achieve
significance.
Appendix B Figure 4 shows the analyses of CRP amongst the four ethnicities, when
analyzed by TAG/HDL-C ratio ≥ or < 3.8. No significant differences were observed between the
two groups within the respective ethnicities. However, a trend is seen, in which case, MHD patients
allocated in the ≥ 3.8 ratio group had higher CRP levels when compared to their counterparts of
the < 3.8 ratio group.
Appendix B Table 1 shows the demographics of the collective cohort in the US and
Malaysian cohort. Noted differences are MM patients have are significantly younger than AA,
MC, and MI. Roughly 83% of the collective cohort are non-smokers, 48% of the combined studies
have DM, and 85% are hypertensive. While in the US, many physicians have begun to scale back

106

on prescribing statin since various studies have found that LDL is not a primary issue in ESRD
patients; in Malaysia statin use is still considered. BMI was significantly different due to AA
patients being obsessed with a BMI of 30, whereas the Malaysians had a lower BMI of 25. Other
differences were observed in albumin concentration, systolic B/P and Kt/V.
Appendix B Table 2 shows the lipoprotein composition between gender and differences
between ethnicities. Analyses show that females overall have higher L-HDL, I-HDL, and S-HDL,
in addition to VLDL and IDL subfractions. Males have a higher composition of the S-LDL.
Appendix B Table 3 shows lipid analyses in statin versus the non-statin group. The statin
group overall has higher levels of TAG (129 ± 72 vs. 105 ± 52 mg/dL) and higher nonHDL
cholesterol. Analyses show differences between the ethnicities within the statin or non-statin
groups; of which the differences are observed between AA patients and the Malaysian cohort.
Appendix B Table 4 shows lipoprotein subfraction analyses composition with respect to
statin and non-stain use. No significant difference due to statin use was observed in lipoprotein
analyses. Only differences shown are between ethnicities in either the statin and/or nonstatin
group; thus, the use of statin is not a factor in subfraction composition.
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CHAPTER 6: DISCUSSION
The US is the most industrialize and developed nation in the world, although, despite the
advancements in science and medicine in the past 20 years has yet to provide answers on how to
slow the development and progression of diseases such as CKD and ESRD. More disappointing is
the fact that both diseases CKD and ESRD, cost of care are on the rise and expected to reach $100
billion ($34 billion just for ESRD) [126], which is an unsustainable development. Moreover, this
burden is shared with similar parallels across the world. Malaysia, one of the fastest developing
countries, composed of multiple ethnicities (Malays, Chinese, Indian), has had an upsurge in the
incidence of ESRD due to DM nephropathy, which has nearly reached a seven-fold increase and
continue to rise [221, 222]. Moreover, progression into ESRD has been increasing at an estimated
rate of 6-9%, which as of late has catapulted the country in the 8th place as industrialized nations,
which will face the peril of the disease, and economic burden [16].
Moreover, the significant increases in CVD and the associated mortality within the
population, cannot be explained by the traditional risk factors such as elevated LDL-C serum and
low levels of HDL-C [78]. Usually, ESRD patients present with declined HDL-C and increases
in TAG levels [223]. However, these patients are affected by a phenomenon known as “reverse
epidemiology,” in which parameters such as high HDL-C and low LDL-C plasma concentration
may not be as protected when compared with their healthy counterpart [81]. Moreover, both HDL
and LDL lipoproteins consist of multiple subfractions, composed of different sizes, different
densities, that appear to exhibit different metabolic behaviors. Numerous studies have indicated
that the quality of these subfractions was maybe more important than quantity, which leads us to
believe in the possibility of lipoprotein subfraction dysfunction as a major issue [224, 225]. HDL
in specific has been an area of interest due to the anti-inflammatory and antioxidant properties it
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exhibits. Thus, many studies and clinical interventions have focused on raising the HDL with
inconclusive results. It has been suggested that dysfunctional HDL is caused by exposure to
prolonged inflammation and oxidative stress; moreover, this may mitigate cholesterol efflux in
ESRD patients. [65]. Numerous investigations have also looked at the RCT pathway, and the
associated enzyme CETP, LCAT, or LPL, but studies have had inconclusive results.
ApoA-I has been another area of investigation, since it is the most abundant protein on
the HDL particles, wherein various reports have shown a decrease in ApoA-I concentration,
which has been linked with the downregulation of the ApoA-I gene [66, 226]. ESRD is a
multifaceted process, which involves various confounding factors over time. The patients
experience a series of abnormal disorders such as inflammation, OS, D, malnutrition, and
endothelial dysfunction. D is primarily the result of decreased HDL and increased TAG levels,
followed by normal and/or increased LDL. However, the contribution of each of these parameters
to D is poorly understood; moreover, the contribution of the following parameters to D in
different ethnicities is unknown. Additionally, ESRD patients present with the accumulation of
oxidized lipids, lipoproteins followed with low plasma HDL-C along with impaired HDL
maturation and function [78].
This investigation was developed in order to shed light and understand the complexity of
inflammation and D in a group of multi-ethnic cohorts of MHD patients. Subjects in this study are
part of the “PATCH” USA, and Malaysia, where patients were provided with a TRF supplement
or placebo for the duration of 12-months. Specifically, this dissertation focuses on the baseline
analyses of the multi-ethnic MHD patients, with the primary objective of characterizing and
describing dyslipidemia through lipids, lipoproteins, reverse cholesterol transport key enzymes,
and other markers of inflammation and or OS.
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The central hypothesis of this study is that dyslipidemia amongst MHD patients of different
ethnicities will reflect underlying alterations in lipoproteins and enzymes of lipid metabolism. The
rationale for the proposed study is that once a dyslipidemic MHD profile is determined,
interventions could be used to manage dyslipidemia.
The study dissertation is composed of four ethnicities, AA, MM, MC, and MI, with an
average age of 56 ± 13 years old. Age was noted to be significantly higher (older) in AA patients
compared to their counterparts. The majority of the MHD cohort is composed of 61%, males,
whereas 39% are females. Collectively US and Malaysian cohort was more hypertensive 85% and
48% DM. This was a surprising finding in this study since the leading cause, and the most
prominent contributor to disease development is primarily DM followed by HTN. Another
confounding factor was BMI. Analyses showed a difference between the ethnicities, with AA
having the highest BMI. At 30.0 ± 7.5 kg/m2, it is classified as obese, whereas the Malaysian
cohort had a BMI of 25 ± 4.1 kg/m2 which is overweight. To the generally healthy population, a
higher BMI has been linked to being unhealthy and prone to disease. However, this is not the case
for MHD population; a high BMI considered is protective due to the obesity paradox in the context
of reverse epidemiology [227, 228]. An investigation by Kalantar-Zadeh et al (2014) postulated
the U-shaped BMI, in CKD patients between <25 kg/m2 and/or ≥35 kg/m2 were associated with
worse outcomes in all patients; this happens to be independent of severity of CKD [229], thus
based on the study cohort, AA subjects may be more protected than their Malaysian counterparts.
Lipids in the AA and the Malaysian cohort were recorded to be within the normal range:
TAG <150 mg/dL, HDL-C was greater 40-60, TC < 200 and, LDL-C <100mg/dL. Nonetheless, a
difference between the two cohorts was recorded. Results showed AA patients having different
values in lipids when compared with MM, MC, and MI.
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The lipid profile for AA subjects was characterized by significantly lower TAG, TC, LDLC, NonHDL, TAG/HDL ratio, TC/HDL ratio, LDL/HDL ratio, and higher HDL-C when compared
with the Malaysian patients. Furthermore, the study did not observe any differences within the
Malaysian ethnicities. Other lipid analyses based on the genders, showed that irrespective of the
ethnicity, females overall had higher TAG levels compared to men. Women also had higher HDLC, higher TC, LDL-C, NonHDL, in addition to the lipid ratios. Dyslipidemia was also assessed
amongst the complete cohort (n=348) and ethnicities based on the TAG/HDL-C ratio (≥ or < 3.8).
The ≥ 3.8 TAG/HDL-C ratio group, was significantly higher in TAG, TC, LDL-C, NonHDL, and
lower HDL-C lipid values. Similar results were attained when dyslipidemic grouping (≥ 3.8 ) were
analyzed for the four ethnicities AA, MM, MC and MI. Moreover, another investigator Moradi et
al. (2014) [83], applied the lipid ratios, obtaining similar results in lipid profiles.
Characterizing HDL and LDL lipoprotein subfractions distribution was one of the primary
goals of this investigation. However, unlike lipid analyses, data on lipoproteins and their
distribution, especially in a multiethnic cohort of MHD patients, lacks results to compare findings,
in addition to uncertainties on how to interpret results in such a dynamic population.
Advancements in molecular techniques have made it possible to assess the concentration of
individual HDL and LDL lipoprotein subfractions. Using the Lipoprint by Quantimetrix gel
electrophoresis as the basis to separate the lipoproteins into different subfractions. HDL Lipoprint
analysis can generate ten fractionated lipoproteins (HDL1-10); additionally, it combines the
particles into three classes creating the L-HDL (HDL1-3), I-HDL (HDL4-7) and S-HDL (8-10).
Few studies in the field of cardiovascular disease have attempted to understand HDL functionality,
as well as the three subfractions, large, intermediate and small, on what they may represent in
CVD. Even less is known concerning the field of MHD on what the subfractions represent. Using
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the Lipoprint method, the understanding used to be that the L-HDL was similar to HDL2 which
meant was protective. However it is not the case, because HDL2 is different species of the
lipoprotein; moreover, it was attained via ultracentrifugation, a different technique thus, not
possible to compare at this time [176]. I-HDL was also shown to be on the protective part of the
HDL spectrum; and, the S-HDL was interpreted and identified to be the atherogenic part of the
HDL family depictive of HDL3, again not the same lipoprotein species [230, 231]. However, the
above premise that L-HDL is protective, and S-HDL was not has been a heated debate and a new
shift in different thinking. The IDEAL and EPIC case-control studies have shown contrary
evidence to the old belief, that the L-HDL was protective. Analyses showed that elevated plasma
HDL-C levels (≥70 mg/dL) and the L-HDL particles were associated with a higher risk for CVD.
In contrast, the S-HDL particle has shown that it may be more functional thus, more efficient in
promoting cholesterol efflux from macrophage to remove excess cholesterol [108].
The LDL-subfraction analysis has been a robust understanding; using the same method, it
can generate seven LDL subfractions [LDL1-7], as well as measuring concentrations of VLDL
subfraction, followed by IDL. The seven LDL-subfraction are further combined into three groups:
L-LDL (LDL1), I-LDL (LDL2), and S-LDL (LDL3-7). This analysis can also provide the patients
mean LDL particle size (diameter) of the lipoprotein for which three-phenotype profiles are
generated A, B, and Intermediate [AB]. Suggested evidence points to the importance of this feature
since it can predict the development and progression of coronary heart disease (CHD) [232]. More
studies have looked at the importance of these phenotypes, that were established based on
cholesterol LDL subfractions, for which a “pattern-A” corresponds to the larger and more buoyant
(LDL1) lipoprotein, speculated to be protective. The other profile is “pattern-B” corresponds to
the smaller, denser, and more atherogenic LDL-[3-7] lipoproteins, which bears a higher risk for
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oxidation. It has been recognized through various investigations that the small denser LDL
lipoprotein has the potency of being uptake more freely by arterial tissues where they can oxidize
during disease physiology.
Additionally, they decrease the receptor-mediated uptake and increase the proteoglycan
binding, thus decreased anti-oxidant concentration [78]. The least described profile, which is in
the middle between “A & B” is “pattern-Intermediate” corresponds to (LDL2), also known as [AB]
profile. It is a very fluid and influx profile for which dependent on the different stages of the disease
the subject could be under; it can shift to either side “A” or “B” if there are improvements or
unfavorable regression [233, 234]. This [AB] phenotype is highly prevalent in patients who are
presented with lipid disorders and additionally have been associated with significantly elevated
intermediate-density lipoprotein (IDL), an increased risk that has been linked to atherosclerosis
and heart disease in hemodialysis (HD) patients [235].
Lipoprotein subfraction analyses showed in the Malaysian cohort that I-HDL was the
prominent HDL lipoprotein, followed by L-HDL and least represent S-HDL. Analyses also
revealed that there were differences in the L-HDL between the three ethnicities, MC had the
highest values in L-HDL, followed by MI and MM. Changes were also observed in S-HDL, while
not very pronounced MC subjects had the highest content of the S-HDL, followed by MM and MI.
In all three ethnicities, IDL showed to have a significantly higher content than VLDL. No major
differences were recorded in LDL analyses. When the lipoprotein subfraction was compared with
the AA cohort, there were significant differences in the L-HDL and S-HDL. AA patients had
significantly higher L-HDL, and lowest VLDL, whereas MM had the highest content of the SHDL, and MC had a higher value in VLDL. No changes were recorded in LDL analyses.
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Subfraction data was analyzed for the two groups; TAG/HDL-C ratio (≥ or < 3.8). Patients
with ≥ a 3.8 TAG/HDL-C ratio observed a significant decrease in L-HDL and an increased in the
S-HDL and S-LDL, whereas <3.8 ratios observed a rise in the L-HDL, and I-HDL whereas S-LDL
decreased. A study by Gluba-Brzozka et al. (2017) looked and analyzed the lipoprotein
subfraction, in CKD and a healthy control group. Their analyses found that CKD patients all had
more abundant L-HDL (similar what our data shows), whereas the healthy subjects had abundant
of the S-HDL, and it was hypothesized that the S-HDL might be a better HDL lipoprotein to
facilitate cholesterol efflux. [236]. In another investigation, a retrospective analysis in a Caucasians
group of Polish ESRD patients Gluba-Brzozka et al. (2017), found a notable difference in both
HDL and LDL subfractions. Polished ESRD patients were characterized by significantly higher
L-[HDL and L-LDL] countered by the lower composition of small-[HDL and LDL] which was
concluded that the L-HDL maybe a contributor to impairment of RCT [78]. In an earlier
publication by our group Tashkandi. B et al., (2019) [237] we investigated a cohort of Saudi Arabic
patients, finding different results in their HDL distribution, unlike the US and Malaysian cohorts
who had higher components of large and small. Their L-HDL (30%) and S-HDL (14%)
distribution were relatively equal throughout the 3-time point measured, with 55% of the particles
account for I-HDL.
CETP was measured and showed a significant decrease in MC and increases in MM and
MI patients. Moreover, the dyslipidemic patients had lower activity of CETP activity versus its
counterpart. LCAT activity was higher in AA concerning MC and MI. Additionally, we measured
CRP in ESRD subjects regardless of sex, age, and ethnicity experience above the normal
inflammation (extremely high CRP). Although plasma CRP is elevated for all four patients,
African Americans expressed a 2X-fold increase in levels of inflammation than their counterparts,
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which could place AA at a much higher risk for a cardiac event. Other analyses, for oxidation was
analyses of AGEs-CML in plasma. Results were inconclusive. Even on DM patients whom
theoretically and based on various publication should have expressed a higher level; thus it will be
an area which needs further future analyses [238, 239]
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CHAPTER 7: CONCLUSION AND RECOMMENDATIONS
Summary conclusion
The first part of this study was to document the degree of dyslipidemia (D) in a cohort of
African American (AA) MHD patients, and characterize lipid, lipoprotein composition, and
associated enzymes. Additionally, we wanted to document the status of the cohort inflammation
by measuring the C-reactive protein (CRP) in the plasma; moreover, on a subset of this cohort, we
measured the advanced glycation end-products- Nε-carboxymethyl-lysine (AGEs-CML) in the
plasma an oxidation marker.
Lipid and lipid ratios for the 123 AA MHD patients showed to be within the normal range.
TAG concentrations were lower than 150 mg/dL, HDL was within the desirable range 40 – 60
mg/dL, TC was <200 mg/dL and LDL-C was < 100 mg/dL. To assess for dyslipidemia in the AA
cohort, the Adult Treatment Panel (ATP III) guidelines were utilized. Results showed that 14% of
the population with ≥ a 3.8 TAG/HDL-C ratio was dyslipidemic, which was characterized by
elevated TAG, TC, LDL-C, and lipid ratios, whereas HDL-C had significantly declined.
Lipoprotein analyses revealed that AA subjects had borderline equal L-HDL and I-HDL, which
were the prominent HDL lipoproteins, and significantly higher when compared to the distribution
of the S-HDL. AA patients also had significantly more IDL than VLDL; furthermore, the L-LDL
was the prominent lipoprotein with regards to I-LDL and S-LDL which was least represented.
Overall, AA patients had 65% of phenotype “A” in LDL particle type. Other analyses within
dyslipidemia showed a decrease in the L-HDL and I-HDL; consequently S-HDL increased twofold. LDL analyses revealed a significant rise in the atherogenic S-LDL and a rise in I-LDL.
Adding to the case was LDL particle phenotype “B” was present in 47% of dyslipidemic patients,
in line with the rise of the atherogenic particles.
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Dyslipidemic AA patients had a significant decline in CETP active; however, no changes
in the LCAT activity. Collective the cohort had significantly elevated CRP levels, irrespective of
whether the patients were D or not. AGEs-CML analyses, in the AA subgroup was inconclusive
in the finding, any difference, amongst genders, diabetics as well as dyslipidemic MHD subjects.
The second aim of the study was to document dyslipidemia in a multi-ethnic cohort of
MHD patients, composed of Malaysian-Malay (MM), Malaysian-Chinese (MC) and MalaysianIndian (MI). Lipid analyses showed that parameters were all within normal range. The only noted
difference was MM, and MI had significantly lower levels of HDL-C when compared to MC.
Overall the Malaysian cohort was 29% D, for subjects in a ≥ 3.8 TAG/HDL-C ratio group,
characterized by the significant increase in TAG and the decreases of the HDL-C level. HDL
lipoprotein analyses, collectively revealed that I-HDL was the most pronounced subfraction,
followed by L-HDL, and least shown was the S-HDL. Changes in both L-HDL and S-HDL were
documented amongst ethnicities, leading us to deduce that most changes in HDL lipoproteins
seemed to be driven by the fluctuations among the two subfractions. No significant changes were
observed in the LDL subfraction composition.
An overall analysis and comparison between the four ethnicities revealed that AA patients
had lower TAG, TC, LDL-C, and higher HDL-C when compared with Malaysian patients.
Combined, the two cohorts showed to have 24% of patients being D, with results depictive of
elevated TAG and significantly decreased HDL-C. In HDL lipoprotein analyses, data showed that
AA patients had a significantly higher content of the L-HDL subfraction, whereas MC, MM had a
higher composition of the S-HDL. VLDL analyses were observed to be significantly higher in
Malaysian patients with respect to AA subjects, and no changes were observed in LDL
lipoproteins. Moreover, a thorough analysis of dyslipidemia concerning subfractions, revealed a
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pattern in which L-HDL and I-HDL had significantly decreased, whereas the S-HDL and S-LDL
had increased.
CETP activity in Malaysian patients showed a decrease in its activity; however, it did not
reach significance. Analyses also uncovered differences between the four ethnicities, mainly,
depictive of AA patients having the lower activity within this study cohort. LCAT activity was
significantly higher in AA patients, while no other changes were recorded with respect to
dyslipidemia. Inflammation in the Malaysian cohort revealed to be substantial. Analyses between
the four ethnicities showed a remarkable difference between AA, who had significantly higher
CRP levels when compared to MM and MC.
In this dissertation, we were able to fulfill our primary objective in characterizing
dyslipidemia and lipoprotein subfraction composition in a cohort multi-ethnic MHD set, which to
our knowledge is the first study of its kind to tackle such task. Furthermore, the data in this study
were also supportive of the proposed hypothesis, in associating dyslipidemia in MHD to abnormal
lipoprotein particles, and higher inflammation was recorded in all four ethnic patients.
Recommendation and future directions
For future directions: One key area to investigate is to explore and measure ApoA-1
protein. This inquiry should be conducted in order to help facilitate a better understanding of the
reverse cholesterol transport (RCT) mechanism and look into the effect of dyslipidemia that may
have on this protein.
Secondarily, PON1 should be investigated, since it is considered to be the antiatherogenic
component of the HDL lipoprotein.
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Thirdly, a future investigation should examine the functionality of the HDL lipoprotein;
with the purpose of understanding which of (L-HDL vs.S-HDL and/or L-LDL vs. S-LDL) maybe
protect and ones that could contribute to disease in MHD subjects.
Furthermore, a follow up into the PATCH clinical trial should be, to measuring after 12month of intervention all of the lipoproteins, CETP, LCAT, LPL (part of RCT), and CRP, and
attempt to answer the questions on how did TRF supplementation affect these parameters in MHD
patients, and whether the intervention affect dyslipidemia.
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APPENDIX A
Appendix Tables 1: Dyslipidemic profile criteria assessed based Adult treatment panel III
(ATP III) guidelines.

Dyslipidemia Categories
Lipid Concentrations
Dyslipidemic group [D]
Mixed Dyslipidemic group [MD]
Normo-lipidemic group [NL]

TAG
(mg/dL)
Higher >150

HDL-C
(mg/dL)
Lower HDL < 40

LDL-C
(mg/dL)
Higher > 100

At least one criteria of for dyslipidemia
Lower < 150

Higher > 40

Lower < 100

[D], the dyslipidemic group; [NL] normo-lipidemic group; [MD], mixed dyslipidemic group. Criteria based on the
Adult Treatment Panel (ATP III) guidelines [240-242]
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Appendix Tables 2: Recommended lipid ranges.

Lipid Parameters

Low

Normal/
Desirable

Borderline
High

Very
High

TAG (mg/dL)

---

< 150

150 – 199

200 – 499

Extremely
High
≥ 500
Hypertriglycerimia
domain

HDL-C (mg/dL)

< 40

40 – 60

≥ 60

---

---

TC (mg/dL)

---

< 200

200 – 239

≥ 240

Hypercholesterolemic
domain

LDL-C (mg/dL)

---

< 100

130 – 159

160 – 189

≥ 190

NonHDL-C (mg/dL)

---

< 130

130 – 159

≥ 159

---

TAG/HDL-C ratio

---

<2

2 – 3.8

≥ 3.8

---

TC/HDL-C ratio
(Men)

---

< 3.5

3.5 – 5.0

≥ 5.0

---

TC/HDL-C ratio
(Women)

---

< 3.0

3.0 – 4.4

≥ 4.4

---

LDL/HDL ratio

---

< 2.5

2.5 – 3.3

≥ 3.3

---

Lipid parameters are recommendations based on ATP-III guidelines; [243], ACC/AHA [242] and KDIGO [9, 244].
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Appendix Figures 1: CRP versus hs-CRP in the Malaysian plasma samples.

Samples analized for CRP and hsCRP in order to standarized the two experiments was (n) = 36. The adjustment
formula was: [ y = 1.31 + 0.99x ] with a R2 = linerar = 0.930
Additional analyses of the Pearson Correlation showed an r = 0.965 (p < 0.001) a significant association between the
two assays.
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Appendix Figures 2: CETP activity and TAG concentration correlation for all samples.

CETP activity (nmol/mL hr.) has an inverse correlation with TAG concentration (mg/dL) in (n = 348) plasma sample
from MHD patients. R2 = 0.040 with a y = 47.45 - 0.05x equation.
Pearson Correlation showed a strong association between parameters with an r = -0.201 which is inversely
significantly associated (p<0.001).
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Appendix Figures 3: CETP activity and TAG/HDL-C ratio correlation for all samples.

CETP activity (nmol/mL hr.) has an inverse correlation with TAG/HDL-C ratio in (n = 348) plasma sample from
MHD patients. R2 = 0.023 with a y = 44.19 – 0.98x equation.
Pearson Correlation showed a strong association between parameters with an r = -0.153 which is inversely
significantly associated (p<0.004).
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Appendix Figures 4: LCAT activity and TAG concentration correlation for all samples.

LCAT activity a ration between (470/390 FI) has an inverse correlation with TAG concentration levels in (n = 345)
plasma sample from MHD patients. R2 = 0.020 with a y = 0.89 – 2.65E-4x equation.
Furthermore, Pearson Correlation showed a strong association between parameters with an r = -0.141 which is
inversely significantly associated (p<0.009).
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APPENDIX B: Other Analyses
Appendix B Figures 1: AGEs-CML based on BMI analyses in the US cohort.

9
4.94 ± 2.98
8

6.37 ± 0.61

4.43 ± 2.59

Plasma CML in (ng/mL)

7
6
3.54 ± 1.20

5

4 ± 1.23

2.75 ± 2.45

4
3
2

0.92 ± 0.50

1
0
<20

20-25

25-30

30-35

35-40

40-45

>45

n=2

n = 14

n = 18

n=9

n=9

n=5

n=2

BMI
Values are reported as mean ± SD. The values with different superscriptabc represent significant differences from each
other (p < 0.05) when using One-Way ANOVA. Statistics showed, N.S., between the seven subgroups p-value =
0.141.
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Appendix B Figures 2: Percent risk factor and atherogenic index of plasma in MHD ethnic

PERCENT RISK %

patients.

42
40
38
36
34
32
30
28
26
24
22
20
18
16
14
12
10
8
6
4
2
0

0.2
22.6 ± 16.3

a

0.163 b
0.15
17.5 ± 15.0 ab
0.089

0.069 b

17.8 ± 13.4

b

0.1

12.9 ± 10.7 b 15.4 ± 8.0 b

0.05
0.026
0

-0.05

-0.1
-0.114

a

-0.15
AA

MM

MC
PRF %

MI
AIP

All MHD
Patients

Values are reported as mean ± SD. The values with different superscriptab represent significant differences from each
other (p < 0.05) when using One-Way ANOVA. Data were adjusted using ANCOVA, for fixed variables: gender,
DM, HTN, and Tabaco in relation to covariate factors.
PRF%: < 5% low risk; 5-7.4% borderline risk; 7.5-19.9% intermediate risk; ≥ 20% high risk.
AIP: 0.11 - low risk; 0.11 - 0.21 intermediate risk; ≥ 0.21 increased risk.
Abbreviations: AA, African American (n = 123); MC, Malaysian-Chinese (n = 110); MM, Malays (n = 69); MI.,
Malaysian-Indian (n = 46); PRF%, percent risk factor; AIP, Atherogenic Index of Plasma.
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Appendix B Figures 3: CRP analyses based on dyslipidemia.
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Appendix B Figures 4: CRP among ethnicities according to TAG/HDL-C ratios ≥ or < 3.8.
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Appendix B Table 1: Demographics of the collective in the US and Malaysian cohort.
Demographics

Total
(n = 348)
56 ± 13

AA
(n = 123)
59 ± 13a

MM
(n = 69)
48 ± 14b

MC
(n = 110)
57 ± 11a

MI
(n = 46)
55 ± 12 a

P-value
<0.001*

Males

211 (60.6)

77 (62.6)

37 (53.6)

65 (59.1)

32 (69.6)

NS

Females

137 (39.4)

46 (37.4)

32 (46.4)

45 (40.9)

14 (30.4)

Smokers

57 (16.4)

36 (29.3)

9 (13)

10 (9.1)

2 (4.3)

Non-Smokers

289 (83)

87 (70.7)

59 (85.5)

99 (90)

44 (95.7)

Other-unknown

2 (0.60)

-

1 (1.4)

1 (0.90)

-

DM

167 (48)

68 (55.3)

27 (39.1)

48 (43.6)

24 (52.2)

Non-DM

181 (52)

55 (44.7)

42 (60.9)

62 (56.4)

22 (47.8)

HTN

296 (85.1)

108 (87.8)

57 (82.6)

96 (87.3)

35 (76.1)

Non-HTN

52 (14.9)

15 (12.2)

12 (17.4)

14 (12.7)

11 (23.9)

User

190 (54.6)

55 (44.7)

37 (53.6)

73 (66.4)

25 (54.3)

Non-User

158 (45.4)

68 (55.3)

32 (46.4)

37 (33.6)

21 (45.7)

27.0 ± 6.0

30 ± 7.5 a

26 ± 4.6b

25 ± 4.2b

26 ± 3.2b

<0.001*

Albumin (g/dL)

3.9 ± 0.43

3.8 ± 0.3

a

a

b

<0.001*

Systolic B/P (mmHg)

150 ± 23

140 ± 21a

151 ± 21b

158 ± 21b

159 ± 24b

<0.001*

Diastolic B/P (mmHg)

79 ± 15

79 ± 15

78 ± 16

79 ± 14

77 ± 16

0.807

Dialysis/Vintage (months)

73 ± 61

66 ± 65

84 ± 66

76 ± 55

71 ± 56

0.285

Kt/V

1.6 ± 0.3

1.5 ± 0.2 a

1.6 ± 0.3ab

1.6 ± 0.3b

1.6 ± 0.3ab

0.030*

Age (yrs.)
Gender (n, %)

Tobacco Smokers (n, %)
<0.001*

Diabetes (DM) (n, %)
NS

Hypertension (n, %)
NS

Statin (n, %)

BMI (kg/m2)

3.8 ± 0.4

4.1 ± 0.4

b

4.0 ± 0.4

0.011*

Values are reported as mean ± SD. The values in a given row with different superscriptabc represent significant
differences from each other (p < 0.05) when using One-Way ANOVA.
Data were adjusted using ANCOVA, in relation to covariate factors such as age, gender, tobacco, statin, BMI,
Albumin, systolic, and diastolic as well as Kt/V.
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Appendix B Table 2: Lipoprotein composition between genders and ethnicities.
Lipoproteins in Men
(n, %) (n=211)

AA
77 (36)

MM
37 (18)

MC
65 (31)

MI
32 (15)

L-HDL (mg/dL)

18.9 ± 12.5 a

10.8 ± 5.90 b

16.0 ± 9.90 ab

12.7 ± 7.0 b

I-HDL (mg/dL)

21.0 ± 5.36

22.0 ± 3.72

22.0 ± 5.25

22.1 ± 4.04

S-HDL (mg/dL)

5.86 ± 3.00 a

7.43 ± 3.47 b

6.74 ± 2.94 ab

5.31 ± 2.13 a

VLDL (mg/dL)

24.7 ± 10.7 a

33.9 ± 10.6 b

32.7 ± 9.21 b

30.8 ± 7.32 b

IDL (mg/dL)

44.9 ± 14.6

46.5 ± 12.8

43.1 ± 10.8

49.4 ± 12.7

L-LDL (mg/dL)

20.4 ± 8.89 a

23.4 ± 8.37 ab

23.5 ± 8.77 ab

26.0 ± 8.36 b

I-LDL (mg/dL)

11.8 ± 7.00

14.8 ± 8.17

12.8 ± 6.36

15.1 ± 7.64

S-LDL (mg/dL)

4.26 ± 6.29

6.19 ± 8.10

4.31 ± 6.67

4.87 ± 9.08

AA
46 (34)

MM
32 (23)

MC
45 (33)

MI
14 (10)

L-HDL (mg/dL)

27.3 ± 19.2 a

16.8 ± 9.90 b

19.6 ± 13.9 ab

20.0 ± 12.5 ab

I-HDL (mg/dL)

24.0 ± 5.92

23.2 ± 4.80

25.1 ± 5.51

24.1 ± 5.80

S-HDL (mg/dL)

6.09 ± 3.52

6.75 ± 3.87

8.13 ± 4.16

5.92 ± 3.58

VLDL (mg/dL)

26.6 ± 9.17 a

33.6 ± 8.72 b

37.7 ± 10.7 b

28.8 ± 11.2 ab

IDL (mg/dL)

49.9 ± 16.4

47.7 ± 12.9

50.2 ± 15.6

52.2 ± 19.0

L-LDL (mg/dL)

25.4 ± 9.84

22.7 ± 7.92

22.9 ± 9.43

24.7 ± 8.19

I-LDL (mg/dL)

13.7 ± 9.41

13.4 ± 9.82

11.9 ± 7.71

10.9 ± 6.03

S-LDL (mg/dL)

3.15 ± 5.82

4.50 ± 6.70

4.58 ± 7.23

4.29 ± 10.1

Lipoprotein in Women
(n, %) (n=137)

Values are reported as mean ± SD. The values in a given row with different superscriptabc represent significant
differences from each other (p < 0.05) when using One-Way ANOVA.
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Appendix B Table 3: Lipid analyses in statin analyses.
Lipid
Statin group

Total
(n = 190)1

AA
(n = 55)

MM
(n = 37)

MC
(n = 73)

MI
(n = 25)

TAG (mg/dL)

129 ± 72 a

94 ± 50 a

146 ± 73 b

139 ± 68 b

145 ± 96 b

HDL (mg/dL)

47 ± 15

51 ± 19

45 ± 11

47 ± 13

43 ± 12

TC (mg/dL)

160 ± 39

148 ± 46

165 ± 33

165 ± 35

162 ± 38

LDL (mg/dL)

88 ± 33

79 ± 42

92 ± 30

91 ± 28

90 ± 26

NonHDL (mg/dL)

113 ± 41

98 ± 48 a

120 ± 35 b

119 ± 34 b

118 ± 39 ab

TAG/HDL- Ratio

3.19 ± 2.45 a

2.21 ± 1.66 a

3.71 ± 2.46 b

3.38 ± 2.24 b

3.97 ± 3.72 b

TC/HDL-C Ratio

3.68 ± 1.37

3.28 ± 1.59

3.90 ± 1.17

3.75 ± 1.12

4.02 ± 1.63

LDL/HDL-C Ratio

2.05 ± 1.02

1.84 ± 1.34

2.17 ± 0.87

2.08 ± 0.81

2.25 ± 0.95

Lipid
Non-Statin group

Total
(n = 158) 1

AA
(n = 68)

MM
(n = 32)

MC
(n = 37)

MI
(n = 21)

TAG (mg/dL)

105 ± 52 b

93 ± 44 a

138 ± 75 b

104 ± 41 a

100 ± 33 a

HDL-C (mg/dL)

47 ± 16

50 ± 19 ab

41 ± 9 a

51 ± 17 b

43 ± 11 ab

TC (mg/dL)

156 ± 35

148 ± 38

162 ± 36

160 ± 34

165 ± 22

LDL-C (mg/dL)

88 ± 32

80 ± 36 a

95 ± 29 ab

88 ± 28 ab

103 ± 23 b

NonHDL (mg/dL)

109 ± 38

99 ± 42 a

121 ± 37 b

109 ± 30 ab

122 ± 25 ab

TAG/HDL-C Ratio

2.60 ± 1.87 b

2.27 ± 1.55 a

3.76 ± 2.76 b

2.26 ± 1.32ac

2.54 ± 1.26 abc

TC/HDL-C Ratio

3.60 ± 1.31

3.38 ± 1.45 a

4.15 ± 1.42 b

3.30 ± 0.84ac

4.04 ± 1.04 abc

LDL/HDL-C Ratio

2.10 ± 1.05

1.92 ± 1.20

2.44 ± 1.01

1.87 ± 0.72

2.56 ± 0.86

Values are mean ± SD for the numbers indicated in parentheses1. Values in a given row with different superscripts ab
were significantly different from each other (p < 0.05), using one-way ANOVA.
Overall: Statin patients (n = 190) vs. Non-statin (n = 158) patients showed a significant difference (P<0.001) in TAG
composition Statin (128 ± 72 mg/dL) vs. Non-Statin (105 ± 52 mg/dL) and in TAG/HDL-C ratio (P=0.015) (3.19 ±
2.45 vs. 2.60 ± 1.87).
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Appendix B Table 4: Subfraction composition in the statin analyses.

Lipoproteins
Statin group (n=190)

AA
55 (29)

MM
37 (19)

MC
73 (38)

MI
25 (13)

L-HDL (mg/dL)

22.0 ± 16.2 a

14.9 ± 9.43 b

15.5 ± 10.2 b

15.2 ± 9.56 ab

I-HDL (mg/dL)

22.5 ± 5.46

23.5 ± 4.05

23.1 ± 5.35

22.1 ± 5.51

S-HDL (mg/dL)

6.20 ± 3.52 a

7.00 ± 3.73 ab

8.01 ± 3.69 b

5.96 ± 2.92 ab

VLDL (mg/dL)

25.5 ± 11.3ac

33.0 ± 8.27 bc

36.6 ± 10.3 b

30.1 ± 9.98 c

IDL (mg/dL)

46.8 ± 16.1

46.9 ± 13.4

46.6 ± 12.5

48.4 ± 13.5

L-LDL (mg/dL)

22.2 ± 10.3

23.0 ± 8.04

22.5 ± 8.63

24.1 ± 7.42

I-LDL (mg/dL)

12.8 ± 8.75

14.8 ± 8.56

12.9 ± 6.70

14.4 ± 7.54

S-LDL (mg/dL)

4.02 ± 6.97

5.22 ± 7.28

5.16 ± 7.14

6.44 ± 11.8

AA
68 (43)

MM
32 (20)

MC
37 (24)

MI
21 (13)

L-HDL (mg/dL)

22.0 ± 15.7 a

12.0 ± 7.11 b

21.3 ± 13.8 ab

14.7 ± 9.68 a

I-HDL (mg/dL)

21.8 ± 5.98

21.4 ± 4.31

23.5 ± 5.98

23.3 ± 3.44

S-HDL (mg/dL)

5.74 ± 2.90ab

7.25 ± 3.60 a

5.92 ± 2.76 ab

4.95 ± 2.18 b

VLDL (mg/dL)

25.3 ± 9.29 a

34.6 ± 11.2 b

31.3 ± 8.89 b

30.3 ± 6.84 ab

IDL (mg/dL)

46.7 ± 15.0

47.3 ± 12.3

44.8 ± 15.2

52.5 ± 16.2

L-LDL (mg/dL)

22.4 ± 8.96

23.1 ± 8.32

24.9 ± 9.62

27.4 ± 8.96

I-LDL (mg/dL)

12.3 ± 7.40

13.4 ± 9.44

11.5 ± 7.34

13.1 ± 7.30

S-LDL (mg/dL)

3.71 ± 5.37

5.62 ± 7.80

2.95 ± 6.14

2.62 ± 4.35

Lipoproteins
Non-Statin group (n=158)

Values are reported as mean ± SD. The values with different superscriptabc represent significant differences from
each other (p < 0.05) when using One-Way ANOVA.
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ABSTRACT
ROLE OF DYSLIPIDEMIA ON LIPID METABOLISM IN MAINTENANCE
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by
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Degree : Doctor of Philosophy
Maintenance hemodialysis (MHD) patients experience various abnormalities such as
systemic inflammation (SI), oxidative stress (OS), and dyslipidemia (D). Defined as an imbalance
of plasma lipids, lipoproteins, and lipid metabolism enzymes, D has been associated with a rise in
morbidity and mortality within ESRD patients due to cardiovascular disease (CVD). However, the
contribution of each of these parameters to D is poorly understood; moreover, the impact of the
following parameters on dyslipidemia in different ethnicities is unknown. Hence, the objective of
this study was to characterize D in a multi-ethnic cohort of ESRD patients. We hypothesized that
dyslipidemia amongst MHD patients of different ethnicities will reflect underlying alterations in
lipoproteins and enzymes of lipid metabolism. The rationale for the proposed study is that once a
dyslipidemic MHD profile is determined, targeted interventions could be used to manage it. The
degree of D was investigated in a cohort comprised of African American (AA), Malaysian-Malays
(MM), Malaysian-Chinese (MC), and Malaysian-Indians (MI), of whom were enrolled in the
PATCH clinical trial USA and/or Malaysia.
Lipids, lipoprotein particles, associated enzymes cholesteryl ester transfer protein (CETP),
Lecithin-cholesterol acyltransferase (LCAT), as well as an inflammatory marker C-reactive
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protein (CRP), were measured. Assessment of dyslipidemia was based on the criteria from the
Adult Treatment Panel (ATP III) guidelines. TAG/HDL ratios (≥ or < 3.8) were utilized to
ascertain LDL phenotypes.
All lipid parameters in both groups were within the normal range; however, AA subjects
had lower triglycerides (TAG) levels and higher high-density lipoprotein – cholesterol (HDL-C)
when compared to Malaysian patients. Additionally, a biphasic response was recognized with
regards to the relationship between TAG and HDL; as one rises, the other falls. Dyslipidemic
analyses showed that all lipid values, in the TAG/HDL-C ratio ≥ 3.8 group were significantly
different from the corresponding values in the < 3.8 TAG/HDL ratio group. The effect of
dyslipidemia in the subfractions showed a decline in L-HDL and I-HDL consequently, S-HDL
increased. Also, D increased VLDL and IDL subfractions, as well as I-LDL and S-LDL. Due to
dyslipidemia, the mean LDL particle size decreased significantly in diameter, wherein 63% of
patients were more likely to have a phenotype “B” LDL particle; which has been linked to the
atherogenic small dense LDL. CETP activity was different amongst ethnicities and declined in the
≥ 3.8 TAG/HDL ratio group. LCAT activity was higher in AA with respect to Malaysians patients
and was not affected by dyslipidemia. All patients had significantly elevated CRP levels, of which
AA was the highest.
In conclusion, we analyzed lipids, lipoproteins, CETP, and LCAT activities, for a multiethnic cohort study, in addition to measuring CRP. For future directions, it would be ideal to
investigate the effect of D on Apolipoprotein-A1, PON1, and, most important, test for HDL
functionality.
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